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Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were 
formulated with three model drugs known for their poor aqueous solubility, namely 
phenylbutazone, indomethacin and imipramine in an attempt to enhance the extent and rate of 
their dissolution. Although other forms of mesoporous silica have been investigated in previous 
studies, the effect of inclusion with these specific Syloid® silica-based excipients with 
phenylbutazone, indomethacin and imipramine are unknown. This work reports a significant 
enhancement for both the extent and rate of drugs release for all three forms of Syloid® silica 
at 1:1, 2:1 and 1:3 drug:silica ratios over a period of 45 minutes. An explanation for this 
increase was determined to be conversion from crystalline to the amorphous form and an 
enhanced drug loading ability within the pores. Differences between the release profiles of the 
three silicas was concluded to be a consequence of the physicochemical differences between 
the three forms. Overall, this study confirms that Syloid® silica-based excipients can be used 
to enhance dissolution, and potentially therefore bioavailability, for compounds with poor 
aqueous solubility, such as phenylbutazone, indomethacin and imipramine. In addition, it has 
been confirmed that drug release can be carefully tailored based on the choice of Syloid® silica 
and desired release profile. 
The second part of this study investigated the effect of microwave heating through the 
application of microwave differential thermal analysis to eight model pharmaceutical 
compounds and a set of four model excipients. Benzocaine, haloperidol, ibuprofen, 
indomethacin, ketoprofen, naproxen, imipramine and phenylbutazone were analysed, along 
with four excipients, namely β-cyclodextrin, D-mannitol, stearic acid and Syloid® silica (XDP 
3050) using microwave differential thermal analysis. Samples were heated by microwave 
irradiation at 5 °C/min to a minimum of 160 °C, held isothermally and then slowly cooled to 
room temperature. Thermal profiles were analysed and compared with data obtained using 
differential scanning calorimetry (DSC), x-ray powder diffraction (XRD) and hot stage 
microscopy (HSM). Overall, it was found that the process of microwave heating produced 
different thermal profiles to those seen using traditional, conductive heating. Investigating 
differences in thermal profiles can be a useful way to consider the effect of microwave induced 
heating on formulations which can, in turn, help guide formulation choices.  
The latter part of this study describes the analysis and characterisation of polyvinylalcohol 
(PVA)-based hydrogel polymer beads, developed for the embolisation of vessels, specifically 
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focussing on the quantitative and qualitative aspects of water within such beads in the absence 
and presence of a model drug, namely imipramine. The utilisation of Microwave differential 
thermal analysis (MWDTA) for the characterisation of bound water within the polymer beads 
was unsuccessful because there was no cooling system and as a result, most of the water 
evaporated during the measurement. Following successful incorporation within the beads, 
thermogravimetric analysis (TGA) permitted determination of the total water content within 
the beads (96.8 %) and differential scanning calorimetry (DSC) indicated the water within the 
beads was apportioned as 15.8 % non-freezing, 25.1 % loosely bound and the remaining 55.9 
% unbound. In the presence of drug, the size of the beads decreased with an average diameter 
reduction from 121.4 µm to 78.5 µm, coupled with a reduced total water content of 95.4 %, 
coupled with a reduced percentage of loosely bound water. This study confirms the ability of 
TGA and DSC to characterise the differing types of water within the beads and indicates the 
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Chapter 1: Introduction  
Mesoporous silica materials have been used as carriers for oral delivery of poorly water-soluble 
drugs since their emergence in 1970. The pore diameter of these materials is between 2 – 50 
nm which gives them the name ‘’Mesoporous’’, they are arranged in a crystallographic sense 
meaning the mesopores are identical in size and organised in a uniform manner in the silica 
matrix which itself is amorphous [1]. They have a high surface area as one of their unique 
advantages, adjustable particle size, flexible morphology, large pore volume, excellent 
biocompatibility, facile surface functionalisation and biodegradation [2]. These excellent 
properties make the silica materials appropriate for a wide range of applications in drug 
delivery and development, catalysis, as an adsorbent in environmental studies and 
chromatography [3-5].  
A large number of drugs exhibit poor solubility, causing lots of challenges in formulation, and 
in some cases, because of this, drug candidates are  rejected during the development processes 
[6]. Poor solubility results in low level bioavailability of drugs and therefore improving the 
oral bioavailability without affecting the pharmaceutical activity and stability creates one of 
the challenges in the pharmaceutical industry. Several traditional strategies to modify drug 
release have been developed over the years including gelatin/non-gelatin capsules [7], co-
solvents, solid dispersions, salt formations, lipid-based formulations [8, 9], mesoporous silica 
materials [10, 11], liposomes [12], inclusion complexes such as cyclodextrins [13], polymers 
[14] and many others such as nanocarriers [15]. Such formulations have successfully created a 
wide variety of drug release profiles with a range of positive impacts such as reducing dosing 
intervals or side effects, in some cases increasing bioavailability and generally increasing 
patient compliance. However, even with the strategies previously considered, some drugs 
continue to present formulation issues and still require the development of a suitable modified 
release formulation to enhance their drug release profiles. Compared with these strategies, 
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silica-based substances have attracted lots of attention as novel drug carriers due to their 
textural and structural features, as can be seen in Figure 1.1.  
 
Figure 1. 1. Mesoporous Syloid® silica [16]  
One particular category of mesoporous silicas where only very limited studies have been 
conducted to date is regarding Syloid® silica-based formulations. These forms of silica have a 
highly developed network of mesopores that provide access to the large surface area, i.e. a 
combination of a high adsorption capacity, along with a desirable pore size and surface 
morphology. For these reasons, these silicas tend to be used to improve the flow properties of 
pharmaceuticals where liquid ingredients can be converted into free-flowing powders. 
Although these properties are beneficial, their suitability to enhance dissolution has only briefly 
been considered (by publication) for two forms of Syloid® silica (244 and AL-1FP) with two 
model drugs, namely indomethacin [17] and itraconazole [18]. Interesting, for both compounds 
an enhancement in the rate, and extent of dissolution was observed in both studies. Yet 
surprisingly, other forms of Syloid® silica have not yet been considered even though they may 
provide a plethora of advantages for drug-loading formulations.  
3 
 
1.1. Strategies to enhance dissolution       
Appropriate excipients have to be incorporated into formulations with suitable processing 
techniques in order to utilise mesoporous silica materials in oral drug delivery of poorly water-
soluble drugs. The growing number of research papers concentrating on the formulation of 
these systems is an indication of the growing interest in these drug delivery systems. Following 
an earlier report by Limnell et al., several strategies have attempted to use conventional 
methods to incorporate materials with poorly water-soluble drugs. Methods such as an 
immersion method and melting of drug molecules into the silica has been reported [19]. 
Unfortunately, this strategy is economically challenging, laborious and non-automatic on an 
industrial scale but rather suitable for small sample batches. Another issue is that in the 
filtration method [20], there is a high risk of crystallisation on the surfaces of the particles. 
Regarding the adsorption method [21], small drug particles on the surface of large excipients 
has been a successful strategy for low-dose drugs. Other options such as reduction of particle 
size to nanoscale [22], generation of amorphous forms and co-crystallisation [23], physical 
mixtures and microwave oven heating [6], spray drying and solid dispersions [24] as well as 
the use of buffers [25] have all been previously reported for the formulation of poorly water 
soluble drugs with mesoporous silica.  
A limited number of studies have attempted to use other drug carriers to incorporate materials 
with poor water solubility, such as mannitol formulated with indomethacin and nifedipine as 
reported by Saffari et al. [22] and found that an improved product was the result of this method. 
Loratadine was also formulated with cyclodextrin derivatives and cyclodextrin was 
demonstrated to enhance the dissolution rate and oral bioavailability of the drug [26]. One 
study has successfully enhanced dissolution through the creation of a solid dispersion with 
polyethylene glycol (PEG) 8000 [27]. However, there is still a clear need for developing 
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alternative formulations that can achieve an even greater enhancement in release of active 
compounds. Other techniques reported include; 
1.1.1. Hot melt extrusion (HME) 
Among several methods used to produce solid dispersions, HME is one of them. In this 
technique, the polymer matrix and the active pharmaceutical ingredients (API) are combined 
to produce a physical mixture at the same time accompanied by heating cycle which produces 
a homogeneous dispersion [28]. In order to employ this method, certain parameters need to be 
considered as they contribute significantly to the standard of the final formulation. These 
parameters include barrel design, die geometry, temperature, screw speed, feed rate and shear 
force [29]. The schematic illustration of this technique is shown in Figure 1.2. HME technique 
offers several benefits over other conventional methods, such as, fewer processing steps, 
solvent free and it is one step. This method can improve the bioavailability by dispersing the 
API at the molecular level because compression is not required. However, despite several 
advantages, this technique has some certain limitations that could restrict its use in the 
pharmaceutical industry including the possible exclusion of thermo-labile drugs due to high 
processing temperatures involved and the requirement of the high energy input when compared 
to other amorphous formulation techniques [28, 30]. This technique has gained popularity 
because it has successfully been applied to manufacture various pharmaceutical drug delivery 
systems such as nanocrystals [31], granules [32], topical and transdermal delivery systems [33] 




Figure 1. 2. A schematic illustration of hot melt extrusion process [33] 
1.1.2. Particle size reduction 
Essentially, dissolution is related to particle size because reducing the particle size will provide 
a larger surface area which will result in an enhanced dissolution rate owing to the improved 
solvation of the solute [24]. The technique of particle size reduction is classified in bottom-up 
and top-down approaches, depending on the substance to start with. Some of the advantages of 
the bottom-up technique include its processing time which is very short, low cost and better 
size control when compared to the top down approach [35].  
In confined liquid impinging, drug particles are mixed rapidly and produced in a confined 
mixing chamber using two liquid streams of solution containing drug and anti-solvent [36]. 
Precipitation occurs in this process, due to super saturation by introducing a solution and anti-
solvent in the chamber at the crossing of the micro-channels. Several factors can affect the 
narrow size distribution and ultra-fine particle disposition such as the liquid concentration, 
temperature, reactants flow rate, jet velocity and operating parameters of the jets geometry 
[37]. The micronised method to improve the solubility and permeability of low aqueous 
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solubility drugs including griseofulvin, felodipine and digoxin has been successfully proven 
[38]. Using mechanical pulverisation while jet milling, the micronised drug particles can be 
obtained, pin milling and ball milling are utilised commonly also. Agglomeration of drug 
particles can sometimes result through micronisation which by reducing the available surface 
area can decrease the dissolution rate. Though, to avoid such issues, surface active agents have 
been applied previously [39].  
1.1.3. Solvent evaporation technique      
Drug and a carrier are dissolved in a solvent to form a homogenous solution followed by 
evaporation of the solvent in this technique [40]. For thermo-labile drugs, this is a technique of 
choice [41]. The solvent evaporation method for solid dispersion was developed by Nakamura 
and Tachibana in 1965 to solubilise polyvinylpyrrolidone and β-carotene using chloroform as 
a solvent. By solidification rate, the physical state of the API in the resultant solid dispersion 
is determined [42]. By rapid evaporation of the solvent, fast solidification guarantees the 
amorphous content of drug [43].  
Several approaches have been used previously in removing the solvent using this technique 
including heating on plate [44], rotary evaporation, vacuum drying, freeze drying and spray 
drying [39, 40]. Most commonly used solvents in this technique include water, methanol, 
methylene chloride, acetone, and ethyl acetate. However, most of these organic solvents are 
toxic in nature which is a major drawback of the technique [40]. Other limitations of this 
method include high cost of production and protection against explosion, environmental issues, 
physical instability of the solid dispersion developed as a result of solvent residue among others 
[43].   
These techniques have limitations including: solvent residues using the solvent technique, 
thermal instability using the melting technique, the low in-vivo-in-vitro correlation, the 
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recrystallisation of the API in the developing process, and drug precipitation in dissolution 
media owing to super saturation [43], all of these limitations can result in a decreased 
dissolution rate.  
1.2. Formulation development and drug dissolution 
Traditionally, drug delivery has been administered in various forms including infusion, 
inhalation, topical application and injection [44]. The most preferred route of drug 
administration is the oral delivery route which accounts for more than a 60 % share of the 
worldwide drug delivery market. The high degree of patient compliance and convenience of 
the drug administration make it the most appropriate and frequent route of drug delivery [45]. 
This delivery route is not free from challenges which can result in poor bioavailability [46]. 
The main factors affecting the oral delivery of various existing drugs are poor solubility and 
intrinsic dissolution rate (i.e., mass of the drug dissolved per unit time and area). New chemical 
entities, about 40 % of them generated via discovery of drug, display poor water solubility [45]. 
In most cases, such compounds are classified in Class II or IV as per the biopharmaceutical 
classification system (BCS) [47] and in most cases their oral delivery results in poor 
bioavailability, lack of dose proportionality and erratic absorption [48]. Another factor that 
affects the oral bioavailability of many drugs is poor gastrointestinal permeability. Compounds 
with high membrane permeability but low solubility are classified as BCS Class II drugs [49]. 
Solubility among the physicochemical properties is of prime importance in drug development 
as low water solubility limits the efficacy of drugs. Molecules of the drug need to dissolve and 
permeate through the gastrointestinal tract (GIT) in order to achieve optimal success with oral 
administration [49]. Combining these two factors, namely, permeability and solubility 
describes the basis of BCS. In order to understand the physicochemical and biopharmaceutical 
properties of drugs, the BCS is the main tool, it is utilised when developing products and in 
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decision making [36, 39, 47]. Four different drug groups are classified according to BCS as 
illustrated in Figure 1.3.  
 
Figure 1. 3. The Biopharmaceutical Classification System (BCS) [47] 
The definitions for the BCS according to Alam et al., [49] and Langham [50] are; 
1. A drug substance is considered as highly soluble if the highest dose strength of the 
immediate product release is soluble in 250 mL or less of aqueous media pH range of 
1 – 7.5.  
2. A drug substance is considered as highly permeable when the absorption extent in 
humans is 90 % or more of the dose administered based on a weight – balance discovery 
or when compared with an intravenous dose reference.  
3. A drug substance is considered as rapidly dissolving if no less than 85 % of the amount 
of the drug substance dissolves in 30 min using USP apparatus I at 100 rpm or USP 
apparatus II at 50 rpm in a volume of lees than or equal to 900 mL in any of the 




In gastrointestinal fluids, drugs need to dissolve to permeate the gut wall, pass through the liver 
without being inactivated and reach the systematic blood circulation in order to produce a 
response pharmacologically which requires adequate aqueous solubility [46]. As a result, 
dissolution rate is often the most important factor in controlling a drugs bioavailability.  
1.2.1. Dissociation constant (pKa) 
At different pH values, the extent of ionisation of an ionisable drug molecule can be described 
by the drug’s pKa (acid dissociation constant). The pKa is a very essential chemical parameter 
in drug discovery. This is because in pharmaceutical formulations it helps in determining the 
ionisation profile of a material and predict the behaviour of drugs and their pharmacokinetic 
properties such as charge interaction with the target site, distribution in tissue and the 
permeability through biological membranes [51, 52]. On some essential physicochemical 
properties such as solubility and lipophilicity, the pKa can reveal an impact on such properties 
which could in turn affect the absorption and dissolution rate of the drug from the 
gastrointestinal tract [53].   
A neutral complex is formed when an ionisable drug is combined with a counter ion, this is 
straightforward to administer and allows the refinement of its physicochemical properties. 
Utilising different species of ionisation of a drug can produce a series of compounds with the 
goal of enhancing the solubility and dissolution rate of drug [52]. Moreover, the choice of 
excipients for a drug, also in view of its medical administration, must always account for the 
physicochemical parameters of the drug.  
The variables of the pKa are of great importance since the drugs transport into the cells and 
across membranes is a function of physicochemical properties. The amount of material found 
in the unionised form and ionised form is a function of its pKa and of the pH of the surrounding 
medium [52]. As a result of this, the absorption of the drug with the pH is influenced 
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accordingly. The ionised form normally has greater aqueous solubility while the unionised 
form is more lipophilic [54]. Several approaches has been reported for pKa determination 
including potentiometric titration which depends on the molecule possessing high aqueous 
solubility [55] and capillary electrophoresis which involves measurement of the mobility of 
different ionised species eluted through a capillary under the influence of an electric field [56].         
1.2.2. Solid state and the effect on dissolution 
The most influential factor once the drug substance has been identified is the solid-state 
selection when considering the development of a solid drug formulation. A variety of forms 
may exist in the solid state and each form will have different physicochemical properties 
including stability, dissolution rate, surface energy, crystal habit, density, compressibility and 
flowability [57]. Two substances that have the same chemical composition, but the lattice 
structure is different, are said to be polymorphs and the phenomenon is known as 
polymorphism [39, 40]. Pharmaceutical companies have invested much time and money into 
the determination of polymorph stability hierarchy because of the effect that the solid state has 
on a drug and its properties.    
The majority of commercially available drugs are marketed in the lowest energy crystalline 
form because it is the most stable form thermodynamically. When considering the wide range 
manufactured, and long period of storage for both the bulk drug substance and final product, 
this is of exceptional importance, because it is essential to be able to guarantee that the 
performance of the drug is not affected after such treatment [50]. Compounds when condensed 
into an ordered pattern form crystals. They must possess a high degree of mobility for ordering 
to occur. When a sample is in liquid form, these conditions occur, in the vapour state or in an 
amorphous matrix [57]. To enhance the dissolution of poorly water-soluble drugs, lots of 
consideration has been given to co-crystals. These are defined as a crystalline substance 
comprising of at least two or more different components [58].  
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Unlike crystalline substances, amorphous materials are high energy substances lacking a 
crystal lattice. These materials are highly soluble and usually have a faster dissolution rate than 
their crystalline counter parts, and so to enhance the bioavailability of poor aqueous solubility 
compounds, as a strategy, they offer an alternative [57].  Amorphous materials tend to change 
structure with time because they are thermodynamically unstable, first by relaxation and 
ultimately by crystallisation. Lots of formulations are made in an amorphous form against the 
risk of change upon storage [59].  
1.3. Common techniques used in the analysis of pharmaceutical formulations  
There are several techniques used in the analysis of pharmaceutical formulations, the most 
commonly used ones include the following; 
1.3.1. High performance liquid chromatography (HPLC) 
In the pharmaceutical industry chromatographic techniques are used often to assess safety, 
efficacy and quality of drug formulations. In the chromatography method, the sample 
components are distributed between the mobile phase (liquid or gas) and stationary phase (solid 
or liquid) [60, 61]. The separation may be based on ion-exchange, adsorption or partition, or 
based on other differences in the physicochemical properties of the molecule. Among various 
types of chromatographic techniques used in pharmaceutical analysis, HPLC is the most used 
because it has many advantages such as low detection limit, good accuracy, high sensitivity, 
specificity and obvious separation effect [62].  
HPLC is used for separating mixtures, either to analyse the mixture or to separate required 
products from others in a reaction mixture. It can also be used to find the relative amounts of 
different components in a mixture. This form of separation usually occurs when the sample 
interacts with the mobile and stationary phases. The various parts of the sample are separated 
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based on their polarities i.e. samples having different levels of affinity for the mobile phase, 
resulting in migration through the column at different speed [63].    
HPLC works on the same principle as paper chromatography, a liquid called the mobile phase 
moves through the solid stationary phase. If a mobile phase is more polar than the stationary 
phase, the more polar component of a mixture will tend to move more quickly than the less 
polar one [64].  
In HPLC, the stationary phase is a solid packed into a column, this column contains silica 
particles to which hydrocarbons are attached making the stationary phase non-polar. In this 
technique, the liquid is forced through the column by high pressure pumps. The reservoir holds 
the solvent, and two solvents can be mixed in any proportion to give a mixture, the liquid phase 
must be of a suitable polarity for the separation that is being done. A good example is water 
which is very polar and ethanenitrile which is less polar. The pump produces a pressure of 
15000 kPa i.e. 150 times that of the atmosphere [63]. If a single sample is to be run, it is injected 
into the solvent stream in the injection port. Alternatively, several samples can be run in 
succession by loading them into an auto sampler which will run them in order without any 
human intervention. The pumps force the mixed solvents through the column and the solvent 
emerges from the column carrying the separated components of the mixture which then passes 
into the detector. The time that each component takes to pass through the column is called 
retention time and can be used to help identify compounds [64].    
1.3.2. Ultraviolet (UV) spectrophotometry  
UV-visible spectrophotometry gives information about electronic transitions in atoms and 
molecules. Spectra are produced when electrons in molecules or atoms move from a lower 
energy level to higher energy level. In doing so, the absorbed energy is equal to the gap between 
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the two levels. Transition metal compounds and organic dyes are coloured and absorbed in the 
visible regions while those that absorb only in the ultraviolet region are colourless [65].  
A typical UV-vis spectrophotometer consists of a light source, a monochromator and a detector. 
There are two light sources inside the UV-vis spectrophotometer, one giving out visible light 
and the other one ultraviolet. A Deuterium lamp is usually the light source which emits the 
electromagnetic radiation in the UV region of the spectrum. A second source of light is tungsten 
which is used for wavelengths in the visible region. The monochromator contains a diffraction 
grating that splits the beam of light into its constituent wavelengths. Different wavelengths 
correspond to different colours (about 700 nm for red and 400 nm for blue). Wavelengths 
shorter than about 350 nm are called ultraviolet, shorter wavelengths have higher energy [66, 
67]. 
The source produces white light that includes all wavelengths or colours. The instrument scans 
through the spectrum, sending different wavelengths of light through the sample in sequence, 
this is done by the grating which rotates. A single wavelength passes into the modulator which 
consists of a rotor with mirrors on it, this splits the light into two beams. One beam passes 
through the sample cell while the other passes through the reference cell for a double beam 
instrument. Both sample and the reference beam are directed by mirrors on to a detector which 
compares their intensities and sends a signal proportional to the ratio of their intensities to the 
computer that controls the instrument. The logarithm of this ratio gives a quantity called 
absorbance which is a measure of how much light is being absorbed by the sample at that 
wavelength [66].  
UV spectra are usually run on solutions as light does not normally pass through some solid 
samples. To run the spectrum in a UV spectrophotometer, solvent is placed in a cuvette to act 
as a blank (a reference), the cuvette may be made of glass or plastic if only the visible region 
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of the spectrum is required. Quartz cuvettes are needed for work in the ultraviolet range because 
glass and plastic absorb UV light. A solution of the sample is placed in the second cuvette, the 
blank and the sample are placed in the sample holders. The lid is closed to prevent the light 
from the laboratory from interfering in the spectrum. The wavelength required and scanning 
speed are selected before scanning [66, 68].       
1.3.3. Infrared (IR) spectroscopy  
IR spectroscopy helps analysts to identify the functional groups present in a compound. It helps 
in finding the structure of a compound. Almost any molecule having covalent bonds, whether 
inorganic or organic, absorbs several frequencies of electromagnetic radiation in the IR region 
of the electromagnetic spectrum (EMS) [69]. This region lies at wavelengths longer than those 
associated with visible light, which is found from approximately 400 - 800 nm (1 nm = 10 -9), 
but lies at wavelengths shorter than those associated with microwaves which are larger than 1 
mm. Most bonds absorb energy in the IR region of the EMS which corresponds to heat, such 
as OH, C=O, NH, C-H, C=C which absorb at a particular frequency and this allows compounds 
to be identified.  IR spectra are a plot absorbance against wavenumbers measured per 
centimetre (cm-1) which are proportional to the frequency [65].   
All IR instruments have a source of IR radiation which is a coil of wire surrounded by a ceramic 
capsule which is heated electrically so that it gives out IR radiation (heat) over a whole range 
of frequencies. The IR radiation goes by a series of mirrors into the sample which is placed in 
an appropriate holder. The radiation not absorbed by the sample arrives at the detector. Modern 
IR instruments use a device called an interferometer which consists of a beam splitter and a 
pair of mirrors at right angles to one another, this produces what is called an interferogram 
from the source radiation [70]. The interferogram holds information about the intensity of all 
IR radiation at all frequencies simultaneously, which passes to the sample and then to detector. 
The interferogram that arrives at the detector can be decoded by a mathematical technique 
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called Fourier transformation, which gives the intensity of the IR radiation at each frequency 
separately. The transformation is handled by the computer and produces a graph of percentage 
transmission against wave number [71].  
The sample is placed on a sample holder which is a crystal made of diamond or germanium, 
the IR beam is directed into the sample by a mirror and it is reflected back from the upper 
surface of the sample before being guided into the detector by a second mirror, this process is 
called attenuated total reflection (ATR). In running the instrument, after switching on the 
instrument, the blank is run with no sample in place, this is to find the absorption of the air 
which must be subtracted from the sample [72]. A little sample is placed on the ATR crystal, 
less than a milligram (mg) of solid sample is required, the tool crunch is used to squash the 
sample to ensure a good contact with the surface of the crystal. For most samples, no 
preparation is required, details of the scan are entered into the computer and the spectrum of 
the sample is obtained within a few seconds. The wave numbers of the most significant peaks 
can be labelled on to the spectrum for data interpretation [70].           
1.4. Microwave formulation  
In contrast to the use of microwave radiation as an analytical tool, a comparatively large volume 
of research has been undertaken to investigate the effects (and potential benefits) of using 
microwaves in a formulation capacity. For example, it has been shown that microwave 
radiation can affect the viscosity and gelatinisation of industrially utilised starch [73], be 
applied to synthesise novel maize protein-based functional materials [74], curing composites 
[75], enhancing rates of reaction [76] and considered for biodiesel production [77]. Possibly 
the most researched area of microwave-based formulation is regarding pharmaceutical 
applications where the limited physicochemical properties of compounds can be a significant 
barrier to the development of new medicines thus requiring intervention to enhance their 
properties. Two fundamental properties of ensuring the success of a drug are solubility and 
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permeability as these will ultimately dictate drug absorption within the body and therefore 
efficacy. Microwave treatment has been shown to enhance both the physicochemical and 
pharmacokinetic properties of pharmaceutical preparations, such as the solubility of 
efonidipine hydrochloride ethanolate [78], the formation of cocrystals [79], the solubility of 
nanocomposites [80], the dissolution of gemfibrozil [81], through modifying drug release 
characteristics [82], increased yields [83] or controlling drug delivery profiles [84]. Not long 
ago, a procedure based on sustained-release solid dispersion was proposed for ibuprofen [85]. 
Microwave irradiation is a well-known method for heating and drying pharmaceutical powders 
[86]. Previous work within the Huddersfield research group has highlighted the benefits of 
using microwave processing for pharmaceutical compounds with the presence of excipients to 
create unique products including combinations of ibuprofen with stearic acid and 
polyvinylpyrrolidone along with fenofibrate and mesoporous silicas [87, 88]. An interesting, 
and very recent, application of microwave irradiation is the concept of amorphisation within 
the tablet, i.e. creating the amorphous form of the drug in its final dosage form directly before 
administration [89].  
Overall, microwave radiation has been previously employed for the analysis of compounds 
through the use of microwave differential thermal analysis (MWDTA), and separately, to 
formulate products that possess unique physicochemical properties that can be advantageous, 
especially in the pharmaceutical industry. However, as yet, there has been no consideration for 
the use of MWDTA to investigate pharmaceutical compounds that are to be subjected to 
microwave irradiation during formulation to fully understand if such a process will be suitable 
and identify the interactions that will occur.  
1.4.1. Microwave theory  
Almost twenty years ago a new technique was described for the first time, namely microwave 
differential thermal analysis (MWDTA), that combined the advantages of microwave heating 
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with the benefits of differential temperature measurement to probe the thermal properties of 
materials [90]. The features governing the successful application of microwaves in thermal 
analysis (TA) of pharmaceutical compounds and the physical principles behind it are not well 
known in the pharmaceutical industry, possibly because pharmaceutical compounds have not 
been previously studied in this way [91].      
Microwaves (MWs) are a form of electromagnetic energy found in the electromagnetic 
spectrum with a frequency ranging from 300 MHz - 300 GHz; a region that is found in between 
the radio waves and infrared waves with a wavelength from 1 cm - 1 m [92]. Microwaves have 
electric and magnetic field components (Fig. 1.4) and for most analysis related to the MW in 
the electromagnetic field, it is the electric field component that is of relevance for wave-
material interactions, the magnetic component is mainly only of relevance for interactions with 
transition metal oxides [93].    
 
Figure 1. 4. Electric and magnetic field components in microwaves [91]. 
Heating a material with the electric field component of the MW occurs due to two main 
mechanisms; which efficiently generate rapid volumetric heating (Fig. 1.5) as a result of 
microwave contact with ions or polar molecules; ionic conduction and dipole rotation [93, 94]. 
Interactions that occur as polar molecules aim to realign themselves with the speedily vibrating 
18 
 
electric field component of the microwave are a result of the dipolar polarisation mechanism 
(Fig. 1.4) [91, 93]. As the electric field vibrates, the dipole attempts to realign itself with the 
vibrating electric field and in the process, energy is lost in the form of heat during the 
aforementioned event through dielectric loss (E’’) and molecular friction. The amount of heat 
induced by this process is directly related to the capacity of the substance to align itself with 
the frequency of the applied electric field [93]. In this research, this becomes relevant for 
heating microwave absorbing compounds, such as pharmaceutical drugs and their excipients. 
An ionic conduction mechanism (Ohmic heating) is the second heating mechanism. During 
this mechanism, dissolved charged atoms (usually ions such as electrons) in a sample rotate 
back and forth under the effect of the microwave field, they then come into collision with their 
neighbouring atoms or molecules. A motion or agitation is caused as a result of the collision, 
thereby creating heat [93].  
 
Figure 1. 5. Dipolar polarisation mechanism. Dipolar molecules try to align with an oscillating 
electric field [91] 
1.4.2. Microwave heating versus conventional heating 
The limited thermal response using conventional heating is avoided using microwave heating 
as there is direct interaction of the material with microwave energy. However, more 
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importantly, microwave heating provides a unique means of investigating thermal transitions 
based on the associated changes in the dielectric properties of the materials. These thermally 
induced changes, such as melting or decomposition, are then analysed based on the microwave 
power profiles obtained [95]. In a conventional heating system, heat is transferred from the 
outside of the material by radiation, convection or conduction and is then transferred to the 
cooler part of the material by thermal conduction as illustrated in Fig. 1.6A (hotter region). This 
system of heating is inefficient, relatively slow and depends on the thermal conductivity of a 
substance. On the contrary, microwave heating transfers electromagnetic energy into heat 
energy. Rather than a form of thermal heating, MW heating can, therefore, be described as a 
form of energy conversion; as electromagnetic energy is converted into thermal energy [93]. 
Microwaves can penetrate through any material that has a dipole moment and deposit energy. 
Thus, rather than an external source of the material in conventional heating, the heat can be 
produced throughout the volume of the material. Fig. 1.6B (cooler region) illustrates this type 
of heating as the interior of the material is heated to a remarkably higher temperature than the 
exterior region, contrary to conventional heating [92].  
 
1 = hotter region 2=cooler region  
Figure 1. 6. Conventional heating (A) and microwave heating (B) highlighting the differing 








In conventional heating (Fig. 1.6A), heat is transferred from the outside of the material inwards 
by conduction. Overheating can occur on the outside whilst still maintaining a cooler inner 
region. On the contrary, for microwave heating (B), microwaves penetrate the material and heat 
volumetrically. Energy is then uniformly dissipated throughout the material [92]. The benefits 
of microwave heating compared with conventional heating include high heating efficiency, no 
overheating at the surface, rapid volumetric heating, better and rapid process control and energy 
saving. As such, this has been considered to be a useful method that could be applied for the 
drying of wet materials [95, 96].   
Microwave irradiation is a well-established technique of accelerating and improving chemical 
reactions because it provides the energy directly to the reactant. As a result, heat transfer is 
more effective than in conventional heating and the reaction can be completed in a much shorter 
period [97]. Thus, microwave irradiation is one of the best techniques for reducing the reaction 
time and obtaining a higher yield, for example in the production of biodiesel. In comparison 
with conventional heating, using microwaves improves the speed of the reaction and makes the 
separation process easier [93]. Instead of conventional heating, microwave heating has been 
utilised to change the crystalline nature of a drug as reported by Kerc and Kofler, [98] when 
felodipine and silicon dioxide were used as a model drug and excipient. Furthermore, this form 
of heating has been successfully applied in many studies including bioenergy [92] and 
biochemical processing for bioethanol production via fermentation [99].    
1.4.3. Microwave differential thermal analysis (MWDTA) 
Although the use of microwaves has broadened vastly since the discovery of its heating 
capabilities, its use in thermal analysis is not widely mentioned, other than the work of 
Karmazsin et al. [100] which led to the work of Barnes, Parkes and Bond [101] and the later 
related work of Nesbitt et al. [102]. Typically, transitions are observed using MWDTA within 
the order of 10’s or 100’s of degrees unlike in conventional thermal analysis where they are 
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observed in the order of a few degrees when using similar techniques such as DSC, making the 
transition very noticeable. Increases in sensitivity of this technique allow transitions, such as 
dehydration to be very easy to determine which is an added advantage. This is because water 
couples more strongly to microwave radiation and when the water is lost, the MW power 
required for the instrument to reach the setpoint changes remarkably. This is, therefore, a very 
useful technique, for example for the identification of water in pharmaceutical samples [103]. 
TA techniques are well-established methods for the analysis and characterisation of a wide 
range of materials. These analyses have seen a rapid growth in the range of their applications 
in recent years, particularly in the field of material sciences, nanotechnology, drug discovery 
and polymers. A limited field of thermal analysis involves microwave – based techniques [95, 
104, 105].  Clearly, there is a need to develop an understanding of how changes in such 
materials affect their interaction with microwave energy. With the advances detailed in this 
research, MWDTA is considered to be potentially suitable not only to monitor the changes 
mentioned earlier but also to provide data comparative to conventional thermal techniques such 
as DSC and DTA.    
The ability to provide information on thermally induced transformations in materials is one 
particular benefit of the microwave technique for studying all forms of thermal reactions and 
processing. When a material is subjected to microwave radiation there are two important 
parameters that dictate the nature of the interaction, namely the dielectric constant (ε′) and the 
dielectric loss factor (ε′′). The former considers the way a material is polarised by the electric 
field and the latter the conversion from radiation to heat [95]. The relative extent of microwave 
heating of any given material can be determined by a term called the ‘loss tangent’ (tan δ) 
defined as the ability of a material to absorb and convert electromagnetic energy into heat at a 
given frequency and temperature. The loss tangent is also the ratio of dielectric constant and 
dielectric loss expressed by the equation: 
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tan δ = ε′′/ ε′  
Where ε’’ is the dielectric loss factor and ε’ is the dielectric constant of the material. Materials 
can be classified into three types according to their interactions with microwaves:  microwave 
- insulators/transparent (e.g. ceramics and glass) where the microwaves pass through the 
material without any losses, microwave-conducting (e.g. metals) in which the microwave does 
not penetrate and instead is reflected, or microwave-absorbing (e.g. polar molecules such as 
water and drugs) where the microwaves are absorbed and converted into heat [106]. In general, 
materials can be classified as high (tan > 0.5), medium (0.1 – 0.5) and low microwave 
absorbing (< 0.1) compounds. A reaction medium with high tan δ is needed for rapid heating 
[91]. A low-value tan δ does not preclude material from being used in a microwave-heated 
reaction; additives can be used to achieve rapid heating of the material of low tan δ value. For 
example, poorly coupling compounds e.g. pharmaceutical drugs and excipients can be mixed 
with a subsector (e.g. alumina or SiC) or used with a ‘heat assisted’ sample cell (Fig.1.10) [104, 
106]. Materials with higher values of tan δ will attain higher temperatures than those with lower 
values of tan δ, leading to a thermal gradient within the material that is unique to microwave 
heating. The tan δ is dependent on both the temperature of the sample and the frequency of the 
microwave radiation [104].           
This form of analysis has been successfully applied to a range of materials including 
decompositions, dehydration and phase changes [95] and can provide qualitative and 
quantitative information on solid-state processes [104]. Furthermore, MWDTA can make a 
valuable contribution to the investigation of the so-called ‘microwave effect’, these are 
anomalies that occur when certain materials are heated in a microwave field [107] as well as 
reveal fine detail through the use of derivative plots of either the applied power or the 
temperature [101].  In recent years a variety of studies have investigated the application of 
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MWDTA to both a range of materials, such as ceramics [108], and a range of more complex 
analytical systems [102].  
1.4.4. Thermal runaway  
One disadvantage emerges from the way that the terms ε' and ε" (and subsequently tan δ) are 
reliant both on the substance and crucially, the temperature. For a few substances, their capacity 
to couple with microwave energy can increase sharply with temperature, potentially leading to 
unwanted ‘thermal runaway’ effects (Fig. 1.7). MWDTA is ideally suited to investigate this 
phenomenon. A large number of solids have low dielectric losses, and these losses increase 
with temperature. As the temperature increases, tan δ rapidly increases and the temperature 
then rises exponentially. The temperature can only be stabilised if heat can be removed at a rate 
that equals the rise, or by restricting the microwave power [103]. 
 
Figure 1. 7. Illustration of thermal runaway under microwave heating i.e. where the temperature 
of the material rises rapidly even though the amount of microwave power is unchanged [58]  
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Due to the chance of thermal runaway and the potential heating abilities of microwaves, the 
actual amount of energy applied if the sample is heated to a higher temperature can destroy the 
sample. Microwaves do not have adverse effects on the actual material being heated, they just 
facilitate this process, allowing a faster and a more uniform heating process [58].   
1.4.5. Heating of poorly coupling materials 
Various materials do not heat by any of the systems discussed already and therefore require an 
assistant medium in order to raise their temperature when only utilising microwaves as a 
heating source. The medium most normally used in these cases is known as a susceptor and is 
a material which is able to absorb electromagnetic radiation and convert it into heat resulting 
in the surrounding area heating via conduction. Commonly, the required amount of susceptor 
is mixed with the material of interest creating countless heating sources or ‘intimate furnaces’ 
which heat the material from several points within and around its volume [103].  
The advantage of this arrangement is, although the sample is heating via conduction, (as in a 
conventional method) the material and heating sources are touching therefore nearly 
eliminating thermal mass. In addition to this, the applied power or heating rate required to heat 
a material can be modified by either adding or removing susceptible material. The main 
disadvantage of this technique occurs if the material is not thoroughly mixed or the percentage 
of the susceptor is too high. As a result, localised hot spots can occur prompting thermal 
runaway, and/or inaccurate temperature measurements as illustrated in Fig. 1.4 [103]. 
1.4.6. Description of MWDTA instrument  
The apparatus (Fig. 1.8), described in detail elsewhere [95], is based on a single mode system 
which is tuned to set up a standing wave with a maximum in the electric field component (E) 




Figure 1. 8. Schematic diagram of MWDTA instrument 
The microwave power, which can be varied in 1 W steps to 300 W (Fig. 1.8), is supplied by a 
very stable switch-mode, narrowband 2.45 GHz generator manufactured by Sairem, the 
generator is under computer control. The microwaves are passed from the generator, via a 
water-cooled circulator used to absorb any reflected power, to a launcher incorporated into a 
brass waveguide (Type 340, internal dimensions 86 mm_43 mm) to prevent damage to the 
magnetron by reflected waves. The sample is located in a section of the waveguide which has 
four circular ports, the two larger of which are vertical (diameter 50 mm) and allow insertion 
and removal of the sample cell, while the two smaller are horizontal (diameter 15 mm) and 






Figure 1. 9. Schematic diagram of the microwave components of the MWDTA instrument 
[104]. 
Tuning is supplied by three components. Firstly, a `short circuit' or `plunge tuner' which can 
be utilised to alter the internal length of the waveguide, secondly, a variable iris, consisting of 
a thin copper sheet with a rectangular orifice (50 mm_25 mm) which can be traversed over a 
range of 6 cm, and thirdly an automated four-stub tuner. This latter device provides continuous 
`fine-tuning' via the vertical movement of four brass rods in the waveguide and compensates 
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Figure 1. 10. Heat-Assisted / MWDTA Sample cell – design  [104]. 
1.5. Previous thermal analysis (TA) techniques 
Enhancing research and development throughput is one of the biggest challenges facing the 
pharmaceutical industry. The pharmaceutical industry depends heavily on thermal analysis 
(TA), along with X-ray diffraction (XRD) and spectroscopic methods to perform in-depth 
physical and chemical characterisations of active pharmaceutical ingredients (API) as well as 
inactive ingredients (excipients) that go into pharmaceutical products. Solid-state 
characterisation lays the basis for formulation development and assists in science-driven 
rational decisions in the development of a stable drug product that can be manufactured with a 
reasonable shelf-life. TA techniques allow one to deduce physical and chemical properties as 
a function of temperature [109]. Differential scanning calorimetry (DSC), thermal (hot stage) 
microscopy (HSM), differential thermal analysis (DTA) and thermogravimetric analysis 
(TGA) are the most widely used thermal analytical methods for pharmaceuticals. A collection 
and correlation of data from complementary techniques are often required (i.e. not just a single 
Heat-Assisted / MWTA Cell – the benefits. 
 Sample sizes: 5 to 50 mg. 
 Cell body contributes most (but not all) 
of the heating → any sample can be 
analysed.  




analytical technique) to draw conclusions, in order to gain an in-depth understanding of the 
nature of thermal transitions [110].  
1.5.1 Differential thermal analysis (DTA) 
DTA is a thermal technique similar to DSC, it is used to measure the temperature difference 
between samples under study and an inert reference substance while both are heated at the same 
linear rate [111, 112]. The temperature difference (∆T) is plotted as a function of sample 
temperature or time. The DTA signal provides information on the physical and chemical 
transformations of the sample such as crystallisation, sublimation, dehydration, decomposition 
and melting [113]. It also allows the detection of an exothermic or endothermic event.  
 
Figure 1. 11. Schematic of a typical DTA instrument [109] 
In DTA, the temperature is continuously compared between the reference and the sample. 
Experimentally, this is achieved using a single heat source, which contains a sample holder that 
holds two similar and symmetrical areas for sample placement. The thermocouples (or any 
other temperature measuring device) in these areas are similar. The sample under study is 
placed in one holder, and a thermally inert reference substance (usually silicon carbide, empty 
pan or alumina) is placed in the other, then both holders are subjected to an equivalent 
temperature heating or cooling rate. The difference in temperature (∆T) between the sample 
Sample  Reference  
Thermocouples  




and the reference is measured by two thermocouples (Fig. 1.11) that are coupled back to back 
in the sample and in an inert reference as a function of time or temperature [109].   
1.5.2 Differential scanning calorimetry (DSC) 
DSC is the most commonly employed thermal analysis method due to its simplicity, speed and 
availability. It works in a similar way to DTA, except that it is a calorimetric method so the 
difference in temperature is not recorded but rather energy. DSC measures the heat flow that 
occurs in a sample under study when the sample is heated, held isothermally or cooled at 
constant temperature [114]. This method provides quantitative information on physical 
transitions and chemical reactions a substance may undergo, including; melting, crystallisation 
behaviour and supercooling, the glass transition of amorphous materials, decomposition, 
reaction enthalpies and quantification through peak areas [109, 114, 115]. To construct DSC 
measurements, the sample is placed into a small aluminium crucible. The reference is also an 
aluminium pan usually empty, they both have pierced lids [116]. To have good reproducibility 
and to protect the measuring cell, nitrogen, air or helium are usually used as purging gas at the 
rate of about 50 mL/min. The sample size is usually 4 to 10 mg and the temperature range up 
to about 600 oC [109].  
There are variations in the type of DSC instruments available and in this research; a heat-flux 
DSC was used. In the heat-flux system, the difference in heat flow is measured as the sample 
and the reference are heated in one furnace and heat flows into the sample and reference 
through thermocouples [115].             
1.5.3 Thermogravimetric analysis (TGA) 
TGA is another thermal technique in which the difference in weight of a sample is measured 
as a function of time or sample temperature as it is subjected to a controlled temperature 
program in a controlled atmosphere [117]. Based on the rate at which sample mass changes 
with respect to time or temperature, a differential thermogravimetric (DTGA) curve can be 
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obtained [118]. A mass difference occurs when the sample under study loses material in one 
of several ways or interacts with the surrounding atmosphere. This produces steps in the TGA 
curve or peaks in the DTGA curve. These effects can cause the sample to lose or gain mass and 
produce steps in the curve. Such processes include oxidation of metals in oxygen or air, 
oxidative decomposition of organic substances in air or oxygen [109], thermal decomposition 
of a sample in an inert atmosphere which is also known as pyrolysis [118, 119].  
TGA is mostly utilised to investigate degradation temperatures, absorbed content of materials, 
levels of inorganic and organic parts contained in a material and also analyse solvent residue. 
A thermobalance is used in TGA, with this type of balance the position of the sample in the 
furnace remains the same even if the weight changes [109].  
1.5.4. Hot stage microscopy (HSM) 
The best properties of microscopy and thermal analysis have been combined by HSM as an 
analytical technique to facilitate the characterisation of the physical properties of a substance 
as a function of temperature. The significance of supporting thermal analysis techniques has 
been previously reported [120], and with the coupling of HSM to the aforementioned thermal 
techniques, it offers greater possibilities for the characterisation of materials due to high-
resolution colour cameras and image manipulation software that the technique possesses [121]. 
In the pharmaceutical industry, HSM is used to verify transitions observed using other thermal 
techniques. Solid-state characterisation of bulk drugs can be investigated using HSM [122], 
dehydration in which bubbles emanate from the crystals, evolution of crystal forms, particle 
characteristics such as shape and size, phase transitions, decomposition (if discolouration 
occurs or gases evolved),  and other physio-chemical properties can all be observed using HSM 
[110, 123].   
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In summary, all current conventional TA methods use electrical furnaces as a source of heating 
where the heat passes from the furnace wall to the surface then through the sample by 
conduction. Unfortunately, this process of heat transfer produces temperature gradients within 
the sample that reduces the resolution of data produced. This project seeks to overcome this 
drawback through the application of microwave differential thermal analysis (MWDTA) to 
yield more useful and more reliable thermal analysis data for pharmaceutical compounds.    
1.6. Transarterial Chemoembolisation (TACE) and DC BeadTM 
The 5th most widespread cancer is hepatocellular carcinoma (HCC) with a global occurrence 
of some 500,000 new cases per year, three quarters of those cases being in Asia. The type of 
therapy that a patient will receive is determined according to a staging system classified by the 
development of the cancer [124]. At the present time, the therapy of choice for sufferers at the 
early stage is liver transplant or resection of the tumour. Resection is no longer considered for 
patients with intermediate or advance disease and lots of alternative therapies including 
chemotherapy, palliative or embolisation treatments are available [125].  Due to their quality 
of life supremacy, less-invasive procedures are finding favour and this includes methods such 
as radiofrequency, cryoablation and transarterial chemoembolisation (TACE). Among these 
techniques, two new clinical trials at random have reveal that TACE results in remarkable 
survival benefits over palliative care in the treatment of intermediate stage HCC in both Asian 
and European patient populations [126, 127].        
For over 30 years, transarterial chemoembolisation (TACE) has been practiced in patients [128] 
and explains the delivery target of chemotherapeutic agents followed by subsequent injection 
of embolic particles to hypervascular liver tumours through a catheter placed in the tumour 
supplying arteries [129, 130]. TACE can be categorised into conventional TACE (cTACE) and 
drug-eluting bead TACE (DEB-TACE). cTACE is very often carried out by emulsifying 
chemotherapeutic agents with Lipiodol and then infusing this emulsion through the catheter 
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prior to distribution of embolic substance, while on the contrary, a single distribution system 
of drug loadable microspheres is used by DEB-TACE to achieve co-delivery of drug and 
embolic agent, which both block the chosen vessels and provides controlled drug release [131, 
132]. Drug eluting beads have emerged as a substitute to cTACE more recently [133].  
The most commonly used and well characterised DEB is DC Bead, which is a microspherical, 
cleared drug delivery embolisation device (DDED) used for the treatment of hypervascular 
tumours as well as arterio-venous malformations [124, 128, 134]. The device was developed 
in 2002 and manufactured by Biocompatibles UK Ltd, for the advancement of diagnosis and 
treatment of cancer, with an objective of standardising the TACE procedure for patient benefits 
and also providing handling advantages [128].        
1.6.1. Composition of DC Bead  
The DC bead is composed of a sulfonate-modified polyvinyl alcohol hydrogel, which permits 
subsequent delivery and loading of a variety of positively charged chemotherapeutic drugs 
including irinotecan, doxorubicin and mitoxantrone [124, 135-137]. The beads are available in 
numerous sizes ranging from 100 – 300 µm, 300 – 500 µm and 500 – 700 µm with the former 
two being the most popular for the embolisation of tumours [135]. Lewis et al., reported a rapid 
uptake of doxorubicin by the smallest bead size (100 – 300 µm), in which a complete loading 
was attained before the first sampling point at 10 min. The uptake is slower with increasing 
bead size as a result of a decrease in bead surface area as the size increases. Thus, drug loading 
is proportional to the surface area of bead [124]. The beads are supplied in a 10 mL coded glass 
vial with a rubber stopper and aluminium cap as shown in Figure 1.10. Each vial contains 6 
mL of packing solution (phosphate buffer saline) and 2 mL of beads, intended for one patient 




Figure 1. 12. Available DC beadTM with their size ranges and colour [134]. 
1.6.2. DC Bead Chemistry 
The drug of choice is taken up by the bead via an ion exchange mechanism [137]. The beads 
change colour when loaded with certain chromatic drugs as illustrated in Figure 1.12. The high-
water content (> 95 %) beads, enables the diffusion of water soluble drugs into the network 
structure [132]. When the drug molecule is positively charged, it may interact with the 
sulfonate groups reversibly by an ion exchange mechanism to take over the position of the 
sodium counter ion from the 2-acrylamido-2-methyl propane sulfonate (AMPS) and secure the 




Figure 1. 13. DC Bead™ unloaded (A) and DC Bead™ loaded with doxorubicin (Dox) 
illustrating the intense colour change from blue to red (B) [134]  
The proof of this interaction is illustrated in Figure 1.14, which demonstrates clearly the 
displacement of water from the hydrogel shell. Initially the beads enlarge in size as they are 
reconstituted in water prior to drug loading, but then decrease as water is replaced from the 
hydrogel and the drug molecule is sequestered from the solution [124, 138]. The water content 
in the hydrogel decreases with increasing drug content during loading, which is accompanied 
by an increase in resistance to compression force of the hydrogels. The water content and the 
compressibility were proven by Lewis et al. [124] to return to the level of the unloaded DC 
bead upon elution of all drug from the delivery device.     
A   




Figure 1. 14. DC beadTM mode of loading with doxorubicin (dox) and subsequent displacement 
of water through an ion exchange mechanism [134]. 
1.6.3. Drug loading and elution  
Due to the relative increase in the surface area to volume ratio, the rate of intake of a particular 
drug increases with decreasing bead size. As seen in Figure 1.13A, when the drug is isolated 
into the structure of the bead, it is likely to change colour if the drug itself is coloured, a good 
example is seen in Figure 1.14 for doxorubicin which is red or irinotecan which is straw yellow, 
yielding a turquoise colour and mitoxantrone which is intense blue when loaded into the blue 
beads as Lewis et al. reported [132].  
The process of extracting the drug from the bead may therefore be expressed as a function of 
not only the composition and ionic strength of the elution medium but also dependent upon the 
type and degree of drug-bead and drug-drug interactions. Again, the bead size is an essential 
determinant of the rate of elution, as the surface area to volume ratio comes into play. The 
release rate can be determined by a variety of different elution methods in vitro; the easiest one 
is the USP II equipment in which all of the drug can be eluted very quickly by selection of a 
suitable elution medium under sink conditions (Figure 1.15). This apparatus, while essential 
from a development of the product and quality control perspective, did not offer an insight into 
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how quickly the drug might be released in vivo [132]. Other different types of apparatus 
including flow through cells (USP IV) have been reported, which have been illustrated by in-
vitro-in vivo (IVIVC) correlations to better estimate the fraction of drug that is released into 
the systematic circulation following drug eluting bead (DEB) administration [137, 139].           
 
Figure 1. 15. USP Type II dissolution apparatus [134] 
It was reported that using high performance liquid chromatography (HPLC), doxorubicin (dox) 
does not change chemical structure before and after loading, i.e. the drug does not degrade. 
Moreover, it was found that dox elutes in phosphate buffer (PBS) and plasma, but does not 
release in water as the rate of release is dependent upon the concentration of salt, i.e. a far more 
substantial amount of drug was eluted from beads at higher salt concentrations [137].       
1.7. Bound water analysis  
Drug-eluting beads (DEBs) are known to contain a high percentage of water, essential to their 
physical structure and therefore suitability to be used in drug delivery. Traditionally the water 
content within such beads is calculated based upon a simple size decrease calculation or solid 
content measurement. This process is based upon several assumptions, such as that the volume 
Paddle   
DEBs  
Vessel   
Sample  
Port   
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decrease is a consequence of water content and is potentially neither accurate nor precise. 
Furthermore, the water within the beads can be considered to be in one of three forms with 
regards to its interaction with the solid polymer content: tightly bound, loosely bound or 
unbound. Until now it has not been possible to easily quantify the total water content as well 
as these three individual amounts, thus prompting the method developed within this study.  
Among several strategies to calculate the amount of water content within polymer hydrogels 
[140], particular attention was paid to thermal analysis techniques such as differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA), since the behaviour of the water 
content can easily be identified by these methods through phase transitions [141]. Through 
vaporisation, thermogravimetric analysis can be used to calculate the total water content in a 
hydrogel [142], while using DSC, it was hypothesised that the three forms of water (tightly 
bound, loosely bound or unbound with regards to their interaction with the solid polymer 
content) can be calculated quantitatively from the enthalpies of melting and crystallisation of 
water associated with the polymer [140]. Besides thermal methods, interactions between water 
and different hydrogels have been investigated using nuclear magnetic resonance (NMR) 
[143], spectroscopic techniques [144, 145], dielectric methods [146], viscometry [147] and by 
means of computer simulations as carried out by Mazeau and Rinaudo [148]. 
In summary, several strategies have been adopted to estimate the amount of bound water within 
polymers including poly (2-methacryloyloxethyl phosphorylcholine) (PMPC), in this study, 
we pay particular attention to DC beads as a large number of studies have been concerned with 
PMPC co-polymers. 
1.8. Project aims 
This research considers the suitability of using Syloid® silica excipients as a novel formulation 
system to enhance the extent and rate of dissolution of model drugs and investigate the 
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application of thermal analysis, particularly MWDTA, on such compounds. A secondary aim 
is to consider the potential of thermal analysis to investigate water content within bead-based 
formulations. This will be approached based on the following objectives. 
1. To investigate the suitability of using three types of Syloid® silica-based excipients to 
quantify their potential to enhance the rate of dissolution of drugs and determine the causes 
of any enhancements observed. These forms of silicas have a highly developed network of 
mesopores that provide access to the large surface area, a desirable pore diameter, pore 
volume and surface morphologies.   
2. To use thermal analysis, particularly MWDTA on model pharmaceutical compounds to 
investigate the potential application of this form of thermal analysis on such compounds 
as an indicator of the suitability of microwave-based formulation methods.  
3. As previously discussed, polymers such as those considered in this study contain three 
distinct types of water. Little is known about their relative ratios, yet their composition 
will undoubtedly affect their behaviour. Therefore, the third aim of this study is to portray 
the potential of thermal analysis, particularly MWDTA, TGA and DSC to quantify and 
characterise the water present within polymer beads, including the incorporation of model 
drug to exemplify the effect of drugs on the relative water profiles. 
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Chapter 2: Materials and methods  
2.1 Materials 
Indomethacin (γ-form), benzocaine (BZ), D-Mannitol (D-man), haloperidol (Halo), ibuprofen 
(Ibu), ketoprofen (Keto), phenylbutazone (PhB), naproxen (NPX), β-Cyclodextrin (β-CD or 
Beta-CD), stearic acid (SA), potassium phosphate dibasic and potassium phosphate monobasic 
(both ≥ 99 %) were purchased from Sigma Aldrich (Dorset, UK). Imipramine hydrochloride 
(Imi) (˃99 %) was purchased from Tokyo Chemical Industry Ltd. (Oxford, UK). Polymer 
beads 70-150 µm (DC BeadM1™) were kindly donated by Biocompatible UK Ltd., a BTG 
International group company (Camberley, UK). Syloid® silicas (AL-1 FP, XDP 3050 and XDP 
3150) were kindly donated by Glantreo Ltd, Cork, Ireland and W. R. Grace & Co, Maryland, 
USA. These compounds were selected based on their dielectric properties (dielectric constant, 
dielectric loss and loss tangent) as materials interact differently with the microwaves based on 
these properties. The higher the loss tangent the better the conversion of microwave energy 
into heat and the more effective the microwave heating. These compounds were assumed to 
have either a high, medium or low tangent (i.e. tan ˃ 0.5, tan ˃ 0.1 – 0.5 and tan ˂ 0.1). Table 
2.1 provides a summary of the physicochemical properties of the Syloid® silicas, the data 
presented was determined using nitrogen gas sorption isotherms. These were measured at 77 
K using a Micromeritics TriStar II surface area analyser (Micromeritics, Norcross, GA, USA). 
Samples were pre-treated by heating at 200 °C under nitrogen for 12 hours. The surface area 
was measured using the Brunauer-Emmett-Teller (BET) method. The pore volume and pore 
diameter data was calculated using the Barrett, Joyner and Halenda (BJH) method [149]. 
Specific surface areas were calculated from the measured relative pressure in the range of P/P0 
= 0.01 to P/P0 = 0.3. Mesoporous volumes were estimated from the volume of nitrogen 
adsorbed after the micropores have been filled until after condensation into the mesopores was 
complete. Of particular interest is the range of surface areas and pore volumes exhibited by the 
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three Syloid® silicas as based on previous research, such properties may influence dissolution, 
for example, pore size has been known to effect drug release profiles for other mesoporous 
systems [150]. The materials were stored appropriately to avoid degradation and de-ionised 
water was used throughout the experiments. Physicochemical properties, along with chemical 
structures, are presented in Table 2.2. 












AL-1 FP 7.5 – 10 Irregular 605 0.40 26 
Syloid XDP 3050 48 – 66 Irregular 320 1.70 229 
Syloid XDP 3150 120 – 170 Irregular 320 1.70 200 
 
Table 2. 2: Physicochemical properties of the chemicals used  
Phenylbutazone  Structure 
Abbreviation  PhB  
Molecular weight 308.37 g mol-1 
Melting point 105 – 108 oC 
Log P 3.16 
Charge  Neutral  
pKa 4.50 
Solubility 0.034 mg/mL at 23 oC 







Abbreviation  IMC  
Molecular weight 357.79 g mol-1 
Melting point 158 – 161 oC 
Log P 4.27 
Charge  Anionic  
pKa 4.50  
Solubility  0.00094 mg/mL at 25 oC 
BCS  Class II 
Benzocaine  
Abbreviation  BZ  
Molecular weight 165.19 g mol-1 
Melting point 88 – 92 oC 
Log P 1.95 
Charge  Cationic  
pKa 2.80 
Solubility  1.310 mg/mL at 25 oC 












Abbreviation  IBU  
Molecular weight 206.28 g mol-1 
Melting point 75 – 78 oC 
Log P 3.72 
Charge  Anionic  
pKa 4.40 
Solubility  0.021 mg/mL at 25 oC 
BCS Class II 
Ketoprofen  
Abbreviation  KETO  
Molecular weight 254.28 g mol-1 
Melting point 91 – 93 oC 
Log P 2.81 
Charge  Anionic  
pKa 4.45 
Solubility  0.051 mg/mL at 22 oC 












Abbreviation  HALO  
Molecular weight 357.86 g mol-1 
Melting point 152 oC  
Log P 4.30 
Charge  Cationic  
pKa 8.66 
Solubility  0.014 mg/mL at 25 oC 
BCS Class II 
Imipramine hydrochloride 
Abbreviation  IMI  
Molecular weight 316.87 g mol-1 
Melting point 189 oC 
Log P 4.80 
Charge  Cationic  
pKa 9.20 
Solubility  0.47 mg/mL at 25 oC 












Abbreviation  NPX  
Molecular weight 230.26 g mol-1 
Melting point 154 – 156 0C 
Log P 3.18 
Charge  Anionic  
pKa 4.30 
Solubility  0.016 mg/mL at 25 oC 
BCS  Class II 
Stearic acid  
Abbreviation  SA   
Molecular weight 284.48 g mol-1 
Melting point 67 – 70 0C 
Log P 8.22 
Charge  Anionic  
D-mannitol  
Abbreviation  D-MAN  
Molecular weight 182.17 g mol-1 
Melting point 165 – 167 0C 
Log P -3.10 








Abbreviation  ΒETA-CD  
Molecular weight 1134.98 g mol-1 
Melting point 290 0C 
Log P -2.3 
Charge  Neutral  
Structure, molecular weight, melting point, dissociation constants, solubility  and Log P were 
generated from chemspider [152, 153].  
The majority of drugs are either weak organic acids or weak organic bases or their salt. The 
degree to which these compounds are ionised in solution is highly dependent on the pH. 
Phenylbutazone and indomethacin have low aqueous solubility because they are weak acids 
with pKa values falling in the range of 4.50 – 5.0 while the pKa of imipramine is 9.20, a weaker 
acid than phenylbutazone and imipramine. These compounds released hydrogen ions (H+) upon 
dissociation. The more H+ are released, the more acidic the solution becomes, and this will 
inhibit the solubility of these drugs because weak acids dissolve to a greater extent when in 
mild basic conditions. A phosphate buffer pH 7.0 was used to improve the solubility of these 
compounds because acidic buffers may lead to slowing down of drug release [154]. Silica 
matrices are freely soluble at a pH 5.0 – 8.0, whereas some polymer matrices such as Eudragit® 
polymer is only soluble in an acid environment up to pH 5.0 [155]. The solubility is pH 
dependent and increases with increasing pH, this can be related by the following equations: 
pKa = -logKa                           (1.1) 
Ka = [H+] [A-] / [HA]             (1.2) 
[H+] = Hydrogen ions  
[A-] = Ionised drug 




2.2.1 Preparation of physical mixtures of drugs- silicas 
Physical mixtures of phenylbutazone, were prepared by mixing the drug with Syloid® silica 
XDP 3050 in a Turbula mixer (Turbula T10B) for 10 min at 72 revs per min. Different ratios 
of drug: silica (1:1, 2:1, and 1:3) were prepared for comparison. This process was repeated with 
the replacement of XDP 3050 with XDP 3150 and AL-1 FP to produce a total of three unique 
drug-Syloid® silica mixtures. The procedure was repeated for indomethacin and imipramine 
with the same silicas at the same ratios of 1:1, 2:1, and 1:3 drugs to excipient mass ratio. The 
reason for these ratios was to investigate solid-state interactions between the drugs and 
excipients because the comparison of thermal curves of single components with their physical 
mixtures will provide an insight into the solid-state interaction, behaviour and modification of 
the resultant products compared with the components as a consequence of the method utilised 
for complex preparation. The powders were stored in screw-capped glass vials in a desiccator 
until required after the mixing process. 
2.2.2. Microwave formulation 
A known mass (30 - 80 mg) of the physically mixed phenylbutazone, indomethacin and 
imipramine with syloid XDP 3050 at 1:1, 2:1 and 1:3 drugs to excipient mass ratios were 
transferred into a quartz crucible and placed in the microwave. The microwave heating system 
was operated and controlled by software previously published [95]. The software was set to 
continuously modify the microwave power such that the samples were heated at 5 oC/min to 
the melting temperature of each drug from 25 to 160 oC or from 25 – 200 oC (as exemplified 
in Fig. 2.1 for indomethacin), depending upon the sample under analysis. The formulations 
were held isothermally for 5 min and then cooled over a period of 60 – 80 min under an air 
atmosphere utilising a microwave power of 30 to 45 W. This process was repeated with the 
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replacement of XDP 3050 with XDP 3150 and AL-1 FP to produce a total of three unique drug-
Syloid® silica formulations at the same ratios of 1:1, 2:1, and 1:3 drugs to excipient.        
 
Figure 2. 1. An example of the temperature and power profile for microwave formulation of 
indomethacin and Syloid® silica XDP 3050 (1:1).  
2.3 Characterisation methods 
2.3.1 In vitro dissolution studies  
To assess drug release from the Syloid® silica formulations, dissolution analysis was carried 
out using the USP type II (paddle method). This was a fully automated assembly, comprising 
a dissolution bath (Pharmatest DT 70), peristaltic pump and UV visible spectrophotometer 
(Cecil 3021, series 3000). Formulated samples with a total drug content (based upon suitable 
calibrations using calibration data) of 22.50 mg for phenylbutazone, 21.60 mg for indomethacin 
and 54.0 mg for imipramine were placed in 900 mL of pH 7.0 phosphate buffer, stirred at 75 
rpm and at 37.0 ± 0.5 ºC, maintaining sink conditions throughout the duration of the 
experiment. Samples were taken by an auto-sampling system every 5 min equipped with µm 








































by UV spectrophotometry (set at a wavelength (λ) of 282, 280 and 284 nm for PhB, IMC and 
Imi) to calculate the drug concentration released using a standard calibration plot for the drugs, 
as exemplified in Figure 2.2. All the samples were analysed in triplicate to determine mean 
drug release percentages and associated error limits. Drug release from Syloid® silica 
formulations were compared with pure drugs for comparison.    
 
Figure 2. 2. Dissolution apparatus used for analysing formulations. 
2.4 Solid state characterisation  
2.4.1 Differential scanning calorimetry (DSC) for solid-state characterisation  
Differential scanning calorimetry (DSC) was performed using a Mettler Toledo DSC 1 
equipped with chiller cooling apparatus. Samples of pure drugs, physical mixtures as well as 
their formulations were scanned individually using a mass ranging from 4 to 10 mg in sealed 
aluminium pans heated at a rate of 10 °C/min under a nitrogen flow of 80 mL/min from 25 to 
160 °C or from 25 to 200 °C depending upon the sample under analysis. The resultant profiles 
were obtaind, analysed and compared. 
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2.4.2 X-ray diffraction (XRD) 
Powder X-ray diffraction data were collected on a Bruker D2-Phaser instrument equipped with 
a Cu Kα1 radiation source at 30 kV and 10 mA current at a scanning range of 5 – 100 for 4 
min. The drugs and excipients were scanned individually followed by their physical mixtures 
and formulations. Diffraction patterns were obtained and compared.  
2.4.3 Fourier transform infrared (FT-IR) 
For stability, functional group identification, drug-drug, and drug-excipient bonding 
information, a Nicolet-380 Fourier Transform Infrared spectrometer (FT-IR) with an ATR 
crystal was used to record the infrared spectrum of pure drugs and their formulations. Powdered 
samples were placed directly onto the diamond crystal and the anvil lowered to ensure that 
samples were in full contact with the diamond. Each spectrum was obtained in the range of 400 
– 4000 cm-1 with 2 cm-1 resolution.  
2.4.4 Scanning electron microscopy (SEM) 
The morphology of the prepared samples was characterised using scanning electron 
microscopy (SEM), (JEOL JSM-6060LV, Japan) with gold-plating using a sputter coater 
(SC7620) prior to imaging. The procedure involved mounting the samples to a specimen stub 
and coating the surface of the material in an ultrathin layer of gold to inhibit accumulation of 
electrostatic charges, making the surface of the sample electrically conductive.  
2.5. Preparation of binary mixtures of drugs-excipients  
Two compounds were selected for further analysis, namely benzocaine, and indomethacin, 
prepared along with the four distinct excipients (XDP 3050, D-man, Beta-CD and SA). 
Initially, a total mass of 500 mg benzocaine (BZ) and 500 mg Syloid® XDP 3050 silica was 
transferred into a 25 mL glass jar, i.e. to create a 1:1 (BZ: XDP) mixture. The sample was 
placed in a Turbula mixer (Turbula T10B) for 10 min at 72 rpm to achieve a homogeneous 
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mixture a+nd then removed and allowed to settle for 2 min. The procedure was repeated for 
the same mass of drug with a further three excipients: β-CD, D-man and SA, at the same ratio 
of 1:1 (BZ: β-CD, BZ:D-man and BZ:SA) drug to excipient mass ratio. This process was 
repeated with the replacement of BZ with Indo. This ratio was selected to maximise observable 
changes in the behaviour of the resultant products compared with the components. 
2.5.1. Microwave differential thermal analysis (MWDTA) of pharmaceutical compounds 
Microwave thermal analysis of benzocaine (BZ), haloperidol, ibuprofen, indomethacin, 
ketoprofen, naproxen, imipramine and phenylbutazone, together with binary mixtures of 
benzocaine (BZ), and IMC with four excipients, β-cyclodextrin, D-mannitol, Syloid XDP 
(3050) and stearic acid, were performed using a known amount of each sample (30–90 mg) 
using a system previously published [104]. A known mass of each sample was placed into a 
quartz cell and heated at 5 °C min−1 from 25 to 160 °C or from 25 to 200 °C, depending upon 
the sample under analysis. The sample was held isothermally for 5 min and then cooled over 
a period of 70–90 min. All experiments were carried out under an air atmosphere utilising a 
microwave power of 30 W. 
2.5.2 Differential scanning calorimetry (DSC)  
DSC analysis was conducted using a DSC 1 apparatus (Mettler Toledo) containing 5–8 mg 
samples in sealed aluminium pans. Samples were heated at a scanning rate of 10 °C min−1 
under a nitrogen flow of 80 mL min−1 from 25 to 160 °C or from 25 to 200 °C, depending 
upon the sample, and then cooled to 30 °C. The eight model pharmaceutical compounds were 
analysed individually, as well as the binary mixtures of BZ, and IMC with the four excipients 
(BZ: XDP, BZ: β-CD, BZ:D-man and BZ:SA), the resultant curves were analysed and data 
compared with that obtained with MWDTA and HSM. 
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2.5.3 Hot-stage microscopy (HSM)  
Particle morphology and visible changes (as a consequence of heating samples) were 
examined using hot-stage microscopy (HSM). An Olympus (SZ-CTV, Japan) polarising light 
microscope equipped with in-house constructed hot stage and software was used. A small 
amount of each sample was transferred into a quartz crucible, placed on the hot stage and 
heated at 5 °C min−1 from 25 to 160 °C or from 25 to 200 °C, depending upon the sample, and 
then cooled to 30 °C. Photomicrographs of the samples were collected at temperatures 
corresponding to any changes noticed in the sample as a function of temperature under a 
magnification of 4.5. 
2.6. Imipramine loading into beads 
Polymer beads were supplied in saline solution and the majority of the packing salt solution 
was removed with a pipette to leave a slurry of beads. The beads were then washed five times 
with 5 mL deionised water per wash. The washed beads were centrifuged in a 10 mL screw 
cap, plastic tube at 3000 rpm for 5 minutes, allowed to settle for 2 minutes, and excess water 
was removed by first using a syringe followed by filter paper to remove residual surface water. 
Imipramine hydrochloride solution (10 mg/mL) was added into samples of beads under study 
with a volume of 1 mL, 2.5 mL, and 5 mL to target 10, 25, and 50 mg/mL loadings via an ion 
exchange mechanism to consider approximately below, equal and above saturation followed 
by occasional gentle agitation and left for 8 hours.  The residual solution was diluted, and the 
UV absorbance was measured using UV-Vis spectrophotometry at 250 nm and compared with 
a standard plot to determine the amount of drug remaining in solution (and hence by subtraction 
that loaded into the beads).  
2.6.1 Optical microscopy, bead sizing and water content estimation 
Optical microscopy and measurement of bead sizes were carried out using a BX50 microscope 
and a 10x dry objective.  (Olympus UK Ltd, Essex, England). The eyepiece graticule used to 
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measure the beads was verified using a calibrated graticule placed on the microscope stage 
(Graticules Ltd, Kent, England).  A monolayer of bead sample was placed in a Petri dish on 
the microscope stage and using the 10x objective and eyepiece graticule, the diameter of 200 
individual beads was measured. The bead sizing data was entered into a spreadsheet and the 
size histograms generated using Prism 6 (GraphPad Software, Inc., La Jolla, CA). Based on 
the size change of beads and the assumption that size decrease is a consequence of water 
displaced from beads by the drug, the water content in drug loaded beads was calculated as 
follows: 
𝑊𝑎𝑡𝑒𝑟 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 =   
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑖𝑛 𝑏𝑙𝑎𝑛𝑑 𝑏𝑒𝑎𝑑𝑠−𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑙𝑜𝑠𝑠 𝑎𝑓𝑡𝑒𝑟 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑒𝑑 𝑏𝑒𝑎𝑑𝑠
× 100 %   
2.7 Thermogravimetric analysis (TGA) 
A Mettler Toledo (TGA) was used to investigate the total water content of the beads. Samples 
were filtered to remove excess water, ranging from 4 – 16 mg, placed on an aluminium holder 
and heated from 25 to 120 °C with a nitrogen carrier gas flow of 80 mL/min and a heating rate 
of 1 °C/min. Weight loss as a function of temperature change was recorded with the total loss 
equated to the water content within the beads (n=3) both with and without the presence of drug.  
2.8 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) was performed using a Mettler Toledo DSC 1 
equipped with chiller cooling apparatus. Samples of water, beads (filtered to remove excess 
water) and drug with beads ranging from 4 to 10 mg in sealed aluminium pans were heated at 
a rate of 1 °C/min under a nitrogen flow of 80 mL/min from -20 to 20 °C (n=3). Using this 
data, it was possible to quantify the amount of water within the beads that was able to undergo 
the freezing process, i.e. was not tightly bound to the polymer structure. This assumed that 
‘bound’ water would not contribute to the peak observed within the DSC profile thus 
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subtracting the water associated with the peak observed with DSC from the total water content 




















Chapter 3: Microwave formulations of phenylbutazone (PhB), indomethacin (IMC) and 
imipramine hydrochloride (Imi) using three mesoporous silica excipients (Syloid® silicas 
AL-1 FP, XDP 3050 and XDP 3150) 
3.1. Introduction  
Mesoporous silica has been shown to exhibit great potential to aid in the formulation of 
pharmaceutical compounds with poor aqueous solubility, as reviewed by Choudhari et al. 
[156]. As a drug carrier system, mesoporous silica can accommodate drugs that have been 
introduced through organic solvent immersion, incipient wetness impregnation or melted in 
[149]. Specific advantages of using excipients such as mesoporous silicas are their nonporous 
structures, high surface areas, clinical safety and large pore volumes [157]. Current opinion is 
that substantial progress has been made in recent years in the characterisation and development 
of mesoporous drug delivery systems although more work is needed regarding dissolution 
enhancement potential and related physicochemical properties [158]. There are several reasons 
for this need to continue exploring the possible use of mesoporous silica including practical 
considerations such as manufacturability to large-scale quantities (e.g. tonne) and regulation, 
as well as physicochemical considerations such as the possibility of re-adsorption onto the 
silica surface [158]. Adsorption of small drug particles on the surface of large excipients has 
been a successful strategy for low-dose drugs, poorly water-soluble drugs, targeted drug release 
[159], sustained drug delivery [160] and stability enhancement. This is mainly a result of 
improving the dissolution profile by increasing drug surface area or transformation of the drug 
from a crystalline to amorphous form [161], and its ability to be retained within the silica pores 
[162]. In many cases, the method of formulation can be critical in defining the properties of the 
resultant formulation. For example, silica-based drug delivery vehicles have been investigated 
to avoid hydrolisation of the active compound using supercritical CO2 [163, 164], a formulation 
method known for its high drug-loading ability [165] amongst other advantages [166]. Several 
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other formulation methods have also been attempted, for example, to create liquid (also known 
as liquid-solid) formulations [167] and paediatric (solvent free) formulations [168]. Previously 
published studies have confirmed the application of conventional methods for formulation with 
mesoporous silicas [6]. Furthermore, there is clearly an interest in developing mesoporous 
silica formulations as evidenced by recent work to predict in vivo performance, for example, 
using in silico techniques [169], to overcome multi drug resistance [170] as well as to 
ameliorate toxic side effects [171]. 
This study investigates the suitability of using microwave formulations and three types of 
Syloid® silica-based excipients to quantify their potential to enhance the rate of dissolution of 













3.2. Results and discussion 
3.2.1. Solid state characterisation of PhB formulation   
3.2.1.1. Differential scanning calorimetry (DSC) 
DSC analysis was completed for PhB, PM and MWF of PhB with XDP 3050 silica at 1:1, 2:1 
and 1:3 drug-silica ratios. Examples of the data obtained for the samples are presented in Figure 
3.1. The analysis was used to monitor the presence of PhB in pure form and determine the 
interactions with syloid silica. Analysis of the δ-polymorph of PhB in Figure 3.1 (a) showed 
the expected well defined, sharp melting peak of the crystalline drug with high intensity with 
corresponding fusion of 107.98 oC (δ-form) as previously reported [172, 173]. This confirms 
the crystalline nature of the drug.  
 
Figure 3. 1. DSC profiles for phenylbutazone (PhB) along XDP 3050 based physical mixtures 
(PM) and microwave formulations (MWF). (a) Pure PhB, (b) PM 1:1 (c) PM 2:1 (d) PM 1:3 
(e) MWF 1:1 (f) MWF 2:1 and (g) MWF 1:3  
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Analysis of the physical mixture of PhB with the silica in Figure 3.1 (b), (c) and (d) at 1:1, 2:1 
and 1:3 ratios did not reveal any changes other than reduction in the intensity of the peak thus 
implying that the drug had been converted from crystalline to partially amorphous form after 
physical mixture. In Figure 3.1 (e), a single broad melting peak with reduced intensity for the 
drug was observed at 81.64 oC thus confirming a shift to a lower temperature in comparison 
with the melting peak of the pure drug. This single melting peak indicated the presence of an 
α polymorphic form of phenylbutazone [173] which implies that there is residual presence of 
the drug in crystalline state even after the formulation as previously reported [174]. At this 
ratio, the pore volume (1.70 cm3g-1) and pore diameter (229 Å) of the silica were unable to 
accommodate the whole content of the drug, possibly some of the drug may be inside the pores 
of the silica while some could be on the surface. Figure 3.1 (f) illustrates three polymorphic 
peaks for phenylbutazone at 83.13 oC for α-form, 96.62 oC for β-form and 105.58 oC  for δ-
form which shows the highest melting temperature [173]. The first two were broad with 
reduced intensity and shifted to a lower temperature in comparison to the most stable form (δ-
form), possibly indicating a transformation of the drug from a crystalline to a partially 
amorphous form during the formulation. The later peak was sharper with reduced intensity and 
occurred very close to the melting peak of the pure drug (107.98 oC); this implies the presence 
of drug molecules in a crystalline state after formulation, which suggests an incomplete drug 
inclusion. At this ratio (2:1), the pore volume (1.70 cm3g-1) of the silica was insufficient for 
hosting the extra phenylbutazone molecules. However, in Figure 3.1 (g), there was a complete 
disappearance of the drug-melting peak after the formulation, thus confirming the conversation 
of crystalline drug to amorphous form as a result of microwave formulation. A complete 
transformation of the drug to an amorphous form at this ratio (1:3) was the reason behind the 




DSC was undertaken for phenylbutazone formulated with Syloid® XDP 3150 and AL1 FP at 
the same ratios mentioned earlier. Figures 3.2 and 3.3 illustrate the DSC thermograms for XDP 
3150 and AL1 FP based physical mixtures and microwave formulations along with pure PhB. 
 
Figure 3. 2. DSC profiles for phenylbutazone (PhB) along XDP 3150 based physical mixtures 
(PM) and microwave formulations (MWF). (a) Pure PhB, (b) PM 1:1 (c) PM 2:1 (d) PM 1:3 
(e) MWF 1:1 (f) MWF 2:1 and (g) MWF 1:3  
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Figure 3. 3. DSC profiles for phenylbutazone (PhB) along AL1 FP based physical mixtures 
(PM) and microwave formulations (MWF). (a) Pure PhB, (b) PM 1:1 (c) PM 2:1 (d) PM 1:3 
(e) MWF 1:1 (f) MWF 2:1 and (g) MWF 1:3 
Physical mixtures in the two figures, showed similar characteristics to those observed in Figure 
3.1 (b), (c) and (d). There was no significant difference between Figure 3.2 and 3.3 other than 
some small variations in the melting peaks of phenylbutazone of not more than ±1 oC. Figure 
3.3 (e) showed two well-defined, sharp endothermal peaks at 96.67 oC and 107.07 oC indicating 
a β and δ-polymorph for phenylbutazone [175]. The former at the lower temperature, confirmed 
the presence of the partially-amorphous form of the drug while the latter was very close to the 
melting peak of the pure drug thus indicating the presence of some PhB molecules in a 
crystalline state after formulation. Possibly the small pore volume and diameter (0.23 cm3g-1 
and 26 Å) could be the reason why the AL1 FP accepts the drug molecules beyond its capacity 
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even though an equal mass was used for physical mixing and therefore, drug molecules were 
deposited on the external surface of the silica.  For the 2:1 ratio (Figure 3.3f), a peak with 
reduced intensity at 96.82 oC (β-form) for phenylbutazone was observed which shifted to a 
lower temperature compared with the melting peak of the δ-form indicating a transition from a 
crystalline to partially amorphous form as a result of formulation. A sharp and well-defined 
peak with high intensity was recorded at 106.89 oC, close to the melting peak of the drug thus 
indicating the existence of drug molecules in a crystalline state, which suggests an incomplete 
inclusion complexation. At a 1:3 drug-silica ratio (Figure 3.3g), the high surface area of AL1 
FP (605 m2g-1) could be the reason why the silica accommodated the major portion of the drug 
inside its pores, and the residual presence of the drug melting peak observed could be due to 















3.2.1.2. X-ray diffraction (XRD) 
Following on from the DSC results discussed earlier, XRD investigations of the samples were 
conducted to support the studies. The X-ray diffraction (XRD) patterns of pure phenylbutazone 
and XDP 3050 based physically mixed and microwave formulations at 1:1, 2:1 and 1:3 are 
presented in Figure 3.4. Previous XRD studies using naproxen noted that the diminishment of 
peak intensities confirmed that the crystalline drug had molecularly dispersed within the 
mesoporous silica material [176], resulting in an amorphous formulation with an absence of 
characteristic peaks [88].  
 
Figure 3. 4. XRD patterns for (a) PhB, (b) XDP 3050, (c) PM 1:1, (d) PM 2:1, (e) PM 1:3 (f) 
MWF 1:1, (g) MWF 2:1 and (h) MWF 1:3. 
A similar result was observed in this work whereby the purely crystalline phenylbutazone that 
could be seen in Figure 3.4 (a) with sharp diffraction peaks at 8.12o, 12.95o, 18.59o and 20.88o 
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in comparison with the featureless pattern for the syloid XDP 3050 silica (Figure 3.4b). 
Phenylbutazone peaks were still evident in the physical mixtures of 1:1, 2:1 and 1:3 drug-silica 
ratios (Figure 3.4c, d and e) even though the mixing process reduced them. In contrast, 
diffraction patterns for the samples formulated using microwave (Figure 3.4f, g) show small 
diffraction peaks with reduced intensity suggesting that the samples were largely non-
crystalline.  
In Figure 3.4h, the sample was converted to the amorphous form following formulation with 
the Syloid® XDP silica. As discussed earlier, from analysing the 1:1, 2:1 and confirming the 
entire drug had remained within the formulation, the presence of small peaks can be explained 
by a reduced concentration of drug in the former and a transformation to the amorphous form 
in the latter. In summary, XRD results are in good agreement with those reported using DSC.  
Figures 3.5 and 3.6 show the XRD patterns of XDP 3150 and AL1 FP based physical mixtures 
and microwave formulations at 1:1, 2:1 and 1:3 drug silica ratios. Sharp diffraction patterns 
with high intensity for the pure drug were observed in both the figures, which were discussed 
earlier while the absence of diffraction peaks in Syloid® XDP 3150 and AL1 FP indicates the 




Figure 3. 5. XRD patterns for (a) PhB, (b) XDP 3150, (c) PM 1:1, (d) PM 2:1, (e) PM 1:3 (f) 
MWF 1:1, (g) MWF 2:1 and (h) MWF 1:3. 
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Figure 3. 6. XRD patterns for (a) PhB, (b) AL1 FP, (c) PM 1:1, (d) PM 2:1, (e) PM 1:3 (f) 
MWF 1:1, (g) MWF 2:1 and (h) MWF 1:3. 
The characteristic diffraction peaks of crystalline phenylbutazone in the physical mixes with 
XDP3150 and AL1 FP were still evident with a higher intensity for the 2:1 ratio compared with 
1:1. The diffraction peaks in 1:3 were not visible due to the three times mass of the silicas used 
in the physical mixing. The less intense peaks observed in the 1:1 ratio using the microwave 
formulation indicates that the crystalline drug, highly dispersed in the amorphous XDP and 
AL1 FP silicas, was brought to a less crystalline state due to the microwave energy applied 
during the formulation. In the 2:1 ratio, the diffraction peaks of the drug were more visible, a 
consequence of pore volumes (1.70 and 0.40 cm3g-1) and the large mass of the drug used for 
the formulation, indicating that the two silicas were unable to accommodate the whole content 
of the drug in their pores. There was a complete disappearance of diffraction peaks after the 
microwave formulations in 1:3 ratios. This confirms that the drug was no longer in a crystalline 
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state in such ratios, which provides proof of its actual inclusion within the silicas [177]. These 
results were in full agreement with DSC, confirming amorphisation was achieved using 
microwave formulation with each amorphous silica.  
3.2.1.3. Fourier transform infrared spectroscopy (FT-IR) 
FT-IR spectroscopy was utilised to monitor the presence of phenylbutazone and determine 
interactions with the three syloid (XDP 3050, XDP 3150 and AL1 FP) silicas. Figure 3.7, 3.8 
and 3.9 all include the spectra for pure phenylbutazone, indicating the expected absorption 
bands at wavenumbers (with corresponding functional groups) of 2922 cm-1 for C-H, 1713 cm-
1 for C=O and 1290 cm-1 for C-N (aromatic amine) respectively.                
 
Figure 3. 7. FT-IR analysis of (a) PhB (b) XDP 3050, (c) MWF 1:1, (d) MWF 2:1, and (e) 1:3 













Figure 3. 8. FT-IR analysis of (a) PhB (b) XDP 3150, (c) MWF 1:1, (d) MWF 2:1, and (e) 1:3 
drug-XDP 3150 formulations 
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Figure 3. 9. FT-IR analysis of (a) PhB (b) AL1 FP, (c) MWF 1:1, (d) MWF 2:1, and (e) 1:3 
drug-AL1 FP formulations 
The three Syloids silicas were analysed using FT-IR spectroscopy and all displayed the 
expected intense and broad Si-O absorption band at 1064–1070 cm-1 [178]. The absorption 
band at 962 cm-1 corresponds to Si-OH bending. On the other hand, the symmetric stretching 
vibrations of Si-O-Si appeared at 788 cm-1 and its bending vibration appeared at 453 cm-1 [179].  
The IR spectra for microwave formulations of phenylbutazone and the three syloid silicas (1:1 
and 2:1 ratios) was reflected by the appearance of the characteristic intense peaks for drug and 
less intense peaks for the silicas. For the 1:3 ratio (i.e. having a higher silica content) in all the 
three phenylbutazone-silica formulated products, the results indicated a shift in the peaks, 
suggesting a successful interaction of the drug with the silicas. The microwave formulation 
method did not reveal any changes in the specific absorption bands for the drug, suggesting a 
lack of degradation because of the formulation process. Furthermore, the spectra did not display 
400900140019002400290034003900
Wavenumber (cm-1)








any obvious additional peaks, thus indicating there had been no significant changes in the 
chemical structure or drug-silica interactions. 
3.2.1.4. Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM) was used for solid-state characterisation of the drug-
silica system; the technique allowed an in-depth investigation into the morphological aspect of 
the interacted mixtures obtained by the microwave formulation method. SEM displayed 
morphological changes, which are associated with the interaction between the drug and silica, 
and any existence of a single component in the formulation obtained.  
Surface morphologies of the pure phenylbutazone (x500 magnification) and the three syloid 
silicas - XDP 3050, XDP 3150 and AL1 FP (x500 magnification) are presented in Figure 3.10. 
The drug’s crystalline state, along with the disordered irregular shapes of AL 1 FP, XDP 3150, 










Figure 3. 10. Scanning electron microscope (SEM) images of (a) PhB, (b) XDP 3050 (c) XDP 





     
     
     
Figure 3. 11. SEM images at x500 of (a) PM of PhB and XDP 3050 (1:1), (b) PM of PhB and 
XDP 3050 (2:1), (c) PM of PhB and XDP 3050 (3:1). (d), PM of PhB and XDP 3150 (1:1), (e) 
PM of PhB and XDP 3150 (2:1), (f) PM of PhB and XDP 3150 (1:3). (g) PM of PhB and AL1 
FP (1:1), (h) PM of PhB and AL1 FP (2:1), and (i) PM of PhB and AL1 FP (1:3).  
Figure 3.11 displays nine images of the physical mixtures of phenylbutazone with three syloid 
silicas - XDP 3050, XDP 3150 and AL1 FP at 1:1, 2:1 and 1:3 (x500 magnifications) drug-
silica ratios. It can be seen evidently in the images the needle-like crystals of the 
phenylbutazone and irregular shapes of the three silicas.  This suggests that the drug and the 
silicas do not well together and remained separated at the microscopic level using physical 
mixing alone as the drug retained a crystalline structure.    
Surface morphologies of phenylbutazone with three syloid-based microwave formulations at 
1:1, 2:1 and 1:3 (x500 magnifications) drug-silica ratios are presented in Figure 3.12. The SEM 
images confirmed the significant effects of the microwave formulation process as the drug had 
(f) (e) (d) 
(c) (b) (a) 
(i) (h) (g) 
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lost its crystalline structure. However, PhB could hardly be seen on the surface of AL 1 FP due 
to a larger surface area (605 m2g-1), smaller pore volume and pore diameter (cm3g-1 and Å). 
For Syloid XDP 3150 and XDP 3050 based formulations, there was an even distribution of the 
former particles with phenylbutazone particles reduced in size while for the latter, possibly 
more of the drug has been molecularly dispersed on the surface as visible in the SEM images 
(Figure 3.12).   
     
     
     
Figure 3. 12. SEM images at x500 of (a) MWF of PhB and XDP 3050 (1:1), (b) MWF of PhB 
and XDP 3050 (2:1), (c) MWF of PhB and XDP 3050 (3:1). (d), MWF of PhB and XDP 3150 
(1:1), (e) MWF of PhB and XDP 3150 (2:1), (f) MWF of PhB and XDP 3150 (1:3), (g) MWF 
of PhB and AL1 FP (1:1), (h) MWF of PhB and AL1 FP (2:1), and (i) MWF of PhB and AL1 
FP (1:3).  
Overall, these results justified an enhancement in the dissolution profiles of phenylbutazone 
formulated with the syloid silicas using the microwave method discussed earlier, due to the 
(i) (h) (g) 
(f) (e) (d) 
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absence of any crystalline structures of the drug and possible dispersion of drug molecules on 
the surfaces of the silicas.  
3.2.2. In vitro phenylbutazone release 
In order to investigate the aim of enhancing phenylbutazone’s dissolution rate using a 
microwave method, in vitro dissolution profiles of formulated products using three carriers 
were compared to those of pure drug. The dissolution profile of phenylbutazone, along with 
Syloid XDP 3050 at different ratios is displayed in Fig. 3.13 over a period of 45 min in pH 7.0 
phosphate buffer. As can be seen, pure phenylbutazone that had not undergone the formulation 
process exhibited 12.4 % (± 0.3 %) drug release after 5 min yet only increased to a maximum 
of 31.9 % (± 3.9 %) release after 45 min. For many drugs, this low percentage of drug release 
after this time would be deemed unsuitably low and may limit bioavailability.  
 
Figure 3. 13. Release profiles for phenylbutazone (PhB), Syloid® XDP 3050 based 
formulations using microwave at 1:1, 2:1 and 1:3 drug to silica ratios. Each data point 
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The XDP 3050 silica-based formulation exhibited a dramatic enhancement in percentage 
dissolution, confirming that the presence of silica contributed to the increase. Firstly, the 1:1 
drug-silica ratio achieved a percentage release of 28.2 % (± 4.1 %) after only 5 min, i.e. almost 
equal to the overall period observed for drug alone. After a period of 45 min, this value had 
increased to 84.3 % (± 5.0 %), far higher than that seen for drug alone. Secondly, 2:1 showed 
a promising percentage release of 29.8 % (± 1.5 %) after 5 min compared with 1:1, yet after a 
total of 45 min had not exceeded the former ratio to reach a maximum percentage release of 
84.5 % (± 8.9 %) i.e. almost similar to the 1:1 ratio discussed earlier. Finally, 1:3 was found to 
be the most successful drug-silica ratio for enhancing percentage release with an impressive 
90.5 % (±1.5 %) released after 5 min, i.e. greater than the total seen for pure drug after 45 min, 
increasing to a maximum of 99.7 % (± 6.4 %) release after 45 min. One reason for this 
impressive release is that the 1:3 formulation is with higher silica content and presents a large 
number of available pores when compared to the formulation with lower XDP 3050 content 
(i.e. 1:1 and 2:1). The chances of pore filling by the molten drug to full capacity in the 1:3 ratio 
is high and some phenylbutazone is being deposited on the surface of the XDP 3050, which 
resulted in an impressive release [19].     
When determining why all three ratios improved the percentage drug release, following the 
microwave formulation of PhB-XDP 3050, it would appear that the transformation from 
crystalline to partially amorphous form as in the case of 1:1 and 2:1 ratios and completely 
amorphous for 1:3 ratio plays a key role. This was evidenced by the DSC, XRD and dissolution 
profiles of the formulated ratios. This is in agreement with other researchers and fits well with 




Figure 3. 14. Release profiles for phenylbutazone (PhB), Syloid® XDP 3150 based 
formulations using microwave at 1:1, 2:1 and 1:3 drug to silica ratios. Each data point 
represents the mean of triplicate results (±SD).  
The release behaviour of phenylbutazone from Syloid® XDP 3150 is presented in Figure 3.14. 
Slow and steady drug release was evidenced for the 1:1 ratio, i.e. 33.2 % (± 6.4 %) and 97.5 % 
(± 5.3 %) after 5 and 45 min respectively. The 2:1 drug-silica ratio made little difference to the 
dissolution behaviour when compared to the aforementioned profiles yet was still significant 
in comparison with pure phenylbutazone, for example 20.6 % (± 5.8 %) and 76.1 % (± 7.9 %) 
was evidenced after 5 and 45 min respectively. As twice the mass of the drug was used during 
the formulation in comparison with the mass of silica, this was possibly because the pores of 
the silica were unable to accommodate the whole content of the drug. This anomaly was 
attributed to the pore diameter of the silica (200 Å) [6], in which some part of the drug may be 
inside the pores of the silica whilst some was on the surface. The 1:3 drug-silica ratio provided 
rapid drug release reaching 93.1 % (± 3.5 %) after 5 min followed by continuous release to 
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The findings showed that the dissolution profile of the 1:3 ratio containing higher silica content 
had the best drug release in comparison to 1:1 and 2:1 ratios with lower silica content.  It is 
interesting to note that conversion from crystalline to amorphous form of the drug in the 1:3 
ratio brought about the increase as evidenced in the DSC and XRD findings. Based on these 
findings, the physicochemical properties of the Syloid® XDP 3150 is best suited to formulate 
the drug using 1:1 and 1:3 drug-silica ratios, the drug is transported and uniformly distributed 
inside the pores of the silica as confirmed by the results of XRD and DSC (discussed earlier).   
The dissolution profile studies with the aforementioned silica provided a high increase 
compared with the pure drug, which could lead to a great enhancement in the oral 
bioavailability of phenylbutazone. Therefore, the microwave formulation technique is a 
potential method to overcome phenylbutazone’s poor solubility and could lead to significant 
enhancement in the therapeutic effect.    
Figure 3.15 displays the dissolution profile of the microwave technique employed with both 
phenylbutazone and AL 1 FP formulations. It can be seen that there was a remarkable 
enhancement of the dissolution rate compared with the pure drug. For the 1:3 drug-silica ratio 
46.4 % (± 1.92 %) of drug was released in 5 min followed by 97.6 % (± 2.4 %) in 45 min. The 
1:3 ratio was much faster than the 1:1 and 2:1 ratio. In 5 min, 23.5 % (± 3.5 %) and 18.5 % (± 
7.3 %) of drug was released for the aforementioned while 78.8 % (± 8.8 %) and 77.6 % (± 4.0 
%) was released after 45 min respectively. The different percentages of release occurred due 
to the different mass of AL1 FP used in this formulation. The AL1 FP silica employed, coupled 





Figure 3. 15. Release profiles for phenylbutazone (PhB), Syloid® AL1 FP based formulations 
using microwave at 1:1, 2:1 and 1:3 drug to silica ratios. Each data point represents the mean 
of triplicate results (±SD).  
All the three ratios have improved the percentage release following a microwave formulation 
method, it would appear that the transformation from the crystalline to partially amorphous 
form (as evidenced by DSC, XRD and dissolution profiles of processed samples) plays a key 
role. This has been the conclusion of other researchers, when investigating alternative 
mesoporous materials [182], and fits well with the results from this work. However, when 
considering why the three ratios did not facilitate the same increase in percentage release, it is 
more appropriate to consider amount of Syloid® AL1 FP used in making the physical mixture 
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3.2.3. Solid state characterisation of IMC  
3.2.3.1 Differential scanning calorimetry (DSC) 
DSC analysis was applied to investigate the phase change during the formation of solid 
dispersions. As reported in Figure 3.16 (a), the thermal curve of pure indomethacin was 
characterised by a well-defined sharp melting peak at 160.7 oC in agreement with the melting 
point previously reported [183].  
 
Figure 3. 16. DSC profiles for indomethacin (IMC) along XDP 3050 based physical mixtures 
(PM) and microwave formulations (MWF). (a) Pure IMC, (b) PM 1:1 (c) PM 2:1 (d) PM 1:3 
(e) MWF 1:1 (f) MWF 2:1 and (g) MWF 1:3 
 
In the thermal profile of physical mixtures 1:1, 2:1 and 1:3 (Figure 3.16 b, c and d), a small 
endothermic peak corresponding to the melting point of indomethacin was detectable, this 
event can be attributed to the transformation of indomethacin from crystalline to a partially 
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amorphous form during the programmed heating. After microwave formulation, there was a 
reduction in the size of the drug-melting peak for the three ratios, indicating a possible 
dispersion of drug into Syloid® XDP 3050 carrier as a result of microwave irradiation. The drug 
was embedded into the Syloid® XDP 3050 thereby bringing it to a less crystalline state in 
agreement with the XRD data discussed earlier. This result was compatible with indomethacin 
confinement into the mesoporous silica as previously reported [184] which resulted in 
amorphisation of the drug. 
Figures 3.17 and 3.18 describe the DSC thermograms for Syloid® XDP 3150 and AL1 FP based 
physical mixtures and microwave formulations along with pure indomethacin at 1:1, 2:1 and 
1:3 drug-silica ratios. Pure indomethacin was characterised by a single sharp melting peak at 
160.7 oC as discussed in Figure 3.16. The DSC thermogram for AL1 FP in Figure 3.18 (b) 
showed a broad dehydration peak in the region of 70.0 oC to 133 oC which also appeared in its 
physical mixtures with the drug (Figure 3.18c and 3.18e) in 1:1 and 1:3 ratios. These events 
occurred ~ 30 oC higher than the boiling point of water indicating that the water molecules are 
held tightly within AL1 FP and therefore higher energy was required to overcome the hydrogen 
bonding because of intermolecular forces. The thermal peak of the drug in the physical 
mixtures showed slight variations in terms of size and broadening when compared with pure 
drug, indicating transformation from crystalline to a partially amorphous form.   
For indomethacin formulated with XDP 3150 at three ratios, endothermic transitions 
corresponding to the drug were observed, the transitions were with reduced intensity and a 
broadened peak when compared with the transition of the pure drug. This phenomenon was 
attributed to the transition from the crystalline to amorphous form of indomethacin. DSC 
thermograms for AL1 FP formulated with indomethacin (Figure 3.18f) at a 1:1 ratio showed a 
glass transition (Tg) at 56.1 
oC, Tg of the mixtures was influenced by the compound 




Figure 3. 17. DSC profiles for indomethacin (IMC) along XDP 3150 based physical mixtures 
(PM) and microwave formulations (MWF). (a) Pure IMC, (b) PM 1:1 (c) PM 2:1 (d) PM 1:3 
(e) MWF 1:1 (f) MWF 2:1 and (g) MWF 1:3 
 
The formulation prepared with a higher drug ratio (2:1) in Figure 3.18 (g) showed a glass 
transition (Tg) at 48.8 
oC followed by a broad exothermic transition possibly corresponding to 
a cross-linking reaction between the drug and the carrier at 114.9 oC initiated by heat or 
microwave irradiation during the formulation, it could also be a recrystallisation peak. A high 
peak intensity was observed at 158.3 oC, indicating that the small pore volume and pore 
diameter (0.40 cm3g-1 and 26 Å) could be the reason why the AL1 FP does not accept drug 
molecules beyond its capacity and therefore, the drug molecules are likely to be deposited on 
the surface of the AL1 FP. This has been the conclusion of other researchers, when 
investigating gemfibrozil with Syl-AL-1 and Syl-72 [177], and fits in well with the results of 
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this research. At the higher AL1 FP 1:3 ratio (Figure 3.18h), there was a complete 
disappearance of the melting peak of the indomethacin because enough pores were available 
to accommodate the molecules of the drug. All the Syloid® XDP 3050, 3150 and AL1 FP-
indomethacin physical mixtures including formulations did not show any thermal transitions 
other than the thermal endotherm and glass transitions for the drug and dehydration for AL1 
FP. This confirms the thermal stability of the product and absence of polymorphic transitions.      
           
Figure 3. 18. DSC profiles for indomethacin (IMC) along AL1 FP based physical mixtures 
(PM) and microwave formulations (MWF). (a) Pure IMC, (b) AL1 FP (c) PM 1:1 (d) PM 2:1 
(e) PM 1:3 (f) MWF 1:1 (g) MWF 2:1 and (h) MWF 1:3 
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3.2.3.2 X-ray diffraction (XRD) 
To support the results of the DSC, indomethacin, Syloid® XDP 3050, XDP 3150 and AL1 FP, 
prepared physical mixtures as well as microwave formulations of the samples were analysed 
by XRD and the results are presented in Figures 3.19, 3.20 and 3.21. From the diffractions 
scanned, it is clear that indomethacin is a crystalline drug with high intensity diffraction peaks 
whereas all the Syloid® XDP 3050, XDP 3150 and AL1 FP carriers are completely amorphous.        
 
Figure 3. 19. XRD patterns for (a) IMC, (b) XDP 3050, (c) PM 1:1, (d) PM 2:1, (e) PM 1:3 (f) 
MWF 1:1, (g) MWF 2:1 and (h) MWF 1:3. 
The diffractograms for the physical mixtures of indomethacin with the three Syloid® silicas at 
1:1, 2:1 and 1:3 drug/silica ratios showed that the indomethacin crystalline peaks were 
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maintained in the physical mixtures indicating that the drug was still in a crystalline state, these 
results agree with the previous DSC results.  
 
Figure 3. 20. XRD patterns for (a) IMC, (b) XDP 3150, (c) PM 1:1, (d) PM 2:1, (e) PM 1:3 (f) 
MWF 1:1, (g) MWF 2:1 and (h) MWF 1:3. 
The microwave formulations of indomethacin with Syloid® XDP 3050, XDP 3150 and AL1 
FP at a 1:1 ratio showed that the drug is completely amorphous and was no longer in a 
crystalline state even though this does not provide definitive proof of inclusion into the Syloid® 
silicas.  
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Figure 3. 21. XRD patterns for (a) IMC, (b) AL1 FP, (c) PM 1:1, (d) PM 2:1, (e) PM 1:3 (f) 
MWF 1:1, (g) MWF 2:1 and (h) MWF 1:3. 
These results prove that the microwave formulation method is suitable for producing 
amorphous solid dispersions. This result fits well with the amorphous solid dispersion of a 
poorly water soluble drug (felodipine) prepared with different polymer matrices [185]. The 2:1 
ratio showed small diffraction peaks for the drug, which is highly evidenced in the microwave 
formulation of the drug with AL1 FP, revealing the transition from crystalline to a partially 
amorphous state of indomethacin.   
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3.2.3.3 Fourier transform infrared spectroscopy (FT-IR) 
FTIR was used to investigate the nature of the interaction-taking place between the carriers 
(Syloid® XDP 3050, 3150, AL1 FP at 1:1) and the active indomethacin. The spectrum of 
indomethacin, three Syloid® silicas as well as their formulations are shown in Figures 3.22, 
3.23 and 3.24.  The spectrum of the active drug (Figure 3.22a) showed an absorption band at 
2930 cm-1 for hydroxyl (O-H) stretching vibrations, 1690 cm-1 for carbonyl (C=O), 1450 cm-1 
for phenyl groups (C=C) and 900 cm-1 for the C-H vibrations of indomethacin [186]. 
 
Figure 3. 22. FT-IR analysis of (a) IMC (b) XDP 3050, (c) MWF 1:1, (d) MWF 2:1, and (e) 
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Figure 3. 23. FT-IR analysis of (a) IMC (b) XDP 3150, (c) MWF 1:1, (d) MWF 2:1, and (e) 
1:3 drug-XDP 3150 formulations 
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Figure 3. 24. FT-IR analysis of (a) IMC (b) AL1 FP, (c) MWF 1:1, (d) MWF 2:1, and (e) 1:3 
drug-AL1 FP formulations 
IR spectra of the three pure syloid silicas showed a broad band at 1056 cm-1 corresponding to 
asymmetric (Si-O-Si) stretching, 792 cm-1 for the symmetric Si-O-Si stretch and at 447 cm-1 a 
bending vibration for Si-O-Si was observed, as previously reported [187]. Following 
microwave formulation of the active with the silicas at different ratios, characteristic stretching 
bands of the active drug were observed, narrow for the 1:1 ratio and intense for the 2:1 ratio 
due to the higher drug content. Moreover, the bands become broader and shifts in the 1:3 
formulations are due to the high silica content. These observations possibly may be due to an 
interaction between drug-silica after the microwave formulation.     
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3.2.3.4. Scanning electron microscopy (SEM) 
An in-depth study of the morphological aspect of single component and interacted mixtures 
was carried out with SEM. The findings are displayed in Figures 3.25 and 3.26 (x500 
magnification). The drug crystalline state is evident while the disordered irregular shape and 
size of syloid silicas has been discussed in Figure 3.10. Differences in images of the physical 
mixtures of the drug with silicas at different ratios are insignificant as confirmed by the SEM 
(x500 magnification).  
                              
        
     
 
Figure 3. 25. SEM images at x500 of (a) IMC (b) PM of IMC and XDP 3050 (1:1), (c) PM of 
IMC and XDP 3050 (2:1), (d) PM of IMC and XDP 3050 (3:1). (e), PM of IMC and XDP 3150 
(1:1), (f) PM of IMC and XDP 3150 (2:1), (g) PM of IMC and XDP 3150 (1:3), (h) PM of IMC 
and AL1 FP (1:1), (i) PM of IMC and AL1 FP (2:1), and (j) PM of IMC and AL1 FP (1:3).  
(j) 
(i) (h) (g) 
(f) (e) (d) 
(c) (b) (a) 
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However, the crystals of indomethacin on the surface of the syloid silicas were not evident after 
microwave formulation. For the 2:1 (x500 magnification) microwave formulation, there was a 
uniform appearance of some drug molecules on the surface of the silicas.     
     
     
     
Figure 3. 26. SEM images x500 of (a) MWF of IMC and XDP 3050 (1:1), (b) MWF of IMC 
and XDP 3050 (2:1), (c) MWF of IMC and XDP 3050 (3:1), (d), MWF of IMC and XDP 3150 
(1:1), (e) MWF of IMC and XDP 3150 (2:1), (f) MWF of IMC and XDP 3150 (1:3), (g) MWF 
of IMC and AL1 FP (1:1), (h) MWF of IMC and AL1 FP (2:1), and (i) MWF of IMC and AL1 
FP (1:3). 
These images confirmed the DSC and XRD results, where amorphous material was detected at 
a 1:1 drug-silica ratio, indicating a homogenised system while for the 2:1 ratio, there was the 
presence of partially amorphous drug on the surface of the silica due to the higher mass of the 
drug used in the formulation. Overall, these results confirmed that subjecting the drug to a 
(i) (h) (g) 
(f) (e) (d) 
(c) (b) (a) 
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microwave formulation process can modify the proportion of crystalline drug and create a 
product that may contain a uniform dispersion of drug within the silica matrix. 
3.2.4. In vitro indomethacin release 
Dissolution studies were performed on pure indomethacin and microwave formulations of 
indomethacin with three syloid silicas at 1:1, 2:1 and 1:3 drug-silica ratios to investigate the 
influence of the silicas and microwave on the dissolution behaviour of the drug. The in vitro 
release profiles of indomethacin from syloid XDP 3050 at aforementioned drug-silica ratios 
along with pure indomethacin in phosphate buffer over a period of 45 minutes are presented in 
Figure 3.27.  
 
Figure 3. 27. Release profiles for pure indomethacin (IMC) and indomethacin Syloid® XDP 
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These results highlight that pure indomethacin (that had not undergone the microwave 
formulation process) exhibited 12.4 % (± 0.8 %) drug release after 5 minutes yet only increased 
to 22.4 % (± 1.7 %) after 30 minutes and to a maximum of 25.5 % (± 1.5 %) after 45 minutes.  
Syloid XDP 3050-based formulations exhibited a significant enhancement in the percentage 
release, confirming the formulation of the drug in the presence of syloid using the microwave 
method contributed to the increase. Formulation of a 1:1 drug-silica ratio achieved a percentage 
release of 80.3 % (± 0.1 %) after only 5 minutes, while after 30 minutes, the value had increased 
to 84.6% (± 0.2 %) and 84.8% (± 0.2 %) at 45 minutes. The initial release was attributed to 
adsorption of the drug into the pores of the XDP 3050 silica [188]. However, a similar drug 
release profile was observed for the 2:1 drug-silica ratio whereby 83.0 % (± 4.0 %) after 5 
minutes was achieved. This was greater than the total seen for the pure drug after 45 minutes. 
The reason for this enhanced release has to do with the physicochemical properties of the syloid 
XDP 3050 [19], and the drug possibly was confined inside the pores and on the surface of the 
silica. This result fits well with the findings of other studies with mesoporous silica for the 
release of gemfibrozil [177]. Finally, the 1:3 ratio did show a promising percentage release of 
82.8 % (± 10.5 %) after 5 minutes compared with the 2:1, yet after a total of 45 minutes had 
exceeded further to reach a maximum percentage release of 86.9 % (± 0.4 %). The IMC-XDP 
3050 formulation with low silica content (i.e. in 2:1) showed greater drug release while the 1:1 
and 1:3 formulations with higher silica content showed an opposite trend. The indomethacin 
molecules are well dispersed in the silica at higher drug content. In 2:1 ratio, the XDP 3050 
partially amorphised the indomethacin by forming an incomplete inclusion complex, this is 
evidenced by the reduction in the melting peak intensity on DSC thermograms of the ratio (Fig. 
3.16). For 1:1 and 1:3 ratios with higher XDP 3050 content, the amount of silica was enough 
for incorporating IMC, and the interaction of IMC and XDP 3050 was reduced, contributing 
improved redispersion of XDP 3050 nanoparticles [189].       
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Figures 3.28 and 3.29 display the dissolution studies of indomethacin formulated with Syloid 
XDP 3150 and AL1 FP at 1:1, 2:1 and 1:3 drug-silica ratios. XDP 3150 and drug (1:1) achieved 
a percentage release of 70.9 % (±6.2 %) after 15 minutes and attained a maximum release of 
76.9 % (±4.8 %) after 45 minutes. The release profile achieved using the 2:1 ratio was greater 
than that obtained with 1:1, where a percentage release of 81.4 % (± 7.5 %) was achieved in 
the first 15 minutes to a maximum of 83.4 % (±7.2 %) after 45 minutes. The greatest percentage 
release achieved using this silica is at a ratio of 1:3 with 90.3% (±3.5 %) and 92.2 % (±3.0 %) 
released after 15 and 45 minutes respectively.  
 
Figure 3. 28. Release profiles for pure indomethacin (IMC) and indomethacin Syloid® XDP 
3150-based formulations at 1:1, 2:1 and 1:3. Each data point represents the mean of triplicate 
results (± SD). 
Interestingly, when comparing the three ratios of IMC loading into XDP 3150 mesoporous 
silica carried out at low and high IMC amounts, it could be observed that for the same type of 
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of drug i.e. 1:3 ratio [18]. This is also in very good agreement with both the DSC and XRD 
findings (Fig. 3.17g and Fig. 3.20g respectively).  The results showed that the dissolution 
profile of the 1:3 ratio containing higher silica content had the best drug release in comparison 
to 1:1 and 2:1 ratios with lower silica content. This is due to conversion from the crystalline to 
partially amorphous form [190] of the drug in the 1:3 ratio brought about the increase. This 
silica displayed a different dissolution profile due to its different properties in comparison to 
the profiles of XDP 3050 previously discussed.  
Lastly, dissolution profiles for indomethacin with Syloid® AL1 FP did not show such a 
promising percentage release of 43.0 % (±0.7 %) after 15 minutes for the 1:1 drug-silica ratio, 
60.1 % (±2.3 %) for the 2:1 and 55.7 % (±4.0 %) for the 1:3. After a total of 45 minutes, the 
values were 52.2 % (±0.7 %), 76.7% (±3.4 %) and 66.7 % (±2.0 %) for the 1:1, 2:1 and 1:3 
ratios respectively. The IMC release was faster for the 2:1 and 1:3 ratios, the drug release in 
the 1:1 ratio was slightly slower compared with the two previous ratios, but still faster 
significantly when compared to the pure IMC.      
It was concluded that, the most influential physical parameter of the mesoporous silicas used 
in this project for enhancing drug release was the pore volume. The particle size highlighted in 
Table 2.1 was not found to have a major effect on the drug release kinetics but other studies 
have shown that larger particle size has been related to slower drug release rate [191, 192] . 
The much higher surface area of Syloid® AL1 FP (605 m2g-1) mesoporous silica did not display 
higher drug release for the three ratios analysed when compared to the Syloid® XDP 3050 and 
3150 carriers with lower surface area (320 m2g-1). The AL1 FP has narrower pores than the 
XDP 3050 and 3150 which has been suggested to contribute to a lower release rate due to steric 




Figure 3. 29. Release profiles for pure indomethacin (IMC) and indomethacin Syloid® AL1 
FP-based formulations at 1:1, 2:1 and 1:3. Each data point represents the mean of triplicate 
results (±SD). 
3.2.5. Solid state characterisation of Imipramine formulations 
3.2.5.1 Differential scanning calorimetry (DSC) 
The physical state of Imi entrapped in Syloid® XDP 3050, XDP 3150 and AL1 FP materials 
was analysed by DSC. As can be seen in Figure 3.30, crystalline imipramine exhibited a well-
defined sharp endothermic peak at 175.3 oC corresponding to its melting in agreement with the 
melting point previously reported [194]. The characteristic peak of the drug appeared in the 
physical mixtures at all drug/silica ratios with little disparities in terms of melting peak 
broadening and depression, providing an insight about solid-state modifications and transition 


























Figure 3. 30. DSC profiles for imipramine (Imi) along XDP 3050 based physical mixtures (PM) 
and microwave formulations (MWF). (a) Pure Imi, (b) PM 1:1 (c) PM 2:1 (d) PM 1:3 (e) MWF 
1:1 (f) MWF 2:1 and (g) MWF 1:3 
When imipramine was formulated with Syloid® XDP 3050 at 1:1 and 1:3 drug/silica ratios seen 
in Figure 3.30 (e) and (g), no sign of a melting peak for the drug could be observed, affirming 
the amorphous nature of imipramine within formulations and this was in good agreement with 
other XRD measurements (Figure 3.33 f). In contrast, two melting peaks of imipramine were 
detected, one broad at 138.7 oC and another small at 171.7 oC for the 2:1 drug/silica ratio. At 
this ratio, possibly even though not confirmed could be due to the pore volume of the XDP 
3050 (1.70 cm3g-1) which is inadequate for accommodating the extra imipramine molecules, 
the residual drug molecules instead could have resided on the external surface of XDP 3050. 
DSC confirmed the presence of crystalline imipramine in this ratio following the formulation 
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process (despite a slight shift from 175.3 oC) and this is in good agreement with other XRD 
measurement (Figure 3.33f).        
  
  
Figure 3. 31. DSC profiles for imipramine (Imi) along XDP 3150 based physical mixtures (PM) 
and microwave formulations (MWF). (a) Pure Imi, (b) PM 1:1 (c) PM 2:1 (d) PM 1:3 (e) MWF 
1:1 (f) MWF 2:1 and (g) MWF 1:3 
Figure 3.31 shows the DSC thermograms of pure Imi, physical mixtures and drug loaded 
Syloid® XDP 3150 at 1:1, 2:1 and 1:3 drug/silica ratios respectively. The melting endotherm 
of pure Imi has been discussed previously (Fig. 3.30), all the physical mixtures prepared 
showed characteristics of an imipramine melting endotherm without any polymorphic 
transition. However, there was a gradual decrease in the intensity of the melting peak with 
increasing XDP 3150 content as can be seen in 1:3 (Fig. 3.31d) drug to silica ratio. When the 
physically mixed and microwave-based formulations are compared, a decrease in melting peak 
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intensity of imipramine was more prominent in solid dispersions than the physically mixed 
formulations.  
 
Figure 3. 32. DSC profiles for imipramine (Imi) along AL1 FP based physical mixtures (PM) 
and microwave formulations (MWF). (a) Pure Imi, (b) PM 1:1 (c) PM 2:1 (d) PM 1:3 (e) MWF 
1:1 (f) MWF 2:1 and (g) MWF 1:3 
The size reduction in terms of the melting endotherm and broadening was attributed to the 
transition from crystalline to partially amorphous form of imipramine and the drug molecules 
being dispersed in the XDP 3150 as previously reported [195, 196]. This size reduction was 
more evident in the 1:3 drug to silica ratio formulation due to the higher weight of the XDP 
3150 in the formulations. The weight of the XDP 3150 has a significant effect on the thermal 
endotherm of imipramine as seen in the DSC results.  
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For Syloid® AL1 FP (Figure 3.32), the melting endotherm was more evident both in the 
physical mix products and microwave formulations, this was attributed to the small pore 
volume and diameter of the silica (0.40 cm3g-1 and 26 Å), the imipramine molecules are likely 
deposited on the surface of the AL1 FP as the DSC scans confirmed, the drug molecules were 
not accepted by the AL1 FP due to its small capacity [181]. Based on the results of Syloid® 
XDP 3050, 3150 and AL1 FP, it can be concluded that pore volume has an effect on imipramine 
loading.     
3.2.5.2 X-ray diffraction (XRD) 
Following on from the scans using DSC, i.e. the implication that possibly the products had 
increased in amorphous content on formulation, X-ray powder diffraction (XRD) analysis of 
pure imipramine, the physical mixtures and microwave-based formulations with Syloid® XDP 
3050, XDP 3150 and AL1 FP at ratios of 1:1, 2:1 and 1:3 were carried out to confirm this. 
Figure 3.33 (a) displays the XRD patterns of pure imipramine with diffraction peaks appearing 
at 12.2o, 16.0o, 18.2o, 19.8o, 23.8o, thus confirming the crystalline state expected for the drug 
in comparison with the featureless patterns for the Syloid® XDP 3050 (Figure 3.33b), 3150 
(Figure 3.34b) and AL1 FP (Figure 3.35b). All the physical mixtures prepared with either XDP 
3050, XDP 3150 and AL1 FP displayed peaks, indicating imipramine was still in a crystalline 
state. In contrast, the XRD patterns for the 1:1 product formulated utilising microwave 
radiation (Figure 3.33f, 3.34f and 3.35f) indicated small peaks of imipramine suggesting 




Figure 3. 33. XRD patterns for (a) Imi, (b) XDP 3050, (c) PM 1:1, (d) PM 2:1, (e) PM 1:3 (f) 
MWF 1:1, (g) MWF 2:1 and (h) MWF 1:3. 
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Figure 3. 34. XRD patterns for (a) Imi, (b) XDP 3150, (c) PM 1:1, (d) PM 2:1, (e) PM 1:3 (f) 
MWF 1:1, (g) MWF 2:1 and (h) MWF 1:3. 
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Figure 3. 35. XRD patterns for (a) Imi, (b) AL1 FP, (c) PM 1:1, (d) PM 2:1, (e) PM 1:3 (f) 
MWF 1:1, (g) MWF 2:1 and (h) MWF 1:3. 
These findings are in agreement with those reported on artemether [195], gemfibrozil [181] 
and fenofibrate [197] where other forms of silica and formulation processes were adopted. 
However, diffraction peaks were absent in the 1:3 drug to silica ratio products due to the higher 
silica content, thus confirming that the imipramine had been converted from a crystalline to 
amorphous form upon microwave heating. Due to the high silica content, a partial crystalline 
peak of imipramine was evident in the 2:1 drug to silica ratio-based products.  In summary, 
these results were in full agreement with the DSC results reported, confirming an amorphous 
product was created using microwave formulation with the three amorphous silicas.  
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3.2.5.3 Fourier transform infrared spectroscopy (FT-IR) 
As previously reported, FTIR has been utilised to investigate the incorporation of aminopropyl 
groups on the surface of mesoporous silica nanoparticles [198]. Figures 3.36 – 3.38 display the 
FTIR profiles for imipramine with Syloid® XDP 3050, XDP 3150 and AL1 FP at 1:1, 2:1 and 
1:3 drug-silica ratios.  
 
Figure 3. 36. FT-IR analysis of (a) Imi (b) XDP 3050, (c) MWF 1:1, (d) MWF 2:1, and (e) 1:3 
drug-XDP 3050 formulations 
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Figure 3. 37. FT-IR analysis of (a) Imi (b) XDP 3150, (c) MWF 1:1, (d) MWF 2:1, and (e) 1:3 













Figure 3. 38. FT-IR analysis of (a) Imi (b) AL1 FP, (c) MWF 1:1, (d) MWF 2:1, and (e) 1:3 
drug-AL1 FP formulations 
In this study, characteristics peaks of pure imipramine were observed at 3008.6 cm-1 for C-H 
stretching, 742.5 cm-1 for C-H bending, 2464.7 cm-1 for C-N stretching and 1573.7 cm-1 for 
C=C stretching vibrations. FT-IR for Syloid® XDP 3050, 3150 and AL1 FP have been 
previously discussed following Figure 3.22. The absorption bands of imipramine were evident 
in the 2:1 drug to silica ratio. For the three imipramine-silica formulated products, the results 
indicated a significant disappearance of the drug peaks, mainly displaying spectra 
corresponding to just each type of silica present. Furthermore, the spectra did not display any 
obvious additional peaks thus indicating there had been no significant changes in the chemical 












3.2.5.4. Scanning electron microscopy (SEM) 
SEM images of pure imipramine, physical mixtures and microwave-based formulations with 
Syloid® XDP 3050, XDP 3150 and AL1 FP at ratios of 1:1, 2:1 and 1:3 (x500 magnifications) 
were analysed to investigate changes in morphology.  
     
         
         
      
Figure 3. 39. SEM images (x500) of (a) Imi (b) PM of Imi and XDP 3050 (1:1), (c) PM of Imi 
and XDP 3050 (2:1), (d) PM of Imi and XDP 3050 (3:1), (e), PM of Imi and XDP 3150 (1:1), 
(f) PM of Imi and XDP 3150 (2:1), (g) PM of Imi and XDP 3150 (1:3), (h)  PM of Imi and 
AL1 FP (1:1), (i) PM of Imi and AL1 FP (2:1), and (j) PM of Imi and AL1 FP (1:3). 
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Images of imipramine and the silicas are shown in Figures 3.39 and 3.40. Imipramine particles 
(Figure 3.39a) have irregular morphology with some of them large and semi rectangular in 
shape while others are relatively small. 
It can be clearly seen in the physical mixtures (Figure 3.39) that drug alone with three Syloid® 
silicas do not mix well together as the crystalline state of the drug was maintained. In 
microwave formulation of the drug with Syloid® 3050 and XDP 3150 at 1:1 and 1:3 drug to 
silica ratios, there is an even distribution of silica particles but imipramine particles are not 
visible possibly the particles are molecularly dispersed on the surface of the silicas after the 
formulation. It can be concluded that the imipramine is partially amorphous upon formulation 
with those two silicas, as confirmed with DSC and XRD findings. Small crystals of imipramine 
can be clearly seen on the surface of Syloid® AL1 FP 2:1 (Figure 3.40h) prepared by microwave 
formulation. This was attributed to the small pore volume and pore diameter (0.40 cm3g-1 and 
26 Å) of the silica compared with Syloid® XDP 3050 and XDP 3150.          
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Figure 3. 40. SEM images x500 of (a) MWF of Imi and XDP 3050 (1:1), (b) MWF of Imi and 
XDP 3050 (2:1), (c) MWF of Imi and XDP 3050 (3:1), (d), MWF of Imi and XDP 3150 (1:1), 
(e) MWF of Imi and XDP 3150 (2:1), (f) MWF of Imi and XDP 3150 (1:3), (g) MWF of Imi 
and AL1 FP (1:1), (h) MWF of Imi and AL1 FP (2:1), and (i) MWF of Imi and AL1 FP (1:3). 
Overall, SEM images confirmed uniform mixing of imipramine with Syloid® XDP 3050, XDP 
3150 but the mixing with Syloid AL1 FP is not uniform as some crystalline drug was evident 
following the microwave formulation. Furthermore, modifying the formulation process such 
as that analysed in this study, can transform the extent of crystallinity in the sample and create 
a formulation that contains a uniform dispersion of imipramine within the silica matrix.       
3.2.6. In vitro imipramine release 
Dissolution profiles of imipramine loaded with Syloid® XDP 3050, XDP 3150 and AL1 FP 
materials at 1:1, 2:1 and 1:3 drug/silica ratios, along with imipramine itself (all containing an 
equivalent drug content), were investigated to determine the rate and extent of dissolution over 
a period of 45 minutes, as shown in Figures 3.41, 3.42 and 3.43. As shown in Figure 3.41, 
imipramine alone can be seen to rapidly undergo dissolution to reach 89.5 % (±2.9%) drug 
release in the first 5 minutes yet only increase to a maximum of 91.2 % (±2.4%) release after 
45 minutes. This amount could have increased up to 100 % drug release over an extended 
period but about 10 % of the drug was not released from the medium due to lowest required 
sampling time.  




Figure 3. 41. Release profiles for pure imipramine (Imi) and imipramine Syloid® XDP 3050-
based formulations at 1:1, 2:1 and 1:3. Each data point represents the mean of triplicate results 
(±SD). 
This dramatic drug release can be explained by considering the physicochemical properties of 
the drug under analysis, i.e. imipramine alone is known to rapidly undergo dissolution due to 
its hydrophilic nature and aqueous solubility of 18.2 mg/L [199, 200], thus partially explaining 
the undesirable frequent dosing intervals required for patients with this drug [201].   
For the Syloid® XDP 3050-based formulations investigated, the presence of the silica slightly 
modified the release profiles as illustrated in Figure 3.41 for 1:1 and 1:3 drug/silica ratios. The 
two ratios displayed a drug release of 86.0 % (±6.9 %) and 92.4 % (± 8.7 %) in 5 minutes 
whereas after 45 minutes, the products displayed a drug release of 98.8 % (± 5.5 %) and 98.2 
% (± 9.4 %) for 1:1 and 1:3 respectively. Surprisingly, the 2:1 ratio did not provide such 
dramatic an increase but instead retarded drug release with a percentage of 81.1 % (± 4.8 %) 
after 5 minutes, yet only increased to 85.2 % (± 2.5 %) after 45 minutes. Hence, the drug may 




























in less drug release. The surface chemistry of the XDP 3050 may be the reason for decreasing 
the imipramine release as a result of interactions between the drug and the functional group of 
the XDP 3050 mesopores [202]. Contrastingly, in 2:1 ratio the amount of drug is rather high 
and as a result, there could be a partial pore blockage during the release experiments due to the 
drug crystallisation on top of the pores as previously reported by Riikonen et al. [203], 
particularly for XDP 3050 with large pore diameter, which may also decrease the imipramine 
release [18].  
 
Figure 3. 42. Release profiles for pure imipramine (Imi) and imipramine Syloid® XDP 3150-
based formulations at 1:1, 2:1 and 1:3. Each data point represents the mean of triplicate results 
(±SD). 
Conversely, for the XDP 3150-based formulations analysed, it can be clearly seen that the rate 
and degree of drug release is dramatically reduced compared with pure drug. This deviation 
can be attributed to the difference in pore diameter of the XDP 3150 (200 Å) compared with 
the XDP 3050 (229 Å). The silica has a far smaller pore diameter which resulted in far less 
drug entering the pores during the microwave formulation process. The 1:3 ratio provided the 




























released after 45 minutes, while the 1:1 displayed a drug release of 76.4 % (±2.4 %) after 5 
minutes and 85.6 % (± 6.7 %) after 45 minutes. Conversely, the 2:1 product provided the 
slowest release of 77.9 % (± 1.3 %) after 5 minutes and 82.1 % (± 0.2 %) after 45 minutes 
respectively.          
Comparing the dissolution profiles of imipramine from XDP 3050 and XDP 3150 samples with 
variation in their pore diameter, Figure 3.42 shows that the imipramine was clearly affected by 
the pore diameter of XDP 3150. The possible explanation for the different dissolution profiles 
between the 3050 and 3150 may emerge from the different pore structures of Syloid® XDP 
3050 and 3150. These findings are in good agreement with previously published works [6, 
150].   
 
Figure 3. 43. Release profiles for pure imipramine (Imi) and imipramine Syloid® AL1 FP-based 
formulations at 1:1, 2:1 and 1:3. Each data point represents the mean of triplicate results (±SD). 
Syloid AL1 FP (Fig. 3.43) did not follow this trend; the drug release for the three ratios was 




























maximum drug release of 84.1 % (± 3.8 %) after 45 minutes. The 2:1 product provided the 
maximum drug release of 80.1 % (± 4.8 %) and 80.2 % (± 1.8 %) drug was released for the 1:3 
ratio after 45 minutes. This dramatic retardation in drug release can be explained by the 
physicochemical properties of the AL1 FP, specifically those identified in Table 2.1. For 
example, AL1 FP and XDP 3050 pore sizes are very different, in that AL1 FP has small 
mesopores, i.e. the silica has by far the smallest particle size (10 µm), smaller pore volume and 
pore diameter (0.40 cm3g-1 and 26 Å) compared with other forms of silica analysed. Based on 
the pattern of increasing percentage release, i.e. from XDP 3150 to AL1 FP to XDP 3050, it 
would appear that two properties of the Syloid® silicas may play a key role in controlling the 
process, namely surface area and/or pore diameter. Interestingly, pore volume does not appear 
to be an influential factor for the rate and extent of dissolution, yet pore diameter is. In this 
work it appears that a large pore diameter, with a small surface area, maximises the extent of 
dissolution, which again, fits well with the findings of other studies with mesoporous 
microspheres [150, 204]. As a consequence of this, it is not only possible to dramatically 
enhance the rate and extent of dissolution, but also to vary the percentage depending upon the 
type of Syloid® silica used. Another potentially influential factor is the formation of complexes 
which may affect the drug release profile through the creation of particle aggregation. If this is 
the case, then it can be proposed that there are two unique structures within the formulation: 
drug within pores and aggregates between particles which can both contribute to drug release.  
3.3. Conclusions  
In summary, all three Syloid® silicas have enhanced the percentage of dissolution following a 
microwave formulation technique, it would appear that the transformation from the crystalline 
to amorphous form (as evidenced by XRD and dissolution profiles of processed samples) plays 
a key role. This has been the conclusion of other researchers, when investigating alternative 
mesoporous materials [176], and fits well with the results from this research. However, when 
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considering why the three Syloid® silicas did not facilitate the same increase in percentage 
release, it is more appropriate to consider their relative physicochemical properties, specifically 
those identified in Table 2.1. For example, AL1 FP and XDP 3050 pore sizes are very different, 
in that AL1 FP has small mesopores, i.e. a smaller pore volume and diameter compared with 
XDP 3050. Based on the pattern of increasing percentage release, i.e. from XDP 3150 to AL1 
FP to XDP 3050, it would appear that two properties of the Syloid® silicas might play a key 
role in controlling the process, namely surface area and/or pore diameter. In this study, it 
appears that a large pore diameter, with a small surface area, maximises the extent of 
dissolution, which again, fits well with the findings of other studies with mesoporous 
microspheres [205, 206]. As a consequence of this, it is not only possible to dramatically 
enhance the rate and extent of dissolution, but also to vary the percentage depending upon the 
type of Syloid® silica used. This finding can be of benefit for not only phenylbutazone, 
indomethacin or imipramine-based formulations but potentially a far wider range of 
compounds that exhibit poor aqueous solubility which will help alleviate bioavailability issues. 
Overall, a higher percentage release was achieved with the drug formulated with the microwave 




Chapter 4. Microwave differential thermal analysis (MWDTA) of pharmaceutical 
compounds 
4.1. Introduction 
Almost twenty years ago a new analytical technique was described for the first time, namely 
microwave differential thermal analysis (MWDTA), that combined the advantages of 
microwave heating with the benefits of differential temperature measurement to probe the 
thermal properties of materials [90]. The limited thermal response using conventional heating 
is avoided using microwave heating as there is direct interaction of the material with the 
microwave energy. However, more importantly, microwave heating provides a unique means 
of investigating thermal transitions based on the associated changes in the dielectric properties 
of the sample. These thermally induced changes, such as melting or decomposition, are then 
analysed based on the microwave power profiles obtained. When a material is subjected to 
microwave radiation there are two important parameters that dictate the nature of the 
interaction, namely the dielectric constant and the dielectric loss factor. The former considers 
the way a material is polarised by the electric field and the latter the conversion from radiation 
to heat. This form of analysis has been successfully applied to a range of materials including 
decompositions, dehydrations and phase changes [207] and can provide qualitative and 
quantitative information of solid state processes [208]. Furthermore, MWDTA can make a 
valuable contribution to the investigation of the so-called ‘microwave effect’, these are 
anomalies that occur when certain materials are heated in a microwave field [209] as well as 
reveal fine detail through the use of derivative plots of either the applied power or  temperature 
[210].  In recent years a variety of  studies have investigated the application of MWDTA to 
both a range of materials, such as ceramics [211], and a range of more complex analytical 
systems [212].  
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In contrast to the use of microwave radiation as an analytical tool, a comparatively large volume 
of research has been undertaken to investigate the effects (and potential benefits) of using 
microwaves in a formulation capacity such as that carried out in one. This research has 
highlighted the benefits of using microwave processing for pharmaceutical compounds with 
the presence of excipients to create unique products. Furthermore, microwave processing has 
been applied for ibuprofen in combination with stearic acid and polyvinylpyrrolidone, along 
with fenofibrate and mesoporous silicas to create a unique formulation [87, 88]. An interesting, 
and very recent, application of microwave irradiation is the concept of amorphisation within 
the tablet, i.e. creating the amorphous form of the drug in its final dosage form directly before 
administration [89].  
In summary, microwave radiation has been previously employed for the analysis of compounds 
through the use of MWDTA, and separately, to formulate products that possess unique 
physicochemical properties that can be advantageous, especially in the pharmaceutical 
industry. However, as yet there has been no consideration for the use of MWDTA to investigate 
pharmaceutical compounds that are to be subjected to microwave irradiation during 
formulation to fully comprehend if such a process will be suitable and to fully understand the 
interactions that will occur. This research considers the use of MWDTA on model 
pharmaceutical compounds to investigate the potential application of this form of thermal 





4.2. Results and discussion 
4.2.1. MWDTA of silicon carbide (SiC) 
The MWDTA profile for the heating and cooling of silicon carbide (SiC) heated at 5 oC/min to 
300 oC and then cooled at -5 oC min-1 to 30 oC is shown in Figure 4.1. Silicon carbide (SiC) is 
relatively chemically inert over a wide temperature range [213], strongly absorbs microwave 
energy which makes it couple strongly and has high thermal conductivity. SiC has no chemical 
or physical changes over the temperature range investigated but was studied to provide 
information to illustrate the variation of phase change parameters which can be found as 
material is heated.   
Figure 4.1(A) is in the form of calculated ∆T as a function of temperature of the sample while 
Figure 4.1(B), shows the relationship between the temperature and power applied during the 
run. Apart from an initial variation at the onset of the experiment, the temperature control was 
smooth and featureless with a slow rise in microwave power, set to control the heating rate. No 
event was observed in both Figure 4.1(A) and 4.1(B) other than a switch upon cooling (X) as 
the fusion of SiC is around 2700 oC [103] and the minimum and maximum temperature used 




Figure 4. 1. Microwave differential thermal analysis (MWDTA) of silicon carbide (SiC) heated 
at 5 oC/min to 300 oC then cooled at -5 oC/min to 30 oC.  
4.2.2. MWDTA of pharmaceutical compounds 
Eight model pharmaceutical compounds were analysed using MWDTA namely; benzocaine, 
haloperidol, ibuprofen, indomethacin, ketoprofen, naproxen, imipramine and phenylbutazone. 
These compounds were selected for their range of physicochemical properties thus covering 
the variety of types of compounds often encountered in the pharmaceutical industry. Firstly, 
benzocaine was investigated, as shown by the temperature and power-profile data in Figure 
4.2.  
Apart from an onset variation at 13.6 W (1.6 min) at the start of the experiment, it can be seen 
that temperature control was smooth and featureless with a slow rise in MW power to maintain 
the set heating rate. However, at around 92.8 oC the power rose to 21.0 W from 20.0 W, i.e. a 




























more energy was required to drive the endothermic process. At 97.1 oC the fusion of benzocaine 
was complete, and the temperature rose sharply to attain an equilibrium at 160 oC. The 
equilibrium was maintained for a further 5 min at which point the temperature was decreased 
from 160 oC to 40 oC. 
 
Figure 4. 2. Temperature and associated power profile for benzocaine heated at 5 oC/min to 
160 oC and then cooled to 40 oC 
There was a rapid decrease in power at the equilibrium stage from 29.3 W to 25.3 W, the stage 
was maintained for 5 min and then dropped again to 18.2 W with the overall change in power 
of 11.1 W. Initially, the applied MW power fell by 4.0 W and then decreased again by 7.1 W 
until the sample temperature returned to its set cooling rate where the power dropped back to 
0 W without any change during the process. The dielectric change from solid to liquid revealed 
that less power was required to maintain the heating rate after the drug had become liquid, 
compared with before the transition. Results obtained for MWDTA of benzocaine (first and 
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second cycle) are displayed in Figure 4.3 in the form of calculated ∆T (Tsample – Treference) plotted 
as a function of sample temperature. 
 
Figure 4. 3. Microwave differential thermal analysis (MWDTA) of benzocaine heated at 5 oC/ 
min to 160 oC for the first and second run (FR and SR) and cooling at -5 oC/min to 40 oC in 
both cases. 
From Fig. 4.3, there was an onset variation at the start of the experiment and a broad 
endothermic event at 91.2 oC corresponding to melting of the drug followed by a rise in ∆T 
indicating an increase in tan ∂ going from solid to liquid. Upon cooling, a sharp exothermic 
event at 47.9 oC corresponding to recrystallisation has a slightly lower temperature, the fusion 
of the drug was slightly above that expected based on DSC data presented later in this study. 
The phase change of the drug due to the effect of temperature has been previously reported 
[214]. Many drugs decompose as a result of the effect of heat, oxygen, light, and moisture 
therefore based on these factors, the second cycle was carried out to an increased temperature 
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of 200 oC in an attempt to encourage decomposition of the compound. The second experimental 
cycle of the same sample showed an initial rise in ∆T after the transition at 91.6 oC with 
recrystallisation occurring at 51.6 oC, i.e. only a slight shift was evident of the aforementioned 
transitions due to heating-cooling-reheating and re-cooling effects. 
Changes observed in the profile of the drug obtained included a change in dielectric properties 
after the transition as the sample became molten which indicates that the sample was heating 
more efficiently than before the transition. This was also apparent in Figure 4.2 whereby the 
power increased and decreased as the sample coupled variably with the microwave energy. The 
resultant profile provided the expected behaviour of a fusion process accompanied by a large 
dielectric change. These changes were not observed during DSC (results discussed later) as a 
consequence of heat capacity.  
 
Figure 4. 4. Microwave differential thermal analysis (MWDTA) of haloperidol heated at 5 oC/ 
min to 200 oC for the first (FR) and second (SR) run then cooling at 5 oC/min to 40 oC in both 
cases. 
















These changes demonstrate the sensitivity of this technique to materials that undergo thermal 
transitions. Secondly, haloperidol was analysed using MWDTA, as displayed in Fig. 4.4.  
The MWDTA profiles of haloperidol (first and second run) shown in Figure 4.4 revealed a 
sharp transition at 151.8 oC corresponding to the melting point of the drug. The temperature at 
which the event takes place is in good agreement with the literature value of  153 oC found 
using a conventional thermal analysis technique [215], followed by a rise in ∆T indicating an 
increase in tan ∂ going from solid to liquid. A dielectric change can be seen after the transition 
as the sample couples more strongly with the microwave energy, which again, suggests that 
the sample was heating more effectively than before the transition. When the temperature was 
changed from increasing to decreasing, a defined recrystallisation temperature was evident. In 
the second run, similar events were observed with a broadened, reduced intensity, and shifted 
to a lower temperature for the fusion of the drug, namely a 12.6 oC difference in comparison 
with the first run which further confirms the nature of crystallinity of the drug, although the 
changes in the latter are relatively small.  Again, minor events observed were not thought to be 
‘real’ transitions but merely artefacts of the method employed. Thirdly, indomethacin was 




Figure 4. 5. Microwave differential thermal analysis (MWDTA) of indomethacin heated at 5 
oC/min to 200 oC for the first (FR) and second (SR) run then cooled at 5 oC/min to 40 oC in 
both cases 
Figure 4.5, displays a sharp transition with an extrapolated onset at 159.3 oC in the first run 
indicating fusion occurred: further evidenced at 165.2 oC, corresponding to the known melting 
point of this drug [216]. The transition was accompanied by a significant dielectric change, this 
change did not return to the baseline (as expected for this drug) as a consequence of the 
differing dielectric properties as the sample underwent melting. Upon subsequent cooling, no 
significant phase transition was observed, implying the drug did not recrystallise. No 
significant phase changes were observed in the second run (other than instrument recovery) 
further justifying the theory that the sample remained in an amorphous form. Fourthly, 
ketoprofen was analysed using MWDTA, as displayed in Figure 4.6.  

















Figure 4. 6. Microwave differential thermal analysis (MWDTA) of ketoprofen heated at 5 
oC/min to 160 oC then cooled to 40 oC for the first (FR) and second (SR) run. 
In Figure 4.6, apart from an initial variation at the onset of the experiment, the differential 
temperature in the first run was smooth and featureless until a transition occured at 94.7 oC, 
corresponding to the melting point of the drug in good agreement with what was previously 
reported  [217]. The temperature was increased further which brought about a change in 
baseline as a consequence of the increased coupling of the sample with microwave energy as 
the sample underwent melting. Upon cooling, no significant transition event was observed, 
implying the sample remained in amorphous form, i.e. no recrystallisation. In the second run, 
there was no event observed other than a decrease in tangent in the region of 124.8 oC – 140.0 
oC, which was brought about by a dielectric change. The tangent gave a good indication of how 
effectively the sample converted the applied microwaves into thermal energy, i.e. the greater 
the heating via polarisation the greater the thermal loss from the drug. The fifth pharmaceutical 
compound to be analysed using MWDTA was phenylbutazone, as shown in Figure 4.7.  


















Figure 4. 7. Microwave differential thermal analysis (MWDTA) of phenylbutazone heated at 
5 oC/min to 160 oC then cooled to 40 oC for the first (FR) and second run (SR). 
The first run displayed in Figure 4.7 does not reveal a significant change in baseline following 
the transition corresponding to the known melting point of the drug at 109.8 oC [218]. This 
finding indicates that there was no change in the dielectric properties of the sample after the 
transition - in contrast with the previously analysed compounds. No observable event 
corresponding to recrystallisation was evident during the first cooling. The second cycle of 
phenylbutazone was characterised by a β polymorphic transition at 93.4 oC [173, 175]. Again, 
upon the second cooling no significant event occurred implying a lack of recrystallisation, as 
was the case with the first run. However, the presence of a small peak at 105.0 oC indicates that 
there was a small amount of partially crystalline compound present.  
















The sixth compound of pharmaceutical interest analysed using MWDTA was ibuprofen, as 
shown in Figure 4.8.  
  
Figure 4. 8. Microwave differential thermal analysis (MWDTA) of ibuprofen heated at 5 oC 
min-1 to 160 oC then cooled to 40 oC for the first (FR) and second (SR) run. 
MWDTA (Figure 4.8) of ibuprofen indicated one transition occurring at 76.2 oC. The transition 
corresponds to the expected fusion of the drug in the first cycle [219] and no increased coupling 
was observed after the transition. Furthermore, no recrystallisation event was apparent upon 
cooling. In the second cycle, a transition at 83.1 oC was unexpectedly observed implying some 
recrystallisation had occurred during the previous cooling cycle and the sample was able to 
undergo a melting transition. The seventh compound of pharmaceutical interest analysed using 
MWDTA was naproxen, as shown in Figure 4.9.  

















Figure 4. 9. Microwave differential thermal analysis (MWDTA) of naproxen heated at 5 oC/ 
min to 200 oC for the first and second run (FR and SR) and cooling at 5 oC/min to 40 oC in both 
cases. 
The MWDTA profile of naproxen in the form of calculated ∆T as a function of temperature is 
shown in Figure 4.9 the endothermic fusion has an onset temperature of 154.6 C for the first 
run, which is in good agreement with the literature value of 152 oC found using conventional 
thermal analysis [220]. The trasition was accompanied by a step change as the sample 
underwent melting. Upon cooling, a sharp exothermic recrystallisation had a slightly lower 
temperature of 95.6 oC. The second run of the sample showed an initial rise in ∆T after the 
transition. All the phase changes observed in the first run were also observed in the second run. 
The eighth compound of pharmaceutical interest analysed using MWDTA was imipramine, as 
shown in Figure 4.10.  
















Figure 4. 10. Microwave differential thermal analysis (MWDTA) of imipramine heated at 5 
oC/ min to 180 oC for the first and second run (FR and SR) and cooling at 5 oC/min to 40 oC in 
both cases. 
The first run displayed in Figure 4.10 does not reveal a significant change in baseline following 
the transition corresponding to the known melting point of the drug at 173.7 oC [194]. This 
finding indicates that there was a small change in the dielectric properties of the sample after 
the transition - in contrast with the previously analysed compounds. The method did not 
observe any event corresponding to recrystallisation during the first cooling. The second cycle 
of the process was characterised by a transition at 145.4 oC, particularly surprising based upon 
data from the first run. Again, upon the second cooling no significant event occurred implying 
a lack of recrystallisation, as was the case with the first run. However, the presence of a small 
event at 145.4 oC indicates that there was a small amount of partially crystalline compound 
present.  
 















4.2.2. Differential scanning calorimetry (DSC) of pharmaceutical compounds 
DSC analysis was undertaken for the eight model pharmaceutical compounds, a summary of 
the values obtained can be seen in Table 4.1. 
Table 4. 1: Physicochemical data and DSC peak values for the melting (Tm) and 
recrystallisation (Tr) of eight compounds and four excipients  
 
Material Mw /g.mol
-1a Crystalline/Amorphous Tm /
oC Tr /
oC 
BZ 165.19 Crystalline 90.7 48.5 
Halo 375.86 Crystalline 152.1 92.3 
IBU 206.28 Crystalline 77.7 - 
IMC 357.79 Crystalline 160.5 - 
KETO 254.28 Crystalline 96.2 - 
PHBU 308.37 Crystalline 107.5 - 
NPX 230.26 Crystalline 156.4 112.6 
IMI 316.87 Crystalline 174.9 - 
β-CD 1134.98 Crystalline  90-140 - 
D-man 184.16 Crystalline  166.5 119.9 
SA 284.48 Crystalline 70.1 61.2 
XDP - Amorphous - - 
  
a Average molecular weight (Mw) according to the supplier  
 
Benzocaine is a crystalline drug having a fusion temperature of 90.7 oC, as previously reported 
in literature [214]. In Figure 4.11(a), pure benzocaine (FR) displayed an endothermic peak at 
91.2 oC followed by a sharp peak with high intensity appearing during cooling at 48.5 oC, 
corresponding to the exothermic recrystallisation event. The appearance of the fusion peak 
confirms the crystallinity of the drug during the first cycle. The second cycle (Figure 4.11b) 
exhibited a broader melting peak with a small shift to 91.5 oC, in comparison with the first 
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cycle. This result suggests that the drug molecules returned to a crystalline form after the first 









Figure 4. 11. DSC thermograms of; (a) Benzocaine first run (FR) and (b) Benzocaine second 
(SR) 
Upon the first heating cycle for haloperidol (Figure 4.12 a), a sharp endothermic peak was 
observed at 152.0 oC, corresponding to the published melting point for the compound [215]. 
Subsequent cooling highlighted an exothermic event occurring at 92.5 oC corresponding to 
recrystallisation of the compound. In the second heating (Figure 4.12 b) and cooling cycle the 
initial peak temperature and subsequent exothermic event were observed at similar, but slightly 














Figure 4. 12. DSC thermograms of; (a) Haloperidol first run (FR) and (b) Haloperidol second 
run (SR), 
The thermal profile for indomethacin (Figure 4.13 a) was characterised by a well-defined sharp 
endothermic peak corresponding to the expected fusion process at 160.5 oC, in agreement with 
published data [216]. The drug did not appear to recrystallise upon cooling. Upon a second 
heating and cooling cycle (Figure 4.13b), an endothermic peak corresponding to glass 
transition was observed at 47.6 oC, melting and recrystallisation peaks were not observed, most 
likely to be a consequence of the drug remaining in amorphous form after fusion in the first 
heating cycle. 
These findings agree with the XRD data to be discussed later. A summary of the DSC profiles 





Figure 4. 13. DSC thermograms of; (a) indomethacin first run (FR), and (b) indomethacin 
second run (SR) 
For the initial heating cycle of phenylbutazone a single sharp endothermic peak was observed 
at 109.3 oC implying melting of the compound, this value corresponded well with published 
data [218]. Upon cooling, no exothermic transition was observed, suggesting that there was no 
recrystallisation as the sample cooled. Upon the second heating and cooling cycle, a small and 
broad melting peak was observed at a slightly lower temperature than that seen in the first 
cycle, namely 99.2 oC. This small event suggests a β polymorphic transition of the drug as 
evidenced in the MWDTA experiment [173]. For ketoprofen only one transition was observed 
at 96.2 oC, in the first heating cycle, corresponding to the published fusion temperature for the 
compound [217]. 
















Figure 4. 14. DSC thermograms of; (a) phenylbutazone first run (FR), (b) phenylbutazone 
second (SR), (c) ketoprofen first run (FR), (d) ketoprofen second run (SR), (e) ibuprofen first 
run (FR), and (f) ibuprofen second run (SR) 
However, a similar event was observed which shifted to a slightly lower temperature in the 
second cycle at 94.9 oC, suggesting that the compound has transformed into a partially 
amorphous form after the initial melt transition. In the case of ibuprofen, the DSC profiles are 
similar to those of ketoprofen. The only observable thermal event for ibuprofen was an 
endothermic peak at 77.4 oC indicating melting of the compound, only seen in the first cycle 
and closely related to that reported in the literature [219]. Once again, after cooling, an event 
at 78.2 oC was observed in the second cycle, implying the sample also melted after the initial 
transition was observed. These results fit well with the findings of the XRD to be discussed 
later. A summary of the DSC profiles for these three drugs is displayed in Figure 4.14.  
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Figure 4. 15. DSC thermograms of; (a) naproxen first run (FR), (b) naproxen second (SR), (c) 
imipramine first run (FR), (d) imipramine second run (SR) 
The comparable DSC profiles of naproxen and imipramine are shown in Figure 4.15. In the 
first run of naproxen, the endothermic fusion has an onset temperature of 156.4 oC which 
corresponds to the fusion of the compound while upon cooling, the corresponding exothermic 
recrystallisation has a slightly lower onset of 112.6 oC. The second run of the same sample 
shows a slightly broadened peak at 157.2 oC while after cooling, an event at 105.9 oC was 
observed in the second cycle, implying the sample also recrystallised after the initial transition 
was observed. In the case of imipramine, a single sharp endothermic peak was observed at 
174.9 oC implying melting of the compound, this value corresponded well with published data 
[194]. Upon cooling, no exothermic transition was observed, suggesting that there was no 
recrystallisation as the sample cooled. In the second cycle, a transition at 113.5 oC was 
unexpectedly observed implying some recrystallisation had occurred during the previous 


















cooling cycle and the sample was able to undergo a melting transition at a slightly lower 
temperature of 175.4 oC.  
4.2.3. X-ray diffraction (XRD) of pharmaceutical compounds  
The XRD patterns of benzocaine (FR and SR), haloperidol (FR and SR) and indomethacin (FR 
and SR) are illustrated in Figure 4.16. The diffraction patterns observed at 8.6o, 16.8o, 20.0o, 
24.0o, and 27.2o correspond to powder diffraction patterns of pure benzocaine (FR) and were 
consistent with patterns reported in the literature for this drug [221].  
 
Figure 4. 16. XRD patterns of; (a) benzocaine first run (FR), (b) benzocaine second (SR), (c) 
haloperidol first run (FR), (d) haloperidol second run (SR), (e) indomethacin first run (FR) and 
(f) indomethacin second run (SR) 
The patterns of benzocaine in the second run presented a different pattern from those of the 
first run. Less intense peaks for this drug in the second run (Figure 4.16b) were observed, 
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possibly due to changes in particle size and shape after the first run. The observed diffractions 
for haloperidol (FR) at 14.9o, 19.9o and 26.2o confirm the crystalline nature of the drug is 
consistent with diffractograms reported in the literature [222] while the second run shows a 
less intense diffraction pattern due to the loss of some crystallinity of the drug after the first 
run. The diffractograms corresponding to the crystalline indomethacin (FR) were observed at 
17.0o, 19.5o, 21.8o, 26.5o, and 29.3o which suggest that indomethacin was γ-polymorph [223]. 
However, there was a complete disappearance of diffractograms in the second run of the drug 
which confirms the transformation from crystalline nature to amorphous form after the first run 
as previously evidenced in the DSC analysis.  
The XRD patterns of PhB (FR and SR), Keto (FR and SR) and Ibu (FR and SR) are illustrated 
in Figure 4.17. Pure crystalline phenylbutazone can be seen in Figure 4.17(a) with sharp 
diffraction peaks at 8.12o, 12.95o, 18.59o and 20.88o and was in agreement with previously 
published data for the drug [11]. Phenylbutazone peaks are still evident in the second run with 
high intensity suggesting the drug is still in a partial-crystalline state. The patterns for 
ketoprofen in the first run were observed at 14.6o, 18.6o, and 23.0o confirming the crystalline 
structure of the drug which fits in well with that reported previously [224]. However, the second 
run shows the diminishment of peak intensities confirming the loss of some crystalline structure 
of the drug after the first run.  Characteristics peaks at 16.7o, 20.3o and 22.4o suggests ibuprofen 






Figure 4. 17. XRD patterns of; (a) phenylbutazone first run (FR), (b) phenylbutazone second 
(SR), (c) ketoprofen first run (FR), (d) ketoprofen second run (SR), (e) ibuprofen first run (FR) 
and (f) ibuprofen second run (SR) 
Figure 4.18 displays the XRD patterns of naproxen and imipramine. The diffraction pattern of 
naproxen (FR) was highly crystalline in nature with peaks appearing at 12.6o, 16.8o, 18.8o and 
22.5o while in the second run, the peaks were still visible confirming the drug crystallinity 
which fits well with the previously published data for the drug [220]. In the case of imipramine 
first run (Figure 4.18c), the diffraction patterns were observed at 12.2o 18.0o 19.8o and 23.6o 
which confirmed the crystalline structure of the drug as expected based on MWDTA and DSC. 
The second run (after processing) can be seen in Figure 4.18d where the drug was converted to 
an amorphous form in contrast to what was observed in MWDTA and DSC discussed earlier. 
This could possibly be due to the conventional method employed in melting the compound. 
0 10 20 30 40 50 60 70
2 Theta (o)
PhB FR PhB SR KETO FR









Overall, these results are in good agreement with the DSC and MWDTA observations 
discussed earlier with the exception of the second run of imipramine.           
   
Figure 4. 18. XRD patterns of; (a) naproxen first run (FR), (b) naproxen second (SR), (c) 
imipramine first run (FR) and (d) imipramine second run (SR) 
4.2.4. Hot stage microscopy (HSM) of pharmaceutical compounds 
HSM was utilised to follow the transformation of the eight compounds as a function of 
temperature to visibly observe changes. Optical images and reflected light intensity (RLI) 
values were recorded and are presented at selected temperatures in Figures 4.19 – 4.26.  
Firstly, benzocaine (Figure 4.19) initially appeared as a white crystalline solid and, upon 
heating, a visible melting event occurred at an appropriate temperature to correspond with that 
previously seen using MWDTA and DSC. Observations during the analysis revealed a 
colourless liquid material suggestive of fusion of the drug at 90.2 oC followed by 
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recrystallisation having a lower temperature during the cooling at 48.1 oC, A gradual decrease 
in the sample RLI values was observed from 10.7 – 10.5 V, correlating with the gradual change 
in the sample temperature going from solid to liquid. Below 10.5 V, a slight decrease in the 
light intensity could be noted upon cooling when the sample began to recrystallise which is 
matched by a sharp decrease in the temperature profile.     
  
Figure 4. 19. Microscope images and optical data of a sample of benzocaine heated from 30 to 
160 oC as a function of temperature  
For haloperidol HSM analysis (Figure 4.20) revealed a white powder at 30 oC before the fusion, 
transforming to a liquid at 149.4 oC followed by recrystallisation at 90 oC during cooling, as 
expected based on MWDTA and DSC data. The sample decolourises around 200 oC after the 
fusion process as the sample begins to decompose due to differences between the furnace and 
sample temperatures. The furnace temperature was greater than the sample temperature as a 
result, the sample was heated at a faster rate when the analysis was carried out. There was a 






















































fusion process. Upon decomposition, no change in RLI values was noted which is matched by 
the sample temperature.  
 
Figure 4. 20. Microscope images and optical data of a sample of haloperidol heated from 30 to 
200 oC as a function of temperature  
Figure 4.21 displays images of solid indomethacin before the melt at 30 oC then the 
transformation at 159.1 oC, indicating melting of the compound. Upon subsequent cooling to 
30 oC, no transformation occurred as the sample stayed in an amorphous form after the initial 
phase change, in agreement with the previously presented MWDTA and DSC data. On looking 
at the RLI values, a gradual decrease could be observed going from solid to liquid from 10.5 
to 9.5 V, correlating with the change in colour of the compound, followed by a sharp increase 



























































Figure 4. 21. Microscope images and optical data of a sample of indomethacin heated from 30 
to 200 oC as a function of temperature  
Optical images for phenylbutazone were recorded at 91.3 oC and 109.7 oC (Figure 4.22) and 
demonstrate that the compound underwent a solid-state transformation that started to occur at 
91.3 oC and was complete at ~ 109.7 oC. Upon cooling the sample returned to a glassy form at 
30 oC. These findings agree with those found using MWDTA and DSC analysis. From the 
optical data, a gradual decrease was observed for the compound from 10.4 to 9.8 V going from 



































































Figure 4. 22. Microscope images and optical data of a sample of phenylbutazone heated from 
30 to 160 oC as a function of temperature  
Figure 4.23 displays optical images of solid ketoprofen at 78.3 oC, upon melting at 96.7 oC and 
upon cooling to 30 oC. No observable transformation occured after the initial melting, in 
agreement with findings previously presented using MWDTA and DSC. The optical data 
shows a gradual decrease of RLI values of the compound from 10.5 to 9.4 V going from solid 
to liquid, almost similar to what was observed in the case of phenylbutazone, correlating with 


























































Figure 4. 23. Microscope images and optical data of a sample of ketoprofen heated from 30 to 
160 oC as a function of temperature  
Figure 4.24 displays images of the white powdered ibuprofen before the melt at 65.4 oC and 
upon melting at 78.5 oC. On cooling to 30 oC, no visible transformation occurred, in agreement 
with data evidenced from MWDTA and DSC analysis. The optical data shows a gradual 
decrease of RLI values of the compound from 10.2 to 9.2 V going from solid to liquid, 



























































Figure 4. 24. Microscope images and optical data of a sample of ibuprofen heated from 30 to 
160 oC as a function of temperature  
Naproxen (Figure 4.25) initially appeared as a white crystalline solid and, upon heating, a 
visible melting event occurred at an appropriate temperature to correspond with that previously 
seen using MWDTA and DSC. Observations during analysis revealed a colourless liquid 
material suggestive of fusion of the drug at ~152.7 oC followed by recrystallisation at a lower 
temperature during cooling at 109.6 oC. A gradual decrease in the sample RLI values was 
observed from 9.7 – 9.0 V, correlating with the gradual change in the sample temperature going 
from solid to liquid. Below 8.4 V, a slight decrease in the light intensity could be noted upon 
cooling when the sample began to recrystallise which is matched by a sharp decrease in the 






















































Figure 4. 25. Microscope images and optical data of a sample of naproxen heated from 30 to 
200 oC as a function of temperature  
Finally, imipramine (Figure 4.26) initially appeared as a white crystalline solid and upon 
heating, a visible melting event occurred at an appropriate temperature to correspond with that 
previously seen using MWDTA and DSC. Observations during analysis revealed a colourless 
liquid material suggestive of fusion of the drug at 170.7 oC without any recrystallisation during 
the cooling. Above 180 oC, the sample decomposed which is matched by the changes in colour 
of the sample.  A gradual decrease in the sample RLI values was observed from 9.7 – 7.9 V, 
correlating with the gradual change in the sample temperature going from solid to liquid. A 
slight decrease in the light intensity was also noted at around 6.6 V, which occurred as the 


























































Figure 4. 26. Microscope images and optical data of a sample of imipramine heated from 30 to 
200 oC as a function of temperature  
4.3. MWDTA of excipients  
Following on from analysis into eight pharmaceutical compounds, four excipients were 
selected for further investigations using MWDTA namely; D-mannitol, stearic acid, beta 
cyclodextrin and Syloid XDP 3050. Firstly, D-mannitol was analysed, as shown by ∆T as a 
function of temperature in Figure 4.27.  
The MWDTA profile of D-man is shown in Figure 4.27 in the form of calculated ∆T (Tsample - 
Treference) as a function of sample temperature. In the first run of the compound, the endothermic 
fusion has an onset temperature of 163.8 oC, followed by a small rise in ∆T indicating an 
increase in tan ∂ going from solid to liquid as the sample melted, while the corresponding 























































Figure 4.27. Microwave differential thermal analysis (MWDTA) of D-mannitol heated at 5 oC/ 
min to 200 oC for the first and second run (FR and SR) and cooling at 5 oC/min to 40 oC in both 
cases. 
A broad endothermic transition was observed in the second run of the same sample at 165.7 oC 
corresponding to fusion followed by a rise in ∆T after the transition while upon cooling, 
exothermic recrystallisation of 124.9 oC was recorded which is consistent with the DSC and 
HSM data discussed later.    
For stearic acid in Figure 4.28, the first profile results for the first run display a broad 
exothermic fusion with an onset temperature of 70.1 oC without any change in baseline or ∆T 
after the transition possibly due to the compound having lower tan ∂ compared with D-
mannitol. Upon cooling, the exothermic recrystallisation was recorded at 61.0 oC.  
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Figure 4.28. Microwave differential thermal analysis (MWDTA) of stearic acid heated at 5 oC/ 
min to 160 oC for the first and second run (FR and SR) and cooling at 5 oC/min to 40 oC in both 
cases. 
The second cycle of the excipients was characterised by a transition at 66.6 oC, and upon the 
second cooling exothermic recrystallisation was recorded at 66.5 oC further justifying the 
sample was still in a crystalline state after the second run. 
Figure 4.29 displays a broad transition with an extrapolated onset of 100.0 oC to 140 oC, 
corresponding to dehydration of beta cyclodextrin. The exothermic fusion shows that the water 
is released in vapor form as expected and the peak extended to a higher temperature. Upon 
subsequent cooling, no significant phase transition was observed, as the sample did not 
recrystallise. No significant phase changes were observed in the second run further justifying 
the theory that the sample remained in an amorphous form.  
  















   
Figure 4.29. Microwave differential thermal analysis (MWDTA) of beta cyclodextrin heated 
at 5 oC/ min to 200 oC for the first and second run (FR and SR) and cooling at 5 oC/min to 40 
oC in both cases. 
Finally, Figure 4.30 displays the heating and cooling of XDP 3050, no significant phase 
transition was observed in the first and second run both upon heating and cooling due to the 
higher melting temperature of the excipient which further justifies the amorphous nature of the 
silica. These findings fit well with the results of DSC, XRD and HSM to be discussed later.  
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Figure 4.30. Microwave differential thermal analysis (MWDTA) of syloid XDP 3050 heated 
at 5 oC/ min to 200 oC for the first and second run (FR and SR) and cooling at 5 oC/min to 40 
oC in both cases. 
4.3.1. DSC for excipients 
Comparable DSC profiles for the fusion and recrystallisation of the excipients in aluminum 
pans heated at 10 oC/min to a maximum of 200 oC and then cooled at 10 oC/min to 25 oC are 
shown in Figures 4.31 – 4.32. The endothermic fusion of D-mannitol (Figure 4.31a) in the first 
run has an onset temperature of 166.5 oC while the corresponding exothermic recrystallisation 
of the compound has a slightly lower onset of 114.6 oC. The second run of the same sample 
did not reveal many changes other than a decreased intensity in the melting peak with a slight 
shift in the recrystallisation peak,  possibly due to heating-cooling and reaheating processess. 
The first run of stearic acid in Figure 4.31c, shows an endothermic fusion at 70.1 oC  followed 
by a broad exothermic recrystallisation at 61.2 oC. The second run did not reveal any changes, 
all the phase transformations observed in the first run were also observed in the second run.    
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Figure 4.31. DSC thermograms of; (a) D-mannitol first run (FR), (b) D-mannitol second (SR), 
(c) stearic acid first run (FR), (d) stearic acid second run (SR) 
The DSC profile for beta-cyclodextrin (Figure 4.32a) was characterised by a broad endothermic 
peak around 90 – 140 oC corresponding to dehydration while upon cooling no event was 
recorded as the sample doesn’t recrystallise. The second run did not reveal any additional event 
as expected. For XDP 3050 in Figure 4.32c, no event was observed both in the first and second 
run due to the higher melting point of the silica. These findings agree with what was observed 
earlier in MWDTA for these excipients.      
 
 



















Figure 4.32. DSC thermograms of; (a) beta-cyclodextrin first run (FR), (b) beta-cyclodextrin 
second (SR), (c) XDP 3050 first run (FR), (d) XDP 3050 second run (SR) 
4.3.3. XRD for excipients  
To follow the results of DSC, XRD was employed to confirm the crystalline or amorphous 
nature of the excipients. The characteristic diffraction peaks observed at 10.7o, 14.9o, 18.9o, 
21.1o and 23.6o correspond to the powder diffraction pattern for the first run of D-mannitol 
(Figure 4.33a) while in the second, the diffraction patterns were still observed but with reduced 
intensity attributed to loss of some crystalline structure of the D-mannitol after the first run of 
the same sample and is consistent with what was observed in DSC analysis. The first run of 
stearic acid (Figure 4.33c) was characterised by diffraction peaks appearing at 10.2o, 14.3o, 
24.0o, 36.9o and 41.1o confirming the crystalline structure while the second run was 
characterised by less intense diffraction patterns indicating a loss of some crystalline structure 
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after the first run of the same sample, consistent with the broadened peak observed in previous 
DSC analysis.   
 
Figure 4.33. XRD patterns of; (a) D-mannitol first run (FR), (b) D-mannitol second run (SR), 
(c) stearic acid first run (FR) and (d) stearic acid second run (SR) 
The XRD patterns of beta-cyclodextrin (FR and SR) and XDP 3050 (FR and SR) are illustrated 
in Figure 4.34. Beta-CD could be seen in Figure 4.34(a) with sharp diffraction peaks at 10.7o, 
12.5o, 17.1o and 22.9o in agreement with previous data for the drug. Beta-CD peaks are still 
evident in the second run with reduced intensity attributed to the loss of some crystalline 
structure after the first run of the same sample, confirming the partial amorphous nature. The 
absence of diffraction patterns in XDP 3050 for the first and second run confirm their 
amorphous nature which fits in well with the results of MWDTA and DSC.   
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Figure 4.34. XRD patterns of; (a) beta-cyclodextrin first run (FR), (b) beta-cyclodextrin second 
run (SR), (c) XDP 3050 first run (FR) and (d) XDP 3050 second run (SR) 
4.3.4. HSM for excipients  
HSM was used to follow the transformation of the four excipients as a function of temperature 
to visibly observe changes. Firstly, D-mannitol (Figure 4.35) appeared as a white crystalline 
solid at 30 oC, and upon heating a visible melting of the compound started to occur at around 
155 oC, transforming to liquid at 165 oC followed by recrystallisation at 113 oC during cooling, 
as expected based on data obtained using MWDTA and DSC. For stearic acid (Figure 4.36), 
HSM revealed a white crystalline powder at 40 oC and complete transformation to liquid at 69 
oC. These findings match those seen in the previously presented MWDTA and DSC data with 
recrystallisation upon cooling at 30 oC.  
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Figure 4.35. Microscope images and optical data of a sample of D-mannitol heated from 30 to 
200 oC as a function of temperature  
 
Figure 4.36. Microscope images and optical data of a sample of stearic acid heated from 30 to 











































































































HSM images for beta-cyclodexrin (Figure 4.37) and XDP 3050 (Figure 4.38) are hard to 
distinguish and did not appear to show any tranformation during heating and cooling due to the 
higher melting points of the compounds.  
  
Figure 4.37. Microscope images and optical data of a sample of beta-cyclodextrin heated from 
























































Figure 4.38. Microscope images and optical data of a sample of XDP 3050 heated from 30 to 
200 oC as a function of temperature  
4.4. MWDTA of benzocaine and pharmaceutical excipients 
Benzocaine was selected from the eight model compounds for further analysis in the presence 
of a selection of four pharmaceutical excipients, namely beta-cyclodextrin, D-mannitol, stearic 
acid and Syloid® silica (XDP 3050). Firstly, microwave thermal analysis of benzocaine with 
Syloid® silica, physically mixed at a 1:1 ratio was considered, and the resultant profile is shown 






















































   
Figure 4.39. Microwave differential thermal analysis (MWDTA) of benzocaine (BZ) with 
Syloid® silica (XDP) heated at 5 oC min-1 to 160 oC for both the first (FR) and second (SR) run, 
cooled in both cases to 40 oC 
Figure 4.39 reveals a change in the baseline as the sample coupled more strongly with the 
microwave energy after the thermal transition of benzocaine at 88.3 oC, indicating a change in 
dielectric coupling. Compared with pure benzocaine (Figure 4.3), a reduction in the melting 
peak was observed, possibly indicating some loss of crystalline structure resulting from 
microwave energy interaction with the sample. Furthermore, this finding was interpreted as 
proof of some interaction between the drug and the XDP with recrystallisation observed upon 
cooling at 54.0 oC within the first heating-cooling cycle. In the second cycle, there was a slight 
shift to a lower temperature with transition occurring at 83.5 oC corresponding to an α- 
polymorph of the drug in agreement with the studies conducted by Gana et al. [225] followed 
by a change in dielectric occurring from 82.7 – 91.6 oC and recrystallisation occurring at 56.3 
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oC. Secondly, MWDTA was undertaken for benzocaine formulated with β-cyclodextrin (beta-
CD), as presented in Figure 4.40. 
  
Figure 4.40. Microwave differential thermal analysis (MWDTA) of benzocaine (BZ) with β-
cyclodextrin (beta-CD) heated at 5 oC min-1 to 160 oC for both the first (FR) and second (SR) 
run, cooled in both cases to 40 oC. 
Fusion of benzocaine in β-cyclodextrin for the first heating cycle occured at 91.2 oC with a 
large dielectric change after the transition suggesting that the sample then coupled more 
strongly. Dehydration of the β-CD occurred in the region of 125.2-145.9 oC. This is consistent 
with previous research where loss of solvation water from the β-CD cavity occurred at 140 oC 
[214]. This event appeared 40 oC higher than the standard boiling point of water, which 
indicated that water molecules are tightly held within the crystal lattice structure as a result of 
intermolecular forces such as hydrogen bonding and therefore, additional energy was required 
to overcome these forces [226]. Upon cooling, recrystallisation occurred at 74.5 oC. Data for 
the second cycle displayed an increase in tan ∂ after the transition with the melting peak 
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occurring at 92.3 oC, recrystallisation at 74.3 oC and no dehydration peak. Observations of the 
samples post-analysis revealed a white coloured material possibly suggestive of the absence of 
decomposition after both cycles.  
Thirdly, MWDTA was undertaken for benzocaine formulated with stearic acid (SA), as 
presented in Figure 4.41 
 
Figure 4.41. Microwave differential thermal analysis (MWDTA) of benzocaine (BZ) with 
stearic acid (SA) heated at 5 oC min-1 to 160 oC for both the first (FR) and second (SR) run, 
cooled in both cases to 40 oC.  
MWDTA (Figure 4.41) of benzocaine formulated with stearic acid was somewhat complex 
with two transitions occurring during the first heating cycle at 79.0 oC and 90.4 oC. It was 
assumed that the first transition corresponds to the melting of the stearic acid and the latter for 
benzocaine with two corresponding recrystallisation events upon cooling at 60.8 oC and 53.2 
oC. There was a dielectric change after the transition yet little (or no) interaction between the 
two compounds had occurred. In the second heating and cooling cycle a sharp endothermic 
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peak was observed at 79.1 oC and another at 87.8 oC then upon cooling at 60.6 oC and 53.0 oC, 
i.e. somewhat similar to those temperatures observed during the first cycle. 
Finally, benzocaine was analysed after formulation with D-mannitol, as shown in Figure 4.42  
   
Figure 4.42. Microwave differential thermal analysis (MWDTA) of benzocaine (BZ) with D-
mannitol (D-man) heated at 5 oC min-1 to 200 oC for both the first (FR) and second (SR) run 
then cooled in both cases to 40 oC 
MWDTA of benzocaine displayed a transition peak at 92.7 oC with a dielectric change 
occurring after the transition, suggesting the sample was heating more effectively after the 
transition. The event observed at 169.2 oC was deemed to be fusion of D-mannitol.  
Recrystallisation appeared to occur at 121.9 oC, with a high intensity peak and another with 
reduced intensity at 64.7 oC, corresponding to that of benzocaine. The second cycle displayed 
an endothermic transition at 95.6 oC followed by a dielectric change and a second transition at 
166.0 oC, i.e. similar to values observed within the first heating and cooling cycle. Upon a 
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second cooling, recrystallisation was evident at slightly different temperatures compared with 
the first cycle, namely at 116.6 oC and at 71.5 oC.      
4.4.1. DSC of benzocaine and pharmaceutical excipients 
Formulations of benzocaine with the four excipients under investigation were analysed using 
DSC, a data with peak values are displayed in Table 4.2. 
Table 4. 2: A summary of DSC peak values for the melting (Tm) and recrystallisation (Tr) of 
benzocaine with four excipients. 
 
Material (1:1) Tm /
oC Tr /
oC 
BZ with XDP  83.8 and 92.0 - 46.5 - 
BZ with β-CD 91.5 - 63.1 - 
BZ with D-man 92.4 166.4 74.1 109.5 
BZ with SA 84.6 69.9 57.9 54.9 
 
Benzocaine is a crystalline drug undergoing fusion at 90.71 oC as reported in literature [214]. 
When benzocaine was formulated with Syloid® silica XDP 3050, two transitions were observed 
at 83.8 oC and 92.0 oC (Figure 4.43), potentially a reflection that some benzocaine was ‘bound’ 
and some ‘unbound’ within the formulation. Upon cooling, recrystallisation was observed at 
46.5 oC with reduced intensity and a broadened peak, i.e. at a temperature lower than that seen 
for pure benzocaine. This phenomenon was attributed to the transition from a crystalline to 
partially amorphous state of benzocaine or that the drug was partially incorporated within the 
pores of the silica [81]. From a second heating cycle a peak at 77.6 oC was observed at a lower 
melting point than for benzocaine possibly due to an α-polymorphic form of the drug [225]. 
Furthermore, the compound appeared to recrystallise at 45.8 oC, significantly lower than that 
observed for pure benzocaine. In the presence of β-cyclodextrin a small, broad endothermic 
peak was observed at 91.5 oC corresponding to fusion and almost a flat event in the region of 
120 – 140 oC suggesting dehydration of β-CD with recrystallisation occurring at 63.1 oC. It 
159 
 
should be noted that the dehydration event was more noticeable using MWDTA, which further 
demonstrates the sensitivity of the microwave-based technique. These events were also 
observed in the second heating and cooling cycle (with the exception of the dehydration event). 
These reversible events suggested that there was a little interaction between benzocaine and β-
cyclodextrin when compared with the melting temperature of the pure compound [227].  
 
Figure 4.43. DSC profiles of (a) BZ with XDP 3050 first cycle, (b) BZ and XDP 3050 second 
cycle, (c) BZ and β-CD first cycle and (d) BZ and β-CD second cycle 
For benzocaine formulated with stearic acid (Figure 4.44) during the first heating cycle a sharp 
endothermic peak was observed with an onset temperature of 69.9 oC and another at 84.6 oC, 
the former attributed to melting of the excipient and the latter to benzocaine. The reduction in 
the melting temperature of benzocaine, compared with pure drug, implies that some fraction of 
the molecules interacts with the excipient. Upon cooling two events occurred at 57.9 oC and 
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54.9 oC implying some lack of homogeneity in the mixture after heating. The second heating 
and cooling cycle displayed peak temperatures of 68.6 oC and 83.6 oC indicating the existence 
of some benzocaine-stearic acid interactions. Recrystallisation at 57.8 oC and at 40.1 oC suggest 
that both benzocaine and stearic acid recrystallised at lower temperatures during the second 
cooling. DSC profiles for D-mannitol (Figure 4.45) display endothermic peaks at 92.4 oC and 
at 166.4 oC. Upon cooling two peaks were observed at 109.5 oC and 74.1 oC, corresponding to 
recrystallisation of the excipient and benzocaine in the first cycle. 
 










Figure 4.45. DSC profiles of (a) BZ with D-man first cycle (FR) and (b) BZ with D-man second 
cycle (SR). 
In summary, all of the benzocaine-excipient formulations displayed no thermal transitions 
other than the fusion endotherm and exotherm of benzocaine, similar events for the excipients 
and, in one case, possibly dehydration of the β-CD, thus confirming thermal stability and 
absence of any polymorphic transitions. 
4.4.2. XRD of benzocaine and pharmaceutical excipients 
To confirm the findings from DSC, i.e. the implication that the products had increased in 
amorphous content on formulation, X-ray powder diffraction (XRD) analysis of benzocaine 
with excipients was carried out. Figure 4.46(a) displays the XRD patterns of benzocaine with 
XDP 3050 (first run). Diffraction peaks with reduced intensity appear at 8.9o, 17.0o, 20.2o, 
23.9o and 27.3o thus confirming that the drug was still in a crystalline state in the first run while 
















in the second run (Figure 4.46b), almost complete disappearance of the peaks was observed in 
full agreement with the DSC, confirming that benzocaine was largely amorphous The XRD 
pattern for BZ with beta-CD in Figure 4.46c and 4.46d (first and second run), showed that 
benzocaine diffraction patterns were maintained in both the runs, confirming that the drug was 
still present in a crystalline state with peaks appearing at 12.6 o, 16.5o, 20.1o, 24.6o and 27.1o, 
this is consistent with the DSC results.  
 
Figure 4.46. XRD patterns of; (a) BZ with XDP 3050 first run (FR), (b) BZ with XDP 3050 
second run (SR), (c) BZ with Beta-CD first run (FR) and (d) BZ with Beta-CD second run (SR) 
Figure 4.47a and 4.44b display the XRD diffraction patterns of benzocaine with stearic acid 
(first and second run). The diffraction patterns observed for the mixtures were with high 
intensities indicating little or no interaction between the compounds with diffraction peaks 
appearing at 6.3o, 10.4o, 17.1o and 20.0o. In the second run (Figure 4.47b), these peaks were 
still visible though with reduced intensities suggesting loss of some crystalline structure of the 
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stearic acid after the first run of the same sample. In the case of benzocaine with D-mannitol 
(first run) in Figure 4.47c, the diffraction patterns were observed at 17.0o, o 18.9o, 21.7o and 
23.2o which confirmed the presence of some crystalline structure of the drug while the second 
run (after processing) in Figure 4.47d, also displayed the diffraction patterns with reduced 
intensities suggesting loss of some crystalline structure of D-mannitol after the first run of the 
same sample. Overall, these results are in good agreement with the DSC and MWTA 
observations discussed earlier.           
 
Figure 4.47. XRD patterns of; (a) BZ with SA first run (FR), (b) BZ with SA second run (SR), 
(c) BZ with D-man first run (FR) and (d) BZ with D-man second run (SR) 
4.4.3. HSM of benzocaine-excipient formulations 
HSM was utilised to follow the transformation of benzocaine with the four excipients as a 
function of temperature to visibly observe changes. Photographic images were recorded and 
are presented at selected temperatures in Figures 4.48-4.51. Firstly, Syloid® silica XDP 3050 
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was analysed (Figure 4.48) and, although hard to distinguish, did appear to show partially 
melted benzocaine at 93.2 ºC (Figure 4.48B), followed by recrystallisation when the sample 
was cooled down to 30 ºC (Figure 4.48C). A small, gradual increase and decrease in the sample 
RLI values was observed, correlating with the gradual change in benzocaine temperature going 
from solid to liquid.  
 
Figure 4.48. Microscope images and optical data of a sample of Benzocaine with XDP 3050 
heated from 30 to 160 oC as a function of temperature 
For benzocaine with β-cyclodextrin HSM (Figure 4.49) enabled observation of the fusion 
process of benzocaine at around 92.8 oC within β-cyclodextrin, confirming that benzocaine 
became molten, as evidenced during MWDTA and DSC profiles with dehydration occurring 
in the region of 120 – 140 oC. Furthermore, HSM confirmed that the drug recrystallised during 
the cooling process as expected based on previous analytical data. The RLI values decreased 
























































cooling, the RLI values gradually increased up to 10.1 V as the sample began to recrystallise 
which is matched in the temperature profile.      
 
Figure 4.49. Microscope images and optical data of a sample of benzocaine with Beta-
cyclodextrin heated from 30 to 160 oC as a function of temperature 
HSM images for benzocaine formulated with stearic acid are shown in Figure 4.50. In 
conjunction with MWDTA and DSC data (shown earlier), it can be concluded that stearic acid 
loses its crystalline structure and undergoes a solid-state transformation near 71.2 oC, which 
corresponds to the melting point of the excipient. A second transformation at 89.4 oC was 
attributed to the fusion of benzocaine, followed by recrystallisation upon cooling. The RLI 
values decreased going from solid to liquid for the fusion of stearic acid from 10.3 – 9.8 then 
increased to 9.9 V for benzocaine melting, correlating with the gradual change in the sample 
temperature. A slight decrease in the light intensity was also noted at around 9.9 V, which 





















































Figure 4.50. Microscope images and optical data of a sample of benzocaine with stearic acid 
heated from 30 to 160 oC as a function of temperature 
For benzocaine formulated with D-mannitol (Figure 4.51) HSM revealed a white powder at 
75.0 oC with some melting at ~ 93.2 oC corresponding to fusion of benzocaine and complete 
transformation at 167.8 oC for the fusion of D-mannitol. These findings match those seen in 
the previously presented MWDTA and DSC data with recrystallisation upon cooling at 30 oC. 
The RLI decreased going from solid to liquid for the fusion of benzocaine from 10.2 – 9.8 then 
increased to 9.9 V for D-mannitol melting, correlating with the gradual change in the sample 
temperature. Slight decreases in the light intensity were also noted at around 9.7 V, which 






















































Figure 4.51. Microscope images and optical data of a sample of benzocaine with D-mannitol 
heated from 30 to 200 oC as a function of temperature 
4.5. MWDTA of indomethacin and pharmaceutical excipients 
Indomethacin was another compound selected from the eight model compounds for analysis in 
the presence of a selection of four pharmaceutical excipients, namely β-cyclodextrin, D-
mannitol, stearic acid and Syloid® silica (XDP 3050). Firstly, microwave thermal analysis of 
indomethacin with stearic acid, formulated at a 1:1 ratio was considered, and the resultant 
profile is shown in Figure 4.52. Apart from an initial variation at the start of the experiment, a 
broad transition could be observed for stearic acid (SA) with an onset temperature of 67.43 oC 
and peaking at 77.53 oC, which is higher by 6.8 oC compared with conventional DSC (Figure 
4.56). Another phase change was observed around 161.9 oC corresponding to the fusion of 
IMC, which had shifted to a slightly lower temperature in comparison with fusion of pure drug 
(Figure 4.5), indicating an interaction between drug and SA. The phase change was followed 





















































dielectric losses from the material, as a result of the microwave effect, a thermal effect that 
cannot be duplicated or achieved by conventional heating as previously reported [228]. Upon 
cooling, there was an event which was not thought to be a transition, it only occurred due to 
the instrument settling from heating to cooling. The crystallisation of SA was observed at 53.2 
oC but the drug stayed in a glassy form and did not show any recrystallisation peak. This profile 
has a high tangent and heated much more rapidly in the microwave field when compared with 
IMC: β-CD profiles (Figure 4.54) with low tangent. 
 
Figure 4.52. Microwave differential thermal analysis (MWDTA) of indomethacin (IMC) with 
stearic acid (SA) heated at 5 oC/min to 200 oC for both the first (FR) and second (SR) run then 
cooled in both cases to 40 oC 
In the second profile, there was also a variation followed by a broad transition with an onset of 
55.6 oC and peaking at 71.6 oC corresponding to fusion of SA. This had shifted to a lower 
temperature as the excipient lost some of its crystalline structure after the first run. Another 
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transition which had again shifted to lower temperature was recorded which could possibly be 
due to an α-polymorph of the IMC around 135.3 oC [229]. This finding implies that there is not 
complete inclusion complexation between drug and excipient. This is contrary to what was 
observed in the second run between IMC: β-CD (Figure 4.54) and IMC: XDP (Figure 4.55) 
where there is complete disappearance of the drug melting peak as a result of drug conversion 
from crystalline to amorphous form by the microwave method and insertion of IMC molecules 
into the β-CD cavity and pore volume of XDP. Upon cooling there was a broad event that was 
not thought to be a transition which occurred due to settling down of the instrument followed 
by a well-defined sharp recrystallisation peak at 50.10 oC for SA. This suggested that even after 
the second run, SA recrystallised with no recrystallisation peak observed for drug or any 
thermal decomposition.   
Figure 4.53 displays the MWDTA of IMC with D-man at a 1:1 ratio for the first run (FR) and 
second run (SR). The lower profile in the figure indicates the first cycle heating. Apart from an 
onset variation at the start of the experiment, the rise in temperature was smooth and featureless 
until a small transition occurred at 162.0 oC, the transition corresponds to the fusion of IMC in 
D-man, which was followed immediately with another at 169.5 oC corresponding to that of D-
man. As expected, there was a change in baseline after the transitions were observed, which 
was due to the microwave effect as the samples were heating differently (and much more 
rapidly) in the microwave field than before the transition. On closer inspection of the profile, 
it was assumed that the dielectric losses from the mixtures were small in comparison with the 
previous analysis discussed (Figure 4.52) and it can be concluded that during heating, the 
thermal materials dielectric properties were responsible for the lower loss-tangent observed. 
On the cooling process, there was a sharp event at 113.86 oC which corresponds to the 
recrystallisation of D-man with no further events observed suggesting that the drug stayed in a 




Figure 4.53. Microwave differential thermal analysis (MWDTA) of indomethacin (IMC) with 
D-mannitol (D-man) heated at 5 oC/min to 200 oC for both the first (FR) and second (SR) run 
then cooled in both cases to 40 oC 
In the upper profile, it is important to note that the only transitions observed were those of D-
man, with the first transition occurring at 167.7 oC for fusion of excipient and then upon cooling 
a sharp recrystallisation was observed at 113.6 oC. The transition for the drug was not reversible 
as expected as the drug stayed in an amorphous form. The change in baseline was small in 
comparison to the first run, which was due to a change in dielectric properties as drug was in 
an amorphous state. The loss tangent in comparison to the two profiles are almost similar 
between the first run and the second but are different in the previous experiment carried out 
due to the different variation in dielectric properties. This reflects the differing physical and 
chemical structures of the products, e.g. thermal conductivity, heat capacity, the 
aforementioned dielectric properties, particle size and density.                   







IMC with D-man 1:1 FR
IMC with D-man 1:1 SR
2 °C 
Exo  





Figure 4.54. Microwave differential thermal analysis (MWDTA) of indomethacin (IMC) with 
beta-cyclodextrin (Beta-CD) heated at 5 oC/min to 200 oC for both the first (FR) and second 
(SR) run then cooled in both cases to 40 oC 
MWDTA results with a linear heating and cooling rate of the physical mixture of 1:1 IMC with 
beta-CD first run (FR) and second (SR) heated at 5 oC/min under an air atmosphere are shown 
in Figure 4.54. The first profile result from the first heating of the mixture displays an initial 
variation at the onset of the experiment, followed by a broad event arising from the dehydration 
of the beta-CD in the region of 90 oC - 130 oC. The smaller event in the profile with an onset 
temperature of 157.42 oC and peaking at 160.56 oC was produced by a solid-liquid fusion of 
drug in beta-CD accompanied by a dielectric change, indicating that the molten drug couples 
to microwaves differently than before the transition. This is assumed to be a result of the 
difference in tangent that the sample possessed which brings about efficient absorption of the 
electromagnetic energy by the sample and, consequently, leading to rapid heating [228]. Upon 
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cooling, no transition was observed as drug remained in an amorphous state and did not 
recrystallise after fusion in beta-CD. In the second run, no transitions were observed both 
during the heating and cooling, demonstrating that all the thermal processes seen in the first 
run were irreversible. The result displayed a close correlation between the events observed with 
those of the DSC and HSM obtained in Fig. 4.57 and 4.62.    
 
Figure 4.55. Microwave differential thermal analysis (MWDTA) of indomethacin (IMC) with 
XDP 3050 heated at 5 oC min-1 to 200 oC for both the first (FR) and second (SR) run then 
cooled in both cases to 40 oC 
The MWDTA profiles from the linear heating and cooling of the physical mixture of a 1:1 IMC 
with XDP first run (FR) and second run (SR) heated at 5 oC/min under an air atmosphere is 
shown in Figure 4.55 in the form of calculated ∆T (Tsample - Treference) plotted as a function of 
sample temperature. Two profiles are displayed; the lower profile shows the first heating while 
the upper profile shows the second run. The first run shows an initial variation at the onset of 
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the experiment, fusion of drug can be seen at 164.2 oC. After the transition was observed, there 
was an increase in the baseline value (a microwave effect) as expected, which does not return 
as the sample was heating differently and couples more strongly with the microwave. The 
change in baseline (shown as a black dotted line) is the opposite of the DSC profiles (discussed 
later) where a negative sloping baseline was observed. Earlier analysis carried out on pure IMC 
in Figure 4.5, and on the mixture of drug with XDP, suggested that there was an interaction 
between the IMC and XDP during fusion. A size reduction, broadening and a shift of the drug 
peak to a lower temperature were observed as a result of the interaction between drug with 
XDP in comparison with pure IMC. DSC and HSM analysis (Fig. 4.5 and Fig. 4.21) undertaken 
on pure IMC and the mixture confirmed this interaction after fusion. This outcome further 
indicated that MWDTA can be a sensitive method for drugs that undergo transitions resulting 
in a large change in dielectric. Upon cooling, there was a broad event that was not thought to 
be a transition, it only occurred due to the instrument settling from heating to cooling. In 
cooling, there was no transition observed as drug stayed in an amorphous form and did not 
recrystallise after fusion in the XDP.   
In contrast, the second heating of the mixture displayed no transition other than a small 
downward peak similar to the one observed during cooling at 173.16 oC. This event has been 
consistently observed during this research and was not thought to be a transition. There was a 
decrease in tan δ though in comparison to the first heating which occured without any losses 
from the material. The drug stayed in amorphous form after the first heating, demonstrating 
that the thermal processes were irreversible.      
4.5.1. DSC for IMC and pharmaceutical excipients  
Formulations of indomethacin with the four excipients under investigation were analysed using 
DSC for comparison with MWDTA data with peak values displayed in Table 4.3. 
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Table 4. 3: A Summary of DSC peak values for melting (Tm) and recrystallisation temperatures 
(Tr) of indomethacin with four excipients. 
 
Material (1:1) Tm /
oC Tr /
oC 
IMC with SA 153.0 74.5 - 50.8 
IMC with D-man 160.7 167.2 - 118.6 
IMC with β-CD 162.5 80-130 - - 
IMC with XDP 162.6 - - - 
 
DSC thermograms of IMC with excipients at a 1:1 w/w ratio for the first and second run are 
displayed in Figures 4.56 – 4.58. IMC is a crystalline drug with a melting point of 159.8 oC as 
reported by Dalmoro [230]. In the thermal profile of the physical mixture of IMC with SA, 
there was a broad event observed in the first run (Figure 4.56a) with reduced intensity at 74.5 
oC corresponding to the melting of SA followed by another at 153.0 oC with a reduced intensity 
corresponding to the melting of IMC.  
 




Only a small shift of the melting peak of drug to a lower temperature was observed attesting to 
a decrease in drug crystallinity due to a minor reaction between drug and SA during heating. 
However, the appearance of an exothermic peak at 50.8 oC confirmed the recrystallisation of 
SA, indicating that SA recrystallised during cooling. A second heating of the physical mixture 
was also carried out (Figure 4.56b). The samples were cooled to room temperature and then 
reheated. During this process, there was a small shift to a lower melting point of the SA with a 
peak temperature recorded at 74.3 oC, which is an indicative loss of some SA crystalline 
structure as a consequence of the heating, cooling and reheating process. An event that 
appeared almost flat was evident at 151.9 oC for the drug indicating loss of drug crystalline 
structure. Recrystallisation of the drug was not evident (only for SA at 56.7 oC). In the thermal 
profile of the physical mixture of IMC with D-man in Figure 4.57a (FR), two events were 
recorded during heating. The first event was characterised by a melting peak of 160.7 oC with 
a reduced intensity corresponding to the fusion of IMC, followed by second event at 167.2 oC 
corresponding to the melting of D-man with high intensity. On cooling, a very sharp 
exothermic peak at 118.6 oC with a high-intensity (corresponding to recrystallisation of D-
man) was observed with no other transition recorded. The second run of the physical mixture 
(Figure 4.57b) displayed two transitions during heating and cooling. The former at 167.8 oC 
was with reduced intensity also, broad when compared to the first run and corresponded to the 
fusion event, while the latter was at 116.1 oC and corresponded to recrystallisation of D-man. 
The fusion of drug was not observed due to the absence of the crystalline structure of drug in 




Figure 4.57. DSC thermograms of; (a) IMC with D-man first run (FR) and (b) IMC with D-
man second run (SR) 
The DSC thermogram of the physical mixture of IMC with beta-CD is shown in Figure 4.58a. 
The first event was broad and less intense in the temperature range of 80 – 130 oC indicating 
dehydration of β-CD followed by a sharp event at 162.5 oC corresponding to the melting of 
IMC. The endotherm was with reduced intensity in comparison to the melting endotherm of 
pure drug suggesting an interaction between IMC and β-CD. In the second run (Figure 4.58b), 
there was an event at 49.2 oC for IMC that looks almost flat, smaller and shifted to a lower 
temperature in comparison to the first run indicating a glass transition of the drug.   

















Figure 4.58. XRD patterns of; (a) IMC with Beta-CD first run (FR), (b) IMC with Beta-CD 
second run (SR), (c) IMC with XDP 3050 first run (FR) and (d) IMC with XDP 3050 second 
run (SR) 
The result of the DSC in Figure 4.58c and 4.58d display the physical mixtures of IMC with 
XDP at 1:1 w/w ratio for a first and second run. The first run of the mixture shows an 
endothermic peak of the drug at 162.6 oC with size reduction in comparison to the endotherm 
of the pure drug suggesting some reaction between the drug and XDP during fusion. In the 
second run, no endotherm was observed as the drug stayed in amorphous form after the first 
run which is comparable to what was observed during the MWDTA (Figure 4.55) of the same 
mixture. The absence of drug endotherm in this run can be assumed as evidence of insertion of 
the drug molecules inside the pores of the silica. This effect can also be directly related to the 
conversion of the crystalline drug to amorphous form, which could be as a consequence of true 
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inclusion complexation. The DSC results showed a close relationship to the transition 
temperatures experienced during microwave thermal analysis (MWTDA) experiments.   
4.5.2. XRD of indomethacin and pharmaceutical excipients 
Following on from DSC, i.e. the implication that the products had increased in amorphous 
content on formulation, X-ray powder diffraction (XRD) analysis of indomethacin with 
excipients was carried out. Figure 4.59(a) displays the XRD patterns of indomethacin with SA.  
 
Figure 4.59. XRD patterns of; (a) IMC with SA first run (FR), (b) IMC with SA second run 
(SR), (c) IMC with D-mannitol first run (FR) and (d) IMC with D-mannitol second run (SR) 
Diffraction peaks with a high intensity appeared at 11.6o, 16.9o, 21.8o, 26.6o and 29.4o thus 
confirming that both the drug and excipient were still in a crystalline state after the first run 
while in the second run (Figure 4.59b), a few diffraction peaks with reduced intensity were 
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observed in full agreement with the DSC data confirming that indomethacin was partially 
amorphous.    
The XRD pattern for indomethacin with D-mannitol in Figure 4.59c and 4.59d (first and second 
run), showed that indomethacin diffraction patterns were maintained in the first run, confirming 
that the physical mixtures were present in a crystalline state with peaks appearing at 14.3o, 
18.5o, 23.2o, 29.3o and 33.4o, consistent with DSC data.  
 
Figure 4.60. XRD patterns of; (a) IMC with Beta-CD first run (FR), (b) IMC with Beta-CD 
second run (SR), (c) IMC with XDP 3050 first run (FR) and (d) IMC with XDP 3050 second 
run (SR) 
In the second run, diffraction peaks were not observed in contrast with what was observed in 
MWDTA and DSC discussed earlier which could possibly be due to the conventional method 
used in melting the mixture.  
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Figure 4.60a and 4.60b displayed the XRD diffraction patterns of indomethacin with beta-
cyclodextrin (first and second run).  
The diffraction patterns observed for the mixtures were of high intensity indicating little or no 
interaction between the compounds with diffraction peaks appearing at 11.8o, 17.4o, 19.5o and 
26.9o, while in the second run, small peaks were still visible confirming that the sample was 
partially amorphous. In the case of indomethacin with XDP 3050 (first run) in Figure 4.60c, 
the diffraction patterns were observed at 11.9o,17.2 o, 20.0o, 22.0o and 29.4o which confirmed 
the presence of some crystalline structure of the drug while the second run (after processing) 
in Figure 4.60d, the sample was largely amorphous which displayed small diffraction patterns 
with reduced intensity. Overall, these results are in good agreement with the DSC and 
MWDTA observations discussed earlier.           
4.5.3. HSM for IMC with excipients  
HSM is mostly utilised with DSC to characterise the solid state of the drug in solid dispersions 
[231]. In Figure 4.61, for the physical mixture of IMC with SA, the mixture was not 
homogeneous, and crystals of the drug and SA were recognisable at around 30 oC. Going from 
solid to liquid, the SA melted completely at around 70 oC thereby leaving crystals of drug, 
which melted further at around 160 oC and turned into a homogeneous liquid because of the 
constant heating rate. Upon cooling, at around 50 oC, recrystallisation of the SA was evidenced. 
The RLI values decreased going from solid to liquid for the fusion of stearic acid from 10.8 – 
10.4 V and decreased again to 10.3 V for indomethacin melting, correlating with the gradual 
change in the sample temperature. A slight decrease in light intensity was also noted at around 




Figure 4.61. Microscope images and optical data of a sample of indomethacin with stearic acid 
heated from 30 to 200 oC as a function of temperature 
The physical mixture of IMC with D-man (Figure 4.62) appeared as a homogeneous mixture 
at 30 oC. Heating of the mixture resulted in melting of indomethacin at around 160 oC that 
turned yellow as expected leaving D-man. At around 163 oC, the D-man gradually solubilised 
producing a homogenous liquid. On cooling, at around 116 oC, a recrystallisation of the D-man 
was evidenced which further confirms the result of the MWTA and DSC analysis discussed 
earlier.  There was a gradual decrease in the sample RLI values observed from 10.8 to 9.3 V 
corresponding to the fusion of the indomethacin and a further decrease to 8.9 V for fusion of 
D-mannitol. Upon cooling, no change in RLI values was noted which is matched by the sample 

























































Figure 4.62. Microscope images and optical data of a sample of indomethacin with D-mannitol 
heated from 30 to 200 oC as a function of temperature 
For indomethacin with beta-cyclodextrin in Figure 4.63, at 30 oC the physical mixture appeared 
homogeneous. During heating at around 160 oC, IMC melted completely in β-CD and turned 
to liquid with yellowish colouration as evidenced earlier for indomethacin with stearic acid 
(Figure 4.61). The RLI values decreased going from solid to liquid for the fusion of 
indomethacin from 10.8 – 9.9 V, correlating with the gradual change in the sample temperature. 
A slight decrease in the light intensity was also noted after the initial decrease, which occurred 
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Figure 4.63. Microscope images and optical data of a sample of indomethacin with Beta-
cyclodextrin heated from 30 to 200 oC as a function of temperature 
Figure 4.64 displays data for IMC with XDP 3050:   
 
Figure 4.64. Microscope images and optical data of a sample of indomethacin with XDP 3050 












































































































The physical mixture of IMC with XDP at a temperature of 30 oC appeared as a seed crystal of 
the drug that completely melted at about 160 oC. There was a change in colour to yellow after 
the melting of the drug, which was not believed to be as a result of decomposition. This further 
confirms an interaction between the drug and the silica as evidenced in MWTA and DSC. 
Again, RLI values decreased going from solid to liquid for the fusion of indomethacin from 
10.2 – 9.8 V, correlating with the gradual change in the sample temperature. It is important to 
state that the data provided by the hot-stage photomicrography experiments was essential in 
supporting the events observed in the MWDTA and DSC analysis.  
4.6. Conclusions  
In summary, the effect of microwave heating was studied through the application of microwave 
thermal analysis to eight model pharmaceutical compounds and a set of four model 
pharmaceutical excipients. The profiles were analysed and compared with the data generated 
using differential scanning calorimetry (DSC), X-ray diffraction (XRD) and hot stage 
microscopy (HSM). The results demonstrated that microwave thermal analysis (MWDTA) can 
be utilised to detect a wide range of thermal transitions including melting, recrystallisation, 
dehydration phase changes and dielectric change via changes in the materials ability to absorb 
microwave energy.   
The dielectric change in some drugs analysed was significantly high, looking at the profiles 
generated while intermediate and low dielectric changes were observed in other drugs. The 
dielectric properties of a multicomponent mixture are dependent on the dielectric properties of 
the components. The thermal transition temperatures are slightly lower or higher in MWDTA 
than those observed with the conventional DSC method. This effect has been reported 
previously but has not received a complete explanation [213]. It should be recalled that the 
peaks seen in conventional techniques arise solely from the transformation enthalpy itself, 
while the temperature changes seen in MWDTA result primarily from the emergence of a 
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product or phase that has different dielectric properties. Overall, it was found that the process 
of microwave heating produced different thermal profiles to those seen using traditional, 
conductive heating. Investigating differences in thermal profiles can be a useful way to 
consider the effect of microwave-induced heating on formulations which can, in turn, help 















Chapter 5: The DSC and TGA approach to study bound water restrained by polymer 
beads (DC Bead M1™) 
5.1. Introduction 
An attempt was made to characterise the bound water restrained by polymer beads using 
microwave differential thermal analysis (MWDTA) but most of the water within the beads 
evaporated when the bead samples were introduced into the technique. The reason for this is 
that the MWDTA technique does not have a cooling system (e.g. chiller) attached to it, as the 
technique is still in development. Addition of a cooling system is another area where the 
MWDTA technique could be developed. The addition of a cooling system will provide several 
advantages including allowing the user to perform experiments at room /ambient temperatures. 
Furthermore, better temperature control could be achieved with cooling apparatus, particularly 
with samples tending to thermal runaway. However, for this study it was decided the most 
appropriate way forward with the time remaining was to focus on the beads and alternative 
forms of analysis. 
DC Bead™ is a microspherical embolisation medium used for the treatment of arteriovenous 
malformations and hypervascular tumours [124, 232]. The bead consists of a poly (vinyl 
alcohol) (PVA) hydrogel polymer that has been modified by the addition of hydrophilic 2-
acrylamido-2-methylpropane to contain sulfonate sodium salt components and is blue in colour 
to allow visualisation of drug loading [132, 233]. The presence of negatively charged sulfonate 
components on the beads (polymer chain) enables ionic interactions with positively charged 
drugs which is reversible in ion rich environments such as blood [137]. The beads are available 
in a range of sizes from 70 – 700 µm. The water content in the beads is ˃ 95 %, enabling 
diffusion of molecules in and out of the polymer structure [234]. The uptake of drug and rate 
of elution is dependent upon the size of the bead, as diffusion is inversely proportional to the 
diameter of the bead, attributed to the increase in the surface area to volume ratio [124]. 
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Nevertheless, a couple of compounds can have a drug-drug interaction, which can affect the 
binding and elution of drug from the delivery device [132]. Initially, the beads increase in 
diameter as they are reconstituted with water, as the water is displaced from the bead, the 
diameter again decreases as the drug is concealed from the solution.  
There are numerous factors affecting the biocompatibility of polymers including; ionic charge, 
chemical groups on the surface, morphological features, surface evenness among others, all of 
these factors have been examined [235, 236]. One factor that has received lots of interest is the 
structural changes of the water on the surface of the polymer, it is reasonable to expect that 
water molecules firmly restrained by biomaterials display distinctive behaviour which is 
different from bulk surface water [141, 235-237]. Water in hydrogels has been grouped into 
three main types by Hatakeyama [235] and Bertasa [238]: (1) free water which crystallises at 
approximately 0 ℃ and is slightly affected by the matrix polymer, (2) freezing bound water 
which crystallises during heating at a temperature lower than 0 oC and is strongly affected by 
the matrix polymer and finally (3) non-freezing water which is non-crystallisable due to strong 
intermolecular interactions with the matrix polymer. Both freezing bound water and non-
freezing bound water are classified as bound water [239].  
The state of water restrained by hydrogel systems have been investigated by various 
techniques, in particular thermal analysis since the phase transition of water behaviour can be 
identified by this method. Thermal analysis methods including thermogravimetric analysis 
(TGA) can be utilised to quantify the amount of different fractions of water in polymers through 
vaporisation as previously carried out by Hatakeyama [142], differential scanning calorimetry 
(DSC) was previously used to identify three kinds of water from temperature and enthalpy of 
transition peaks [238] and nuclear magnetic resonance (NMR) for identifying the amounts of 
water in polymers from relaxation time measurements i.e. correlation time (τc) calculated from 
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the spin-lattice (T1) and spin-spin relaxation times (T2) of water restrained by biomaterials 
[235].         
5.2. Results and discussion  
5.2.1. Drug loading evaluations 
Beads containing imipramine were formulated and analysed as described in the methods 
section. Drug loading studies permitted calculation of the amount of imipramine hydrochloride 
loaded per mL of hydrated beads from the three different drug concentration solutions (Table 
5.1). For the 10 mgmL-1, 25 mgmL-1 and 50 mgmL-1 drug concentrations, beads were found to 
yield 95.2 %, 92.5 % and 61.5 % of the drug respectively. Drug interaction is presumed to be 
via an ion exchange process as for other reported hydrochloride salts [136] through the tertiary 
amine group pendent to the ring structure. At lower concentrations (10 & 25 mg), loading yield 
was relatively high (> 90 %) as the number of cationic charged binding groups on the drug was 
less than the number of anionic sulfonate groups in the bead structure. For the 50 mgmL-1 
loading, the number of drug binding groups is in excess and loading is saturated at 62 % 
loading, where all binding sites are occupied by drug molecules. This equates to around 30 
mgmL-1 maximum loading potential for imipramine hydrochloride. 
Table 5. 1: Drug structure and loading amount and efficiency in 1 mL of DC Bead M1 (n=3) 
 
5.2.2 Optical microscopy  
Optical microscopy analysis of the beads indicated that their average size decreased when drug 
loading was greater than 10 mgmL-1 (Figure 5.1 and 5.2), with the greatest change seen from 
121 ± 19 m to 79 ± 17 m following loading with the highest concentration of drug (see Table 
 






10 9.52 ± 0.01 95.19 ± 0.09 
25 23.13 ± 0.27 92.54 ± 1.09 
50 30.76 ± 2.65 61.53 ± 5.29 
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5.2).  This is consistent with what has been observed previously with other cationically charged 
drugs, where bulky drugs with hydrophobic components enter the hydrogel matrix and bind to 
the anionic sulfonate moieties, resulting in water being displaced from the interstitial spaces 
between polymer chains, decreasing the water content and causing the beads to shrink in 






Figure 5. 1.  Size (A) and volume (B) distribution of bland DC Bead M1, 10 mgmL-1, 25 mgmL-
1, and 50 mgmL-1 drug loaded beads.  
Table 5. 2:  Data for bead sizes and estimated water fraction in beads 
* Data based on a weight measurement previously published by Ashrafi et al. [240].  
Figure 5.2 shows optical micrographs of DC Bead M1 before and after drug loading at different 
concentrations.  The drug loaded beads remain a spherical shape with no signs of deformation 
or fragmentation. The blue colour is due to the presence of the Reactive Blue 4 tint on the bead 
structure and the beads loaded with >25 mgmL-1 drug appear more intense in colour as the bead 
shrinkage intensifies the appearance of the dye.   
 
Bland 10 mgmL-1 25 mgmL-1 50 mgmL-1 
Bead size range (µm) 91.1-175.5 84.4-178.9 57.4-118.2 52.3-124.9 






80.9 ± 14.9 78.5 ± 16.8 
Estimated water content in 
beads (v/v) 






Figure 5. 2.   Microscope images of DC Bead M1 after loading overnight.  A) Bland beads.  B) 
10 mgmL-1 loading.  C) 25 mgmL-1 loading.  D) 50 mgmL-1 loading.  The scale bar is 500 µm.  
5.2.3 Water content analysis  
5.2.3.1 Thermogravimetric analysis (TGA) 
TGA was undertaken for three samples of beads with a mass loss of 97.2, 95.6 and 97.5 % 
indicating the beads to contain an average of 3.2 % solid content and 96.8 % water. Previous 
research has indicated a percentage of water content of 96.3 % using centrifuged mass loss 
analysis [240]. This is the first published result using TGA to analyse this type of beads and it 
is reassuring to see that the values from this work and that published previously are very 
similar, thus confirming the suitability of TGA as a technique to determine total water content 
within such beads. Following drug loading, three samples of beads were analysed with a mass 





1.4 % reduction in water content compared with beads without drug present. This finding 
correlates well with the results observed regarding bead size in that water content decreased as 
the beads reduced in size.  An example of TGA data obtained for the beads in the absence and 
presence of drug is shown in Figure 5.3. 
 
Figure 5. 3. A TGA sample profile for beads alone (solid line) and imipramine with beads 
(dashed line) indicating the associated mass loss from water. 
5.2.3.2 Differential scanning calorimetry (DSC) 
DSC analysis was completed for the bead samples, both with and without drug present, and 
also for water, to quantify the extent of the water within the beads that could undergo the 
freezing process. Examples of the data obtained for water alone and a sample of beads are 






















Figure 5. 4. DSC profiles for water, DC Bead M1 and DC Bead M1 drug loaded. 
Analysis of the data acquired resulted in an average total area for water of 376.8 ± 9.2 Jg-1 per 
mg, 317.3 ± 0.6.2 Jg-1 per mg for beads without drug (assuming an average water content of 
96.8 %) and 314.1 ± 9.3 Jg-1 per mg for the beads with drug (assuming an average water content 
of 95.4 %). As the error associated with the two bead profiles is greater than the difference 
between the values it can be concluded that there was no significant difference in the data, thus 
implying a similar percentage of water within the beads was available to undergo the freezing 
process. However, these values are lower than that recorded for water alone, thus a proportion 
of the water within the beads was so tightly bound that it was unable to freeze (known as non-
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integral for the beads from that of pure water it was possible to calculate the percentage of non-
freezing water present within the beads, with a value for beads alone of 15.8 % (± 3.2 %) and 
beads with drug of 16.7 % (± 2.9 %). These findings indicate that the presence of drug did not 
affect the non-freezing water content of the beads with both values being similar within 
experimental error. Interestingly, the peaks observed for the beads alone, and with drug, were 
not symmetrical, implying that DSC was able to differentiate between the two remaining types 
of water within the beads, i.e. that which is loosely bound (known as freezing bound) and the 
remainder which is unbound (known as free water). Through deconvolution of the peaks and 
subsequent integration of the areas it was possible to determine the percentages of the two 
within the bead. For beads without drug present the 81.0 % water content that was not non-
freezing can be further subdivided into 25.1 % loosely bound with the remaining 55.9 % 
unbound. For beads with drug present the 78.7 % water content that was not non-freezing can 
be further subdivided into 20.5 % loosely bound with the remaining 58.2 % unbound, indicating 
that the presence of drug more significantly decreased the freezing bound water within the bead 
rather than the unbound water. This finding infers that the drug is binding within the beads by 
replacing some of the freezing bound water rather than unbound water, explaining the modified 
release within dissolution analysis as some of the drug is initially bound within the sulfonate 
moieties in the bead before releasing more slowly over time. 
5.3. Conclusions  
In summary, previous studies had focussed on the application of such beads purely for 
embolisation purposes, in conjunction with drug delivery. In this analysis, significant 
differences in the overall water content was demonstrated by DC Bead™ and in the properties 
of water and imipramine concentration loaded into beads. Thermogravimetric analysis of mass 
loss as a function of temperature provided a constant decrease in mass as the temperature 
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increased. In particular, an average of 3.2 % beads solid content and 96.8 % total water content 
were recorded due to evaporation.  
Estimates on the amount of bound water and non-bound water were obtained by DSC 
measurements. The analysis of DSC data provided the enthalpy of melting, area in Jg-1 per mg 
for water, beads with drug and the beads without drug. It was found that for beads without drug 
the amount of non-freezing water was approximately 81.0 % in which 25.1 % was loosely 
bound with the remaining 55.9 % unbound. For beads with drug present the 78.7 % water 
content that was not non-freezing can be further subdivided into 20.5 % loosely bound with the 
remaining 58.2 % unbound, indicating that the presence of drug more significantly decreased 
the freezing bound water within the bead rather than the unbound water.  
These results provide an insight into the binding behaviour of water within the beads and how 













Chapter 6: Conclusions and Future work  
6.1. Conclusions    
The objectives of this thesis as highlighted in Chapter One were successfully achieved and are 
summarised as follows; 
The first objective was to investigate the suitability of using three types of Syloid® silica-based 
excipients to quantify their potential to enhance the rate of dissolution of drugs and determine 
the causes of any enhancements observed. It has been confirmed that it is possible to formulate 
Syloid® silica-based formulations to enhance the dissolution of poorly soluble drugs using a 
microwave formulation method, in this case, phenylbutazone, indomethacin and imipramine 
which is more soluble compared to the former two.  
The formulations were prepared first by simple physical mixing at different ratios and second 
a highly developed microwave method and finally, the resultants products were subsequently 
analysed utilising a variety of analytical techniques. The resultant products from the microwave 
method exhibited improved drug release compared with the pure drugs in agreement with other 
analysis [148]. Solid-state characterisation of the samples implies that there are transformations 
of the drugs from a crystalline state to a more amorphous form as confirmed by DSC and XRD. 
Furthermore, data obtained implies this enhancement is a result of a change in crystallinity and 
the ability of the drug to enter pores within the Syloid® silica structure.  
For functional group identification and also to ensure that long term stability is not a limiting 
factor for formulation possibilities, FT-IR analysis was carried before and after formulation 
and no interactions were observed other than the drugs used and the three Syloid® silicas under 
analysis. All Syloid® silicas analysed demonstrated a dramatic increase in percentage release 
with their final percentage values linked to the Syloid® silica pore diameter and/or surface area. 
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SEM images demonstrated that at the highest drug to silica ratio investigated, it was possible 
to achieve a uniformly distributed mixed product.  
This finding can be of benefit for not only phenylbutazone, indomethacin and imipramine-
based formulations but potentially a far wider range of compounds that exhibit poor aqueous 
solubility which will help alleviate bioavailability issues.  
The second objective was to use MWDTA on model pharmaceutical compounds to investigate 
the potential application of this form of thermal analysis on such compounds as an indicator of 
the suitability of microwave-based formulation methods. The effect of microwave heating was 
studied through the application of microwave differential thermal analysis to different model 
pharmaceutical compounds and a set of four model pharmaceutical excipients. The profiles 
were analysed and compared with the data generated using differential scanning calorimetry 
(DSC), X-ray powder diffraction (XRD) and hot stage microscopy (HSM). The results 
demonstrated that microwave differential thermal analysis (MWDTA) can be utilised to detect 
a wide range of thermal transitions including melting, recrystallisation, dehydration phase 
changes and dielectric change via changes in the materials ability to absorb microwave energy.   
For some drugs, the dielectric change was significantly high from looking at the profiles 
generated while intermediate and low dielectric changes were observed in other drugs analysed. 
The dielectric properties of a multicomponent mixture are dependent on the dielectric 
properties of the components. The thermal transition temperatures are slightly lower or higher 
in MWDTA than those observed with the conventional DSC method. This effect has been 
reported previously but has not received a complete explanation [213]. It should be recalled 
that the peaks seen in conventional techniques arise solely from the transformation enthalpy 
itself, while the temperature changes seen in MWDTA result primarily from the emergence of 
a product or phase that has different dielectric properties.  
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Overall, it was found that the process of microwave heating produced different thermal profiles 
to those seen using traditional, conductive heating. Investigating differences in thermal profiles 
can be a useful way to consider the effect of microwave-induced heating on formulations.   
The final objective was to portray the potential of TGA and DSC to quantify and characterise 
the water present within beads, including the incorporation of imipramine to exemplify the 
effect of drugs on the relative water profiles. The investigations carried out on beads revealed 
significant differences in the overall water content and in the properties of water.  TGA analysis 
of weight loss as a function of temperature showed a constant decline in weight of the sample 
as the temperature increased. The technique facilitated a simple and rapid form of analysis to 
determine the total water content within beads alone or in the presence of three model 
compounds. Furthermore, DSC was successfully employed to look into the water content in 
more detail, to identify the tightly bound, loosely bound and unbound percentages within the 
samples analysed. The values obtained provided the heat of melting of loosely bound and 
unbound water in the beads.   
The results presented in this study confirm the suitability of TGA and DSC to investigate such 
beads with respect to their water content and could potentially be applicable to an even wider 
variety of bead types available commercially. Knowledge of how drugs interact with the 







6.2. Future work   
This work can be improved further in many areas of potential opportunity to develop the scope 
of the techniques including: 
(I) Optimisation of the microwave method  
Drugs with a variable meting point range could be processed to evaluate possible effects of 
heating on the resultant formulations. Moreover, rather than using syloid silicas, the work could 
be expanded further using other excipients like D-mannitol, stearic acid, cyclodextrin, natural 
and synthetic polymers such as chitosan, pectin and gelucire. This could ultimately lead to a 
large range of formulation possibilities.   
Microwave dielectric thermal analysis (MWDTA), dielectric constant, dielectric loss factor, 
and dielectric loss tangent of all the studied compounds can be measured directly as a function 
of temperature using a dielectric spectrometer. It would be interesting to link the results 
obtained with MWDTA to fundamental dielectric measurements. 
An area where the MWDTA technique itself could be developed is through the addition of 
cooling apparatus. The addition of a cooling system will provide several advantages including 
allowing the user to perform experiments at room /ambient temperatures. This will also enable 
the characterisation of different proportions of water within polymer beads which will be 
interesting to link the results obtained with DSC and TGA measurements to MWDTA. 
Furthermore, better temperature control could be achieved with cooling apparatus, particularly 
with samples tending to thermal runaway.  
The ability to compare directly the MWDTA responses with DSC calculations of the energy 
of transitions should be investigated further, along with profiles of transitions types.   
In conventional techniques like differential thermal analysis (DTA) and DSC analysis, 
increasing the heating rate often leads to sharper transitions and it would be interesting to see 
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whether the same style is achievable using MWDTA. Rapid heating rates such as 10 or 20 
oC/min were generally avoided during the current research as they adversely affected 
temperature control.  
 (II) Expansion of analytical techniques  
Techniques including DSC, XRD, FTIR and SEM were used to investigate crystallinity, 
surface morphologies and thermal transitions as well as the stability of resultant products. 
However, other techniques such as transmission electron microscopy (TEM) could help in 
investigating the physical state of the drug within a formulation.  
(III) Bound water analysis 
Other types and sizes of DC beads such as 100 – 300, 300 – 500 and 500 – 700 µm should be 
analysed to explore the state of water and the types of water (the tightly bound, loosely bound 
and unbound) within such beads. Other drugs such as doxorubicin and irinotecan could be 
incorporated into such beads for identification and quantification of the influence of drug 
concentrations on the water behaviour.  
Techniques such as proton nuclear magnetic resonance (1H NMR) could be used to investigate 
the water mobility and localisation surrounding the hydrogel network. 1H NMR could provide 
an in-depth analysis about the hydrogel deformation due to water release and to evaluate the 
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Appendix 2: Release profiles for phenylbutazone (PhB), Syloid® XDP 3050 based 
formulations using conventional method at 1:1, 2:1 and 1:3 drug to silica ratios. Each data point 
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Appendix 3: Release profiles for phenylbutazone (PhB), Syloid® XDP 3150 based 
formulations using conventional method at 1:1, 2:1 and 1:3 drug to silica ratios. Each data point 
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Appendix 4: DSC profiles for phenylbutazone (PhB), and conventional formulation (CFM) of 
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Appendix 5: DSC profiles for phenylbutazone (PhB), and conventional formulation (CFM) of 
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Appendix 8: FT-IR analysis of (a) PhB (b) XDP 3050, (c) CFM 1:1, (d) CFM 2:1, and (e) 
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Appendix 9: FT-IR analysis of (a) PhB (b) XDP 3150, (c) CFM 1:1, (d) CFM 2:1, and (e) 
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Appendix 10:  DSC profiles of (a) DC beads M1, water and (b) TGA of DC beads M1 heated at a rate 
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